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ABSTRACT OF DISSERTATION 
MEDICATION MISADVENTRUES: 
THE CASE OF BENZODIAZEPINES 
For patients afflicted with symptoms of anxiety and insomnia, benzodiazepines are 
generally a safe and effective short-term pharmacological treatment option. Although 
considered safer than other sedative-hypnotic medications, substantial concern exists regarding 
the addictive nature and abuse potential of benzodiazepines along with potentially 
inappropriate prescribing and utilization in clinically vulnerable populations. These medication 
misadventures can have a significant impact on public health. Examples of medication 
misadventures as they pertain to benzodiazepines include the prescribing and use in clinically 
vulnerable populations for whom they are contraindicated or their efficacy has not been 
evaluated, the development of tolerance or addiction, abuse of the medication, and the 
manifestation of negative health outcomes including cognitive impairment, withdrawal 
symptoms upon discontinuation, or the reoccurrence of a preexisting substance use disorder. 
In order to better understand medication misadventures associated with 
benzodiazepines retrospective analyses using populations extracted from large health claims 
databases are employed. To understand how benzodiazepine use may lead to adverse events 
causing patient harm, the risk of exacerbations in benzodiazepine users diagnosed with chronic 
obstructive pulmonary disease was estimated. The inherent risk of benzodiazepine addiction 
and abuse was estimated in an HIV-infected population, a population with a high prevalence of 
substance use disorders. This risk was estimated by first determining whether HIV-infected 
individuals are more likely to have any benzodiazepine use compared to their uninfected 
counterparts, and secondly, by examining the association between HIV-infection and potentially 
problematic benzodiazepine use. Finally, in an effort to mitigate unexpected and undesirable 
consequences to public health associated with the prescription drug abuse epidemic in the US, 
states have implemented prescription drug monitoring programs (PDMPs) to track the 
prescribing and dispensing of controlled substance medications. The effect of these programs on 
benzodiazepine dispensing is evaluated on a state and national level. 
Findings will provide healthcare professionals a better understanding regarding the risk 
of medication misadventures involving benzodiazepines when evaluating their appropriateness 
in patients with anxiety, depression, and insomnia. Additionally, policymakers will understand 
the implications of PDMPs on the dispensing of benzodiazepines as they become a more widely 
used tool to combat prescription drug abuse and diversion.
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CHAPTER 1: A REVIEW OF THE BENZODIAZEPINE LITERATURE: POLICY AND OUTCOMES. 
BACKGROUND 
In 1955, chemist Leo Sternbach, while working for the Hoffmann La Roche company, 
created the drug chlordiazepoxide, the first drug in the chemical class of benzodiazepines 
(informally “benzo”; abbreviated “BZD”).1 Benzodiazepines are indicated for use as anxiolytics, 
sedatives, hypnotics, anticonvulsants, and/or skeletal muscle relaxants.2 At the time of their 
discovery, benzodiazepines were comparatively efficacious and appeared to be safer than 
similar drugs on the market including barbiturates and meprobamate.3 Compared to these 
drugs, benzodiazepines had a lower abuse potential,2,3 produced less toxicity in acute 
overdoses,2 and reduced the risk of respiratory depression.4 Additionally, barbiturates and 
meprobamate often produced unwanted effects including sedation at anxiolytic dosages, 
headaches, paradoxical excitement, confusion, and cognitive and psychomotor impairment.3 
Hoffmann La Roche patented Sternbach’s discovery in 1959, and in 1960 the first 
benzodiazepine was marketed as Librium® (chlordiazepoxide).1 Following the success of 
chlordiazepoxide Roche launched the popular drug Valium® (diazepam).  Between 1969 and 
1982, diazepam was the most prescribed drug in the United States with greater than 2.8 billion 
tablets sold in 19783 and was celebrated as “mother’s little helper” after being referenced as 
such in a 1966 song by the Rolling Stones of the same name.5 
The effects benzodiazepines produce result from action at the limbic, thalamic, and 
hypothalamic levels of the central nervous system (CNS). Benzodiazepines bind to receptors for 
the main inhibitory neurotransmitter in the CNS, the γ-aminobutyric acid (GABA), specifically the 
GABAA receptor located in the synapses of neurons.6 Benzodiazepines bind to the GABAA 
receptor they do not activate it directly, instead they serve to potentiate the inhibitory effects of 
2 
GABA.6 Effects are produced after the first dose and, following oral administration, occur within 
15 to 45 minutes with a duration of action of approximately seven to eight hours.2 In general, 
most benzodiazepines can be used interchangeably6 and diazepam milligram equivalents (DMEs) 
are used to adjust for variations in the potency between individual drugs.7 Differences in use 
between benzodiazepines reflect the manner in which the drugs have been studied and 
marketed by the manufacturer.2 While there is no evidence to suggest that one benzodiazepine 
is more effective than any other at equivalent dosages, pharmacokinetic differences, such as the 
metabolic half-life, are important to consider when prescribing these drugs.2 For example, 
benzodiazepines with a shorter half-life are often preferred in the management of insomnia in 
order to minimize daytime drowsiness8 while longer half-life benzodiazepines are recommended 
for managing symptoms of anxiety to allow the drug to accumulate in the body.9 Drug marketing 
information, therapeutic uses, and DME ratios of benzodiazepines currently marketed in the 
United States are summarized in Table 1.1.  
To date, more than 1,000 benzodiazepines have been synthesized,10 and remain the 
most frequently dispensed psychotropic drug class.11 In 2012 benzodiazepines were the 10th 
most prescribed drug class in the United States with approximately 94 million prescriptions 
dispensed.12 Alprazolam was the most commonly dispensed benzodiazepine with 49 million 
prescriptions dispensed in 2012 and ranked as the 13th most commonly dispensed medication in 
the United States.13 Although considered safer than other sedative-hypnotics drugs, such as 
barbiturates and meprobamate,2,3,6 the potential exists for benzodiazepines to be abused 
because of their addictive nature. Due to their abuse potential benzodiazepines are classified as 
a Schedule IV controlled substance (CS) in the classification system implemented by the 
Controlled Substance Act of 1970.  
3 
The abuse of benzodiazepines typically refers to recreational, non-medical use of the 
drug in order to achieve a “high” or euphoric effect14 and frequently begins with a legitimate 
prescription that is intentionally misused.15 Rarely are benzodiazepines the preferred or the sole 
drug of abuse; instead abuse commonly occurs in conjunction with other substances, mainly 
opioids and alcohol.16 Clinical evidence shows that benzodiazepines and opioids, when used 
concurrently exert synergistic effects.17-23 Further evidence explaining the reasons for the 
concomitant use of these drugs suggest benzodiazepines increase the rewarding and reinforcing 
effects of opioids.24-27 Benzodiazepines with a rapid onset of action tend to be abused more 
frequently.15,28,29 The exception is diazepam, while considered a long-acting benzodiazepine, it is 
highly lipophilic and crosses the blood-brain barrier rapidly making it very susceptible for 
abuse.15,28 
Medication misadventures 
Despite guidelines and recommendations regarding the appropriate prescribing of 
benzodiazepines, they are often misused in the clinical setting. This inappropriate use can result 
in medication misadventures, defined by the American Society of Health-System Pharmacists as 
an iatrogenic hazard or incident associated with medication therapy.30 Medication 
misadventures are comprised of medication errors (any preventable event that may cause or 
lead to inappropriate medication use or patient harm), adverse drug events (an injury from a 
medicine or lack of intended medicine), and adverse drug reactions (any unexpected, 
unintended, undesired, or excessive response to a medicine).30 The literature provides several 
examples of medication misadventures as they pertain to benzodiazepines. 
 For example, benzodiazepines are only recommended for short-term use, as their long-
term anxiolytic efficacy (less than or equal to 4 months) has not been evaluated;2 however, a 
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sizable proportion of the population are considered to be chronic users. Studies from several 
countries have estimated that between 0.5% and 5.8% of the adult population engages in long-
term benzodiazepine use of one year or more.31-33 Concerns have risen that long-term 
benzodiazepine use may lead to cognitive impairment. A significant effect on cognitive functions 
including sensory processing, psychomotor speed, attention/concentration, and motor 
control/performance has been observed following long-term benzodiazepine use.34 Long-term 
use of benzodiazepines also carries the risk of increasing tolerance to the drug’s effects and the 
development of dependence. Tolerance to the effects of benzodiazepines often leads to dosage 
escalation in order to maintain the same level of desired effects.28,35 This tolerance and 
subsequent increase in dosage can lead to dependency although it is possible for 
benzodiazepine dependency to develop within normal therapeutic ranges.34,35 Benzodiazepine 
dependency can manifest physiologically or psychologically and it is has been estimated that 
approximated 35% of all patients who have taken a benzodiazepine for at least four weeks 
develop some type of dependency upon the drug.36  
Physiologic dependence on benzodiazepines leads to the risk of withdrawal symptoms if 
the drug is suddenly discontinued or the dosage drastically reduced.28,34,37,38 Common 
withdrawal symptoms include rebound anxiety and insomnia, agitation, tension, dysphoria, 
sweating, irritability, impaired concentration, and weight loss.2 More serious withdrawal 
symptoms have also been reported such as grand mal seizures,39-41 nonconvulsive status 
epilepticus,42 delirium,39,40 and death.40,43 The severity of benzodiazepine withdrawal and the 
inability to taper successfully can be attributed to factors associated with the benzodiazepine 
therapy along with individual patient characteristics44-46 (Table 3) and to minimize the risk of 
withdrawal symptoms that benzodiazepines be discontinued gradually.47  
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Benzodiazepines are also commonly prescribed in clinically vulnerable populations for 
whom they are contraindicated or their efficacy has not been evaluated. Use of benzodiazepines 
in these clinically vulnerable populations is a controversial practice. Some experts recommend 
that benzodiazepines use be avoided in patients with a substance use disorder (SUD) history as 
they may exacerbate the preexisting SUD.29,48 Additionally, patients with a SUD may be more 
likely to abuse prescribed benzodiazepines. According to a recent study in the Netherlands, 
patients with alcohol dependence are at an increased risk of developing benzodiazepine 
dependence.49 Recent evidence also advises against the use of benzodiazepines among patients 
with very severe respiratory disease including chronic obstructive pulmonary disease (COPD) as 
use may lead to severe adverse events including respiratory depression50 and mortality.51 
Furthermore, benzodiazepine use in the elderly population, has been associated with negative 
health outcomes including cognitive impairment, falls, and fractures.52,53  
The purpose of this series of papers is to review current issues related to the medication 
misadventures as they pertain to benzodiazepines. More specifically, the goals of this series of 
papers is to quantify the prevalence of benzodiazepine misuse and abuse, examine health 
outcomes associated with the suboptimal use of benzodiazepines in clinically vulnerable 
populations, and test the impact of policies designed to reduce prescription drug abuse and 
diversion on the utilization of benzodiazepines. The specific aims of this literature review are to 
describe health outcomes associated with potentially inappropriate benzodiazepine use in 
specific populations, and to review policies that have been implemented to monitor transactions 
involving benzodiazepines and their impact on benzodiazepine prescribing and dispensing. 
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METHODS 
 The search engines of PubMed, Medline, and Google Scholar were used to search from 
combinations of the following key words and phrases: benzodiazepines, drug abuse, nonmedical 
prescription drug use, benzodiazepine poly-drug abuse, benzodiazepine misuse, health 
outcomes, medication misadventures, benzodiazepine monitoring, prescription drug monitoring 
program (PDMP), prescription monitoring program (PMP), and triplicate prescribing program 
(TPP). Searches of these databases were conducted between January and April 2014. Retrieved 
articles published in a language other than English were excluded from further review. Titles and 
abstracts of remaining articles were assessed for relevance to this review. Additionally, 
references cited in selected articles were examined and appropriate articles were considered 
based on their unique contribution to this review. The reviewed articles were grouped into two 
themes: prescription drug monitoring policies designed to mitigate consequences connected 
with prescription drug abuse and diversion, and health outcomes associated with potentially 
inappropriate benzodiazepine use. 
FEDERAL AND STATE BENZODIAZEPINE POLICIES 
 Prescription drug abuse can be categorized as a type of medication misadventure 
leading to an adverse drug event or adverse drug reaction that can lead to injuries, a declined 
state of health, and death. Throughout history, several strategies have been implemented to 
address problems associated with the misuse, abuse, and diversion of psychoactive compounds. 
In the case of benzodiazepines, three strategies imposed by the US federal and state 
governments have had the most profound impact. First was the Controlled Substance Act of 
1970 that classified potential drugs of abuse into Schedules and regulated transactions involving 
controlled substances (CS). Next, in 1989, New York became the first state to include 
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benzodiazepines on their TPP in order to monitor their prescribing and dispensing. Finally, in an 
effort to combat the problem of prescription drug abuse and diversion, many states have 
implemented PDMPs to track the prescribing and dispensing of CS, with the majority of states 
monitoring benzodiazepine transactions. 
Controlled Substance Act of 1970 
 On October 27, 1970, President Richard Nixon signed into law the Comprehensive Drug 
Abuse Prevention and Control Act of 1970 in response to the increasing problem of illicit drug 
use, especially narcotics, which had become widespread in the late 1960s.54 Title II of the 
Comprehensive Drug Abuse Prevention and Control Act of 1970, the Controlled Substance Act of 
1970, created a complex regulatory system to control the distribution of drugs. The Controlled 
Substance Act created a classification system categorizing licit and illicit drugs into five 
categories called “Schedules” based on abuse potential, significance of abuse, dependence 
liability, the risk to public health, and scientific evidence regarding accepted medical use.55 
Substances classified as Schedule I currently have no accepted medical use in the United States 
with drugs included in Schedules II through V considered “necessary to maintain the health and 
general welfare of the American people.”55 Substances in the Schedule II category have been 
determined to have the greatest abuse potential while Schedule V CS have the least. The 
responsibility of adding drugs to CS Schedules and modifying the Schedules of already included 
substances falls upon the Drug Enforcement Administration (DEA) and the Food and Drug 
Administration. According to the criteria outlined by the Controlled Substance Act, 
benzodiazepines are defined as a Schedule IV CS. A description of the CS classification system 
and examples of drugs in each Schedule is provided in Table 3. 
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In addition to classifying CS into Schedules, the Controlled Substance Act also led to the 
regulation of transactions involving CS at the manufacturing and wholesale level. This aspect of 
the legislation was in response to the growing problem of illicit manufacturing and smuggling of 
CS from research laboratories to be sold on the black-market.56 Individuals and firms who 
handle these drugs must register with the DEA and receive a registration number to be used on 
all transactions involving CS. Authorized handlers of CS include manufactures, distributors, 
hospitals, pharmacies, practitioners, and researchers. While all authorized handlers must 
maintain complete and accurate records of all their CS transactions only manufacturers are 
required to make periodic reports to the Attorney General.57,58 An amendment to the Controlled 
Substance Act regarding the reporting of CS transactions occurred in 2008 as part of the Ryan 
Haight Online Pharmacy Consumer Protection Act. This legislation requires certain pharmacies 
distributing CS via the Internet to provide detailed reports of their CS transactions to the 
Attorney General.59 
New York’s Triplicate Prescription Program 
 Since the 1930s individual states have seen the need to collect and analyze prescribing 
and dispensing data pertaining to certain medications. In 1939, California became the first state 
to implement a PMP.60 Early monitoring programs relied upon the use of multiple copy 
prescription forms and were implemented in nine states.61 These monitoring programs required 
physicians to use government-issued serialized forms to write prescriptions for targeted drugs.62 
Ordering physicians would retain one copy of the prescription and give the remaining copies to 
the patient. Patients then would take their prescription to the pharmacy to be filled. At this 
point, the pharmacy would retain the other copies of the prescription, keeping one copy for 
their own records and submitting the remaining copy to the state surveillance unit. 
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 On January 1, 1989, New York became the first state to include benzodiazepines in their 
list of targeted drugs monitored by the state’s TPP with the primary objectives of reducing 
benzodiazepine diversion for illicit use and reducing inappropriate prescribing.63-65 This program 
allowed regulatory agencies to track the prescribing, dispensing, and utilization of targeted 
drugs by providers, pharmacies, and patients suspected of misusing these medications.66 With 
the exception of certain conditions, such as panic and convulsive disorders, the addition of 
benzodiazepines to the TPP limited prescriptions to a 30-day supply. In addition, refills were not 
permitted, requiring a patient to visit their provider when a new prescription was needed.67 
 Multiple copy prescription programs were strongly supported by the DEA, citing vast 
reductions of CS prescribing in states with an operational program.68 Furthermore, it was 
emphasized these reductions were solely due to declines in inappropriate prescribing, in other 
words, there was no negative impact to CS access for patients with a legitimate CS need.68 Early 
reports by the New York Department of Health proclaimed that adding benzodiazepines to the 
targeted drug list monitored by the state’s TPP had not only succeeded in reducing the abuse of 
benzodiazepines and their diversion into the illicit market, but had done so without creating 
access limitations for legitimate users.67 The success in reducing the abuse and diversion of 
benzodiazepines was supported by drastic increases in the street price of benzodiazepines (1mg 
of alprazolam rose from $1.50 to $8.50 and 10mg of diazepam went from $2.00-$2.50 to $4.50-
$6.00), along with reduced mentions of benzodiazepines in the Drug Abuse Warning Network 
(DAWN), and a large decline in the number of Medicaid benzodiazepine prescriptions filled.69 
However, the claim of the TPP accomplishing these objectives without compromising 
benzodiazepine access for legitimate patients was widely challenged in a series of studies 
evaluating the change in policy. 
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A study by Reidenberg70 compared the estimated number of benzodiazepine 
prescriptions written in New York and Pennsylvania for the years 1988, one year prior to, and 
1989, one year after, the TPP implementation in New York. Pennsylvania was chosen as a 
comparator state as there was no policy change regarding benzodiazepine prescriptions during 
the study period. Findings showed a 57% decrease in the estimated number of benzodiazepine 
prescriptions in New York with only an 11% reduction occurring in Pennsylvania. The more 
interesting finding was the dramatic increase in the number of prescriptions during the study 
period for alternate sedative-hypnotics that are less effective in managing symptoms of anxiety 
and insomnia and/or have a higher abuse potential than benzodiazepines (i.e., meprobamate, 
buspirone, chloralhydrate, and hydroxyzine) in New York with no parallel changes observed in 
Pennsylvania. Similar findings were also reported by Weintraub et al.71 Changes in the 
prescribing of alternate sedative-hypnotics from 1988 to 1989 in New York were assessed and 
compared them to nationwide trends using prescribing data from IMS America National 
Prescription Audit. While in New York the prescribing of benzodiazepine alternatives 
dramatically increased during the study timeframe, nationwide prescribing trends for these 
medications remained steady or declined. Hoffman et al.,64 tested the presence of a substitution 
effect by examining the incident cases of overdoses reported to the New York City Poison 
Control Center for benzodiazepine and non-benzodiazepine sedative-hypnotics. The findings 
suggest that following the addition of benzodiazepines to the list of drugs targeted by the New 
York TPP the total number of sedative-hypnotic overdoses remained unchanged, but with a 
significant reduction in benzodiazepine overdoses concurrent with a significant rise in non-
benzodiazepine sedative-hypnotic overdoses. As a result of the findings from the 
aforementioned studies, further questions were raised regarding the impact of benzodiazepine 
triplicate regulations on public health and patient care. 
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Four studies examining the effect of the benzodiazepine triplicate prescription policy on 
population subgroups suggested the triplicate prescription policy might have resulted in an 
unintended decrease in legitimate benzodiazepine use for patients in therapeutic need of this 
newly restricted medication.65,72-74 A large controlled study conducted by Ross-Degnan et al.65 
examining the addition of benzodiazepines to the New York TPP on the dispensing of 
benzodiazepines observed a 50% reduction in dispensing to Medicaid beneficiaries. 
Furthermore, beneficiaries were classified as either problematic or non-problematic 
benzodiazepine users based on the indicators of long-term use (i.e., use greater than 120 days 
duration), excessive dosage (i.e., levels more than twice the recommended maximum), 
concurrent use (i.e., concurrent use of two long-acting or two short-acting benzodiazepines), 
pharmacy hopping (i.e., filling a prescription for the same benzodiazepine in two different 
pharmacies within seven days), and elderly use of long half-life benzodiazepine. Findings of the 
study showed that after benzodiazepines were added to the New York TPP the risk of 
discontinuing benzodiazepine therapy was twice as high in New York compared to New Jersey 
(relative risk (RR): 2.1; 95% confidence interval (CI): 2.1-2.1). Among New York Medicaid 
beneficiaries, the RR of benzodiazepine discontinuation was greater in those with problematic 
use compared to those with non-problematic use (RR: 1.3; 95% CI: 1.2-1.3). However, the 
authors suggested that overall, because at baseline the majority of benzodiazepine dispensing 
was identified as non-problematic the number of non-problematic users that had their 
benzodiazepine discontinued greatly exceeded that of problematic users. This conclusion 
implies that the inclusion of benzodiazepines on the list of drugs monitored by the TPP resulted 
in a barrier to appropriate medication therapy for patients with a legitimate need. Results also 
demonstrated a disproportionate impact on females, and residents of predominately urban, 
black, and poor areas, with these beneficiaries experiencing comparatively higher 
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benzodiazepine discontinuation rates after the policy change. However, differences in 
demographic characteristics between beneficiaries identified as problematic and non-
problematic users were not provided. If problematic benzodiazepine dispensing at baseline 
were greater in these population subgroups then a high discontinuation rate among these 
beneficiaries would be expected and potentially appropriate. 
 Pearson et al.74 further explored the issue of racial disparities in benzodiazepine access 
after the TPP policy change in a study of New York Medicaid beneficiaries. Changes in 
benzodiazepine use in white, black, Hispanic, and mixed race neighborhoods were examined 
and neighborhood racial composition was used as a predictor of benzodiazepine 
discontinuation. The study observed beneficiaries residing in black neighborhoods were 
consistently the most likely group to experience reduced access to benzodiazepines after the 
TPP policy change. This is a concerning observation as residents in black neighborhoods had the 
lowest baseline benzodiazepine utilization rates and the lowest baseline odds of problematic 
benzodiazepine use. Furthermore, this leads to concerns that health policies, in the process of 
achieving their intended goals, may disproportionally affect racial minorities, further widening 
health disparities between people of different racial backgrounds. 
 Evidence of a substantial impact on access to benzodiazepine therapy among clinically 
vulnerable populations was detected in two separate assessments. A 2003 evaluation by 
Wagner and colleagues72 examined new benzodiazepine use among patients recently 
discharged from the hospital for either an acute cardiac event or cancer. Benzodiazepines are 
often prescribed to relieve anxiety associated with acute myocardial infarction and in cancer 
patients to reduce anticipatory anxiety and anxiety related effects associated with the 
administration of chemotherapy.2 The study found new benzodiazepine use among New York 
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Medicaid beneficiaries recently discharged from the hospital for acute cardiac events and cancer 
declined 72.5% and 69.4%, respectively during the two-year observation period after the 
benzodiazepine triplicate regulation was implemented. Additionally, Simoni-Wastila et al.73 
studied patients who had a diagnosis of schizophrenia, epilepsy, or bipolar disorder, where 
benzodiazepines represent an effective first-line or adjunct treatment option, and demonstrated 
a nearly 50% decline in benzodiazepine use six months after the policy change. Patients with a 
seizure disorder experienced a 60% decline, the largest among the conditions assessed. 
However, while benzodiazepines are a first-line agent for status epilepticus and acute seizures 
their efficacy in treating chronic epilepsy is limited by the risk of side effects and development of 
tolerance75 which may explain the significant decline in utilization among this population. 
Furthermore, clinical outcomes for the populations in both studies were not assessed. 
Therefore, it is unknown if patients for whom benzodiazepine therapy was not initiated, or 
discontinued, were adversely affected. However, the authors of these studies concluded access 
to appropriate pharmacotherapy had been restricted by the TPP policy change. 
These studies highlight the potential for health policies to produce unintended 
consequences that create barriers to healthcare access for already disadvantaged individuals. 
While the addition of benzodiazepines to the New York TPP did not restrict physician prescribing 
of benzodiazepines, concerns existed of reduced access to appropriate pharmacological care, 
dubbed a “chilling effect”. The “chilling effect” describes a situation where a patient with a 
legitimate need for a CS is unable to acquire it either due to a physician’s unwillingness to 
prescribe or a pharmacist being unwilling or unable to dispense the CS. The unwillingness to 
prescribe or dispense a CS may be due to fear of legal investigations, fear of confidentially 
violations, increased administrative burden, or confusion between the patterns of addiction and 
pseudoaddiction, where patients who are not being adequately treated for their condition 
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appear, on paper, to be addicts.76-79 Additionally, patients with a legitimate CS need may be 
unwilling to accept the medication due to concerns they may be labeled as a drug user in the 
surveillance system.79 
The reviewed studies support the claim that benzodiazepine monitoring policies result 
in an immediate, significant, and sustained decline of overall benzodiazepine use. In addition, 
these studies identify reductions in problematic or inappropriate benzodiazepine use as a result 
of the benzodiazepine TPP regulation, a primary goal of the policy amendment. Evidence of 
unintended consequences, such as a “chilling effect” and a differential impact among certain 
population subgroups were also supported. However, the reviewed studies only assessed the 
effect of the New York TPP. Benzodiazepine monitoring policies in other states may affect 
patterns of benzodiazepine use differently based on physician prescribing practices, prevalence 
rates of mental illnesses, and variations in abused/misused substances. Furthermore, each of 
these studies exclusively relied upon data from a Medicaid population. Therefore, it is unknown 
how benzodiazepine monitoring programs affect use among privately insured populations. 
Moreover, clinical outcomes of the study populations after the TPP were not assessed. Without 
this information it is undetermined if patients who were discontinued from benzodiazepine 
therapy experienced adverse health outcomes as a result of the new regulation. Use of clinical 
outcomes would provide a more accurate depiction of the impact of the TPP on inappropriate 
and legitimate benzodiazepine use, as the proxy developed by the Advisory Panel described in 
Ross-Degnan et al.65 does not contain diagnostic information, thus limiting the ability to 
distinguish between specific instances of appropriate and inappropriate use. 
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Prescription Drug Monitoring Programs 
 In the 1990s, states began to rely on electronic data transfer systems to track the 
prescribing, dispensing, and utilization of targeted medications in an effort to combat 
prescription drug abuse and diversion. Because of these electronic systems, states have 
repealed their multiple copy prescription programs in favor of PDMPs. In 2006, California 
became the last state to repeal their multiple copy prescription program, which they had been 
using concurrently with their electronic PDMP since 1997.61 Prescription drug monitoring 
programs have an added advantage over multiple copy prescription programs as they provide 
prescribers and pharmacists with the ability to request and receive a patient’s CS prescription 
history with quick turnaround, allowing treatment decisions to be made at the point of care. 
Reports detailing a patient’s CS prescription history can be accessed upon request, or 
proactively distributed to specific healthcare providers and law enforcement officials, depending 
upon the regulations of the individual state’s program. Pharmacies, along with dispensing 
physician and veterinarian offices submit CS dispensing data to the PDMP on a regular basis as 
mandated by state law. The majority of states require CS dispensing data to be submitted at 
least every seven days with some states requiring daily or “real-time” reporting.80 Prescription 
data submitted to PDMPs follows a standard format and includes patient name, prescriber 
name, date of dispensing, and name, strength, and quantity of the CS medication dispensed. As 
of December 2014, 49 states have an operational PDMP. Missouri and Washington DC do not 
currently have a PDMP, however, Washington DC does have pending legislation.80 
 While all PDMPs were designed to facilitate collection, analysis and reporting of 
prescription controlled substance use, in practice they take several different forms based upon 
individual state legislation and differ in terms of objectives, design, and operations.58 Housing 
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agencies of PDMPs vary between states with the majority of PDMPs housed within health 
departments, a single state authority (an entity designated as a state’s administrative authority 
responsible for the planning and implementation of statewide systems that provides substance 
abuse services81), or Boards of Pharmacy.80 Seven states house their PDMP within a law 
enforcement agency.80 Variation exists across states in terms of authorized users and access to 
the PDMP system and PDMP reports. In most states healthcare professionals including 
prescribers and dispensers of CS, along with regulatory and licensing boards are authorized to 
receive the information contained within PDMP reports, however, access among law 
enforcement personnel is less uniform.80 States also differ in the CS schedules monitored. While 
all state PDMPs track the dispensing of Schedule II CS, some states also monitor Schedules III, IV, 
and V. Some state PDMPs also have the authority to monitor non-CS under certain 
circumstances.82 Relevant for this work, of the 49 operational PDMPs as a December 2014, 48 
have the authority to monitor the prescribing and dispensing of Schedule IV CS which include 
benzodiazepines.80,83 A list of states with active PDMPs and a description of CS Schedules 
monitored is provided in Table 4. Of note, Pennsylvania is the only state with a PDMP that does 
not monitor Schedule IV CS, including benzodiazepines. 
 The limited studies conducted regarding the effectiveness of PDMPs suggest these 
programs are successful in reducing the supply of CS. One study conducted by the United States 
General Accounting Office released in 2002 examined the presence of a PDMP in the ten states 
with the highest and lowest per capita OxyContin prescriptions. Among the ten states with the 
greatest number of OxyContin prescriptions per capita, only two (Kentucky and Rhode Island) 
had an active PDMP. Comparatively, six of the ten states with the lowest number of 
prescriptions per capita had a PDMP in place.58 A 2006 evaluation of PDMPs by Simeone and 
Holland84 used state and individual level models to estimate the relationship between the 
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presence of a PDMP, the supply of Schedule II CS, and the abuse of these medications. Using 
data from the Automation of Reports and Consolidated Orders System (ARCOS), which monitors 
the sale of CS through commercial channels, the per capita supply of Schedule II CS over the 
seven-year study period was found to be reduced in states with an active PDMP compared to 
states without a PDMP.  
Conversely, PDMPs may not be associated with improved health outcomes as some 
studies suggest that PDMPs have a limited impact on overall opioid consumption and drug 
overdose mortality. Twillman85 conducted a review of the ARCOS database and identified a 
decrease in the supply of Schedule II opioid analgesics along with a concurrent increase in 
Schedule III opioid analgesics among states with an active PDMP. Paulozzi, Kilbourne, and 
Desai86 also analyzed the ARCOS database and noted that during the study period from 1999 to 
2005, PDMPs were not associated with lower rates of overall opioid consumption and like 
Twillman85 found PDMPs were associated with lower rates of Schedule II opioid analgesic use 
but not Schedule III opioid analgesics. Similar findings were reported in a 2012 cross sectional 
study conducted by Simoni-Wastila and Qian87 who estimated the association between the 
presence of a PDMP and the probability of analgesic use by CS Schedule among older, privately 
insured adults. Results showed the odds of filling any opioid analgesic prescription were greater 
in states with a PDMP. More specifically, beneficiaries in states with an active PDMP had 
decreased odds of filling a prescription for a Schedule II opioid analgesic and increased odds for 
Schedule III opioid analgesics when compared to beneficiaries in states absent of a PDMP. 
Recently, Brady et al.88 found that on a national level PDMPs are ineffective at significantly 
reducing the amount of opioids distributed per capita, but when examined at the state level 
there are marked variations among the effect of programs. Li et al.89 found similar results when 
examining the impact of PDMPs on drug overdose mortality. On a national scale the presence of 
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a PDMP was associated with and 11% increase in drug overdose mortality, however, significant 
state variations were found ranging from a 35% decrease in Michigan to a 337% increase in 
Nevada. The findings presented by Brady et al. and Li et al. suggest that it is specific 
characteristics of PDMPs that have the greatest impact on prescription drug abuse and diversion 
as opposed to the presence of a program alone. 
In clinical practice there is limited literature examining how PDMPs impact CS behaviors. 
Baehren et al.90 studied how PDMP reports affected the prescribing decisions by emergency 
room physicians at a university hospital in Ohio for patients presenting with non-acute pain. In 
41% of cases the physician chose to alter their initial CS pain medication prescribing decision 
after reviewing a patient’s PDMP report with 60% of these cases resulting in fewer of no CS pain 
medications being prescribed. Green et al.91 surveyed pharmacists in Connecticut and Rhode 
Island to understand how PDMPs influence their practice. Responding pharmacists reported 
they used reports generated by the PDMP to screen for abuse and doctor shopping but the 
effect on CS dispensing behavior was not evaluated. A 2010 independent study conducted by 
Blumenschein et al.82 surveyed CS prescribers and dispensers in Kentucky and found that for 
46% of prescribers and 34% of pharmacists the information contained within the PDMP report 
had altered their CS prescribing or dispensing decision.  
To date, studies regarding current PDMP legislation have focused primarily on the 
impact concerning opioid analgesic prescribing and use. Focus on this medication class is 
understandable as opioid analgesics are the primary contributor to the increasing trend of drug 
overdose deaths in the United States.92-94 However, other CS, specifically benzodiazepines, have 
been found to be a factor contributing to the substantial rise in unintentional poisoning 
deaths92,95-97 likely related to the additive or synergistic effects when benzodiazepines are 
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combined with opioids.98 In West Virginia, a forensic drug database review conducted by Shah et 
al.97 found that the proportion of drug-related deaths where alprazolam was a contributing 
factor increased from 7.2% in 2005 to 27.5% in 2007. An analysis of medical examiner records 
from New York City found that benzodiazepine use concurrent with methadone maintenance 
therapy increased the odds of an accidental overdose by 1.66 (95 % CI: 1.12, 2.45).99 Similar 
results were also reported in a study of opioid-related deaths in the United Kingdom. 
Interestingly, among the deaths primarily attributable to methadone in which benzodiazepines 
were detected, the blood concentration levels of methadone were considered to be within 
therapeutic ranges.100  
Utilization of PDMPs can aid in the identification of potentially inappropriate prescribing 
and dispensing involving benzodiazepine medications. In the approximately 50% of drug-related 
deaths in West Virginia where opioids and benzodiazepines were identified through toxicology 
analysis, the deceased had a legal prescription for both medications.97 Additionally, among the 
deceased with more than one benzodiazepine detected at the time of death, the majority (63%) 
had a valid prescription for each medication.97 As many electronic PDMPs allow prescribers 
nearly instantaneous feedback of a patient’s CS prescription history, use of these systems can 
alert prescribers to possible doctor shopping and inappropriate or risky adjunct CS prescribing. 
This information allows the prescriber to intervene in suspected cases of drug abuse and 
diversion by referring the patient to substance abuse treatment or conducting drug screens to 
ensure the patient is taking, and not diverting, the prescribed CS, thereby reducing the risk of 
unintentional poisonings. 
Previous literature on benzodiazepine monitoring has centered on the New York TPP 
from the early 1990s. Given the noticeable absence of literature evaluating the impact of 
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current PDMP legislation on benzodiazepine prescribing, dispensing, and utilization studies in 
this area are warranted. Expanding the literature on current PDMP legislation to incorporate 
benzodiazepines is necessary to understand if these programs are effectively meeting their 
objectives of curbing the prescription drug abuse epidemic. Assessments of how PDMP policies 
affect benzodiazepines is also needed to ensure patient safety by not restring access to 
pharmacotherapy options among patients having a condition where benzodiazepine therapy is 
appropriate. 
BENZODIAZEPINE USE AND HEALTH OUTCOMES 
 In the United States it is estimated that in a given year approximately one-quarter of 
adults 18 and older suffer from a diagnosable mental disorder.101 Anxiety disorders, including 
panic disorder, post-traumatic stress disorder, generalized anxiety disorder, and phobias, are 
the most prevalent mental disorder in the United States affecting about 40 million Americans or 
18% of the adult population.101 Furthermore, patients who suffer from mental disorders, 
including anxiety disorders, are also likely afflicted with symptoms of insomnia.102 
Benzodiazepines are generally an effective pharmacological treatment option and are widely 
prescribed for the management of symptoms related to anxiety disorders and insomnia.11,103  
 Despite their benefits, benzodiazepine therapy is not optimal for all populations. 
Commission of benzodiazepine therapy has inherent risks and medication misadventures 
involving benzodiazepines are common when they are used in clinically vulnerable populations. 
The abuse potential of benzodiazepines and synergistic effect when coupled with opioid 
analgesics can lead to the risk of medication errors including concurrent use of benzodiazepines 
and opioid analgesics, duration of use exceeding that of proven efficacy, and escalation of 
dosage beyond that prescribed by a physician. While medication errors sometimes have little or 
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no potential for patient harm they can be linked with mild to severe adverse drug events and 
adverse drug reactions. Adverse drug events and adverse drug reactions may also present when 
benzodiazepines are used in patients with certain comorbid conditions. These avoidable 
incidents can lead to patient discomfort, progression of disease state, visits to the emergency 
department, hospitalizations, and death.  
Misuse and abuse of benzodiazepines 
The misuse and abuse of benzodiazepines is a prevalent issue. According to the 2012 
National Survey of Drug Use and Health,104 the estimated number of incident benzodiazepine 
abusers was 166,000. National estimates of drug-related visits to emergency departments 
collected by the Drug Abuse Warning Network105 (DAWN) for the year 2011 reported that 
between 2004 and 2011 the number of emergency department visits for the non-medical use of 
benzodiazepines increased 149% from 143,500 to 357,800. Additionally, this report identified 
benzodiazepines as the second leading cause of all emergency department visits concerning 
nonmedical use of pharmaceuticals, as they were involved in 28.7% of all emergency 
department visits for this cause. Another recent study by Cai et al.106 examining data from 
DAWN between 2004 and 2008 reported that benzodiazepines were identified in approximately 
26% of all opioid related emergency department visits. These estimates suggest that 
benzodiazepine misuse and abuse can lead to serious adverse effects on individuals and caution 
must be exercised with their prescribing and use. 
It has been suggested that patterns of benzodiazepine misuse and abuse can be 
separated into two categories: deliberate and unintentional.15 Deliberate misuse and abuse of 
benzodiazepines entails taking the drug to achieve a euphoric effect, while unintentional misuse 
and abuse would include individuals with a valid prescription for the medication but take higher 
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than suggested doses or take it for a prolonged period of time.15 Oftentimes benzodiazepines 
are deliberately abused in combination with other drugs, most commonly alcohol and opioids,16 
in order to enhance the effect provided by other substances. For example, in a survey of 
methadone maintenance patients, 72% of those who were also regular benzodiazepine users 
indicated that benzodiazepines were used in order to increase the effects of their daily 
methadone dose.107 However, patients who are receiving methadone maintenance therapy and 
are also regular users of benzodiazepines experience a greater mean number of overdoses (3.3 
± 0.7) than occasional-users (1.8 ± 0.4) and non-users (0.7 ± 0.2; p=0.003).108 The co-use of 
benzodiazepines and opioids is also common among patients treated for chronic pain with 
surveys estimating between 40-60% of chronic pain patients also regularly using 
benzodiazepines.109 It is undetermined if chronic pain patients use benzodiazepines in order to 
enhance the pain relieving effects of opioids or to manage symptoms of anxiety and/or insomnia 
that frequently coexist with chronic pain.110,111 Despite the frequency of concurrent use, the 
combination of benzodiazepines and opioids can have detrimental effects on physical and 
mental health. With this in mind, physicians should be aware of patterns that may signal 
deliberate drug misuse and abuse in patients using one or both of these medications.  
Benzodiazepine use, mental illness, and substance use disorders 
 Among patients with severe mental illness, such as schizophrenia, bipolar disorder, and 
major depression, benzodiazepines are commonly prescribed to reduce symptoms of anxiety, 
insomnia, and agitation and to manage side effects of other medications.112,113 The use of 
benzodiazepines in patients with mental illness is a controversial practice due to the high 
prevalence of SUDs in this population coupled with the abuse potential of benzodiazepines. The 
2012 National Survey on Drug Use and Health found that 19.2% (8.4 million) of the 43.7 million 
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adults with any mental illness also met the criteria for a SUD as specified within the 4th edition of 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).114 Comparatively, only 6.4% 
(12.3 million) of adults without any mental illness were considered to have a SUD.114 Despite 
concerns, benzodiazepine use is highly prevalent among individuals with mental illness and co-
occurring SUDs.112,113 Clark, Xie, and Brunette112 reported that among Medicaid beneficiaries, 
the prevalence of benzodiazepine use is greater in patients with severe mental illness and co-
occurring SUDs than in patients with a severe mental illness alone. Wixson and Brouwer115 
found that in a privately insured population, males infected with HIV were more likely (OR: 1.68; 
95% CI: 1.05-2.67) to fill a benzodiazepine prescription compared to their uninfected 
counterparts. This finding is of notable concern as the HIV-infected population has high 
prevalence of mental illness and SUDs116 and substance abuse has been linked to poor 
antiretroviral therapy adherence.117 Furthermore, in patients with severe mental illness and co-
occurring SUDs benzodiazepine use did not improve symptoms of anxiety and depression.113 
These findings suggest that further research into the appropriateness of benzodiazepine use in 
mental illness patients with and without a co-occurring SUD is warranted due to concerns 
regarding efficacy and abuse potential. 
Benzodiazepines and adverse health outcomes 
 The use of benzodiazepines in certain clinically vulnerable populations carries a risk of 
negative effects on health outcomes. For example, studies examining patients with COPD have 
found evidence of a link between benzodiazepine use and several adverse respiratory outcomes 
such as decreased minute ventilation,118,119 low levels of oxygen and high levels of carbon 
dioxide in the blood,119,120 and a decrease in respiratory muscle strength.118 Moreover, joint 
American Thoracic Society/European Respiratory Society guidelines recommend that hypnotics 
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such as benzodiazepines not be used in patients with severe COPD.121 Despite these 
recommendations, a 2013 study by Vozoris et al.122 examining benzodiazepine use in older 
patients with COPD in Ontario found that new benzodiazepine use is common, occurring in 
roughly one-third of the study population. The study also found that incident benzodiazepine 
use was more common in patients with severe COPD than less severe COPD, suggesting that 
patients who are most at risk of experiencing an adverse event related to benzodiazepine use 
are the patients most likely to receive this medication class. New benzodiazepine use among the 
COPD population was also found to increase the risk for outpatient respiratory exacerbations 
(RR: 1.45; 95% CI: 1.36-1.54) and emergency department visits for COPD and pneumonia (RR: 
1.92; 95% CI 1.69-2.18) in a 2014 study conducted by Vozoris et al.123 A 2007 study by 
Winkelmayer and colleagues124 found a potential link between benzodiazepine use and an 
increased risk in mortality in patients with COPD.  
 The safety of benzodiazepines in the management of posttraumatic stress disorder has 
also been called into question. According to the Veterans Affairs (VA)/Department of Defense 
Clinical Practice Guideline for Management of Post-Traumatic Stress125 regular benzodiazepine 
use in the PTSD population is discouraged due to insufficient evidence supporting avoidance and 
dissociation symptom improvement and concerns of safety, especially respiratory depression 
and over-sedation when used concurrently with other drugs acting on the CNS. Instead, it is 
recommended that SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs) are used 
as first line pharmacotherapy agents for treating PTSD. Even with these guidelines, Hawkins et 
al.126 determined benzodiazepines were prescribed to nearly one-third (31%) of all VA patients 
diagnosed with PTSD in 2009. Their study examining the comparative safety of adjunct 
benzodiazepine therapy in addition to SSRIs/SNRIs versus SSRIs/SNRIs alone among VA patients 
diagnosed with PTSD found that compared with patients who only received SSRIs/SNRIs, those 
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who also concurrently used benzodiazepines had a significantly greater risk for a mental health 
hospitalization (adjusted hazard ratio (AHR): 1.87; 95% CI: 1.37-2.53) and for any hospitalization 
(AHR: 1.52; 95% CI: 1.16-2.00). The finding of increased adverse events in concurrent users of 
SSRIs/SNRIs and benzodiazepines supports the current guidelines discouraging benzodiazepine 
use for the management of PTSD due to safety concerns. 
Benzodiazepine use in the elderly 
 In an elderly population adverse drug events can lead to increases in morbidity, 
mortality, and hospitalizations.52,127 Often, such adverse events are associated with medications 
that are contraindicated for use in the elderly population. Benzodiazepines are identified by the 
Beer’s Criteria for Potentially Inappropriate Medication Use in Older Adults53 as one specific drug 
class that should be avoided in the elderly due to an increase of cognitive impairment, falls, and 
fractures. Furthermore, these guidelines state the quality of evidence for avoiding the use of 
benzodiazepines in the elderly is high and the strength of the recommendation is strong. The 
high quality of evidence means that consistent results have been found from well-designed and 
well-controlled studies, and the strong recommendation means the burden of the elderly 
population using this medication clearly outweighs the benefits. 
 Even though the recommendations against benzodiazepine use in the elderly exist, 
these drugs are still commonly prescribed in this population. It has been estimated that the 
prevalence of benzodiazepine use in the elderly ranges between 10-30%, significantly higher 
than the 2-5% prevalence ranges estimated in younger adults.128-131 A 2014 study conducted by 
Olfson et al.132 examining variations in rates of benzodiazepine use by age found the use of 
benzodiazepines, specifically long-term use defined as filling at least 120 days of supply during 
the study year of 2008, increases steadily with age. Of adults 65-80 years old, 31% were 
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identified as long-term benzodiazepine users compared to only 15% of those in the 18-35 age 
group.  
Several studies have been conducted investigating relationships between 
benzodiazepine use in elderly populations and adverse health outcomes. Evidence suggests that 
physiological changes associated with aging make the elderly population more susceptible to 
side effects associated with benzodiazepines.2 The use of benzodiazepines among elderly 
populations has been associated with an increased risk of cognitive and psychomotor 
impairment.  
 With an increasingly aging population, problems associated with cognitive impairment 
are a public health concern. Hanlon and colleagues133 suggested current benzodiazepine use 
among community-dwelling elderly is associated with poorer performance on cognitive 
functioning tests. Furthermore, the study results suggested a dose response and a duration 
response relationship where patients taking higher dosages or who had a longer duration of use 
displayed greater cognitive decline than non-users of benzodiazepines. Similar results were also 
reported by Paterniti et al.134 who found chronic benzodiazepine users had a significantly 
greater risk of cognitive decline than non-users (OR: 1.9; 95% CI: 1.0 – 3.5). In a large 
prospective study of elderly people in France, Billioti de Gage et al.135 associated new 
benzodiazepine use with an approximate 50% increase in the risk of dementia. Most recently, 
Billioti de Gage and colleagues136 reported any past benzodiazepine use was associated with an 
approximate 50% increase in the risk of Alzheimer’s disease among community dwelling 
individuals in Quebec. The risk was increased when long-acting benzodiazepines were primarily 
used and as the duration of exposure increased.  
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 Cutson et al.137 conducted a double blind study assessing the effects of benzodiazepines 
on the balance of healthy older adults and found that after taking a single dose of diazepam, 
processes related to balance control were adversely affected. Several epidemiologic studies 
have been published suggesting benzodiazepine use in the elderly is strongly associated with an 
increased risk for falls and fractures. Bayesian adjusted odds ratios from a meta-analysis by 
Woolcott et al.138 suggest benzodiazepine use among older individuals is associated with a 41% 
increase in the risk of falling. Furthermore, these falls are likely to be injurious, especially among 
individuals 80 years of age and older.139 Xing et al.140 conducted a meta-analysis examining the 
relationship between benzodiazepine use and risk of fractures in 18 studies where this 
relationship was investigated in an elderly population. Results of the meta-analysis suggest that 
benzodiazepine use in the elderly is associated with an overall relative risk of fractures of 1.26 
(95% CI: 1.15 – 1.38). Additionally, an analysis of VA databases by French et al.141 found a 
temporal association between outpatient benzodiazepine use and serious injuries resulting in 
inpatient stays, costing $2.89 million for 297 unique patients, and outpatient visits, costing 
$400,000 for 1,352 unique patients.141 Additionally, studies have shown an association between 
benzodiazepine use in the elderly and an increase in the relative risk of motor vehicle accidents 
in this population.142,143 
Benzodiazepine use in adolescents 
To date, few studies have assessed the use of benzodiazepines in adolescent 
populations. Traditionally, benzodiazepines have been used in adolescent populations with 
anxiety disorders, sleep disorders, psychosis, and aggression despite a lack of sound evidence 
indicating benzodiazepines are an effective treatment option in this population.144 In the United 
States the prescribing of CS to adolescents and children has nearly doubled over the previous 
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two decades.145 At the same time that CS prescribing for adolescents has been increasing so has 
the nonmedical use of benzodiazepines in this population.146 A recent study by McCabe and 
West147 estimated that high school seniors the lifetime prevalence of medical benzodiazepine 
use to be 4.3% and 7.5% for nonmedical benzodiazepine use. In two separate studies of 
students enrolled in Detroit metropolitan area public secondary schools, medical use of 
controlled medications, including benzodiazepines, was associated with an increased likelihood 
of nonmedical prescription drug use compared to students who had never received a 
prescription for a CS.148,149 Furthermore, the nonmedical use of benzodiazepines in adolescent 
populations is of significant concern as McCabe et al.150 linked earlier initiation of nonmedical 
benzodiazepine use to an increased risk of developing a SUD compared to those whose initial 
nonmedical benzodiazepine use is later in life.  
CONCLUSION 
 Benzodiazepines are an effective treatment option for many people suffering from a 
wide range of medical conditions including insomnia and anxiety. Due to the abuse liability of 
benzodiazepines and their synergistic effects when taken with other substances, clinicians 
should evaluate the benefits and risks of benzodiazepine therapy prior to prescribing in an effort 
to avoid medication misadventures associated with this drug class. The abuse liability of 
benzodiazepines has led to policies, most notably TPPs, and PDMPs, designed to monitor the 
distribution of benzodiazepines in an effort to reduce inappropriate use. Previous studies 
evaluating state monitoring programs suggest the supply of CS is drastically reduced upon 
implementation. However, the only studies evaluating the effect of state monitoring programs 
on benzodiazepine use focus on the New York TPP and the impact of current state PDMPs on 
benzodiazepine use is unknown. The available literature is also currently unable to definitively 
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evaluate the impact of prescription drug monitoring policies on health outcomes, an important 
aspect to determine the effect PDMPs have on inappropriate and legitimate benzodiazepine 
use. 
 Evaluations of health outcomes associated with benzodiazepine utilization in at-risk 
populations are warranted as many previous studies were conducted prior to the growth and 
notoriety of the prescription drug abuse epidemic. As a result, little is known about 
benzodiazepine use in populations at risk for SUDs. Furthermore, studies are needed to evaluate 
the use and safety of benzodiazepines in clinically vulnerable populations as inappropriate 
benzodiazepine use can increase the risk of medication misadventures involving adverse drug 
events and adverse drug reactions which can include increased healthcare resource utilization, 
morbidity, and mortality. Studies evaluating potentially inappropriate benzodiazepine use can 
help disseminate information regarding the effectiveness and suitability of benzodiazepines use 
in specific populations and thereby optimize health outcomes to the benefit of patients and 
society. 
 Motivated by the evidence suggesting medication misadventures pertaining to 
benzodiazepines are of significant concern, this dissertation will assess the issue in two clinically 
vulnerable populations (COPD and HIV) and examine the impact of a policy designed to mitigate 
their inappropriate use. The second chapter of this dissertation will examine the use of 
benzodiazepines in patients diagnosed with COPD and the risk of acute exacerbations requiring 
hospitalization. The objectives of this chapter will address the definition of a mediation 
misadventure by describing an iatrogenic hazard or incident created through by the 
administration of a medicine during which a patient may be harmed. Chapter 3 will determine 
whether individuals infected with HIV are more likely to fill a prescription for a benzodiazepine 
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compared to those who are uninfected with the disease. Additionally, Chapter 4 will continue 
the investigation pertaining to benzodiazepine use in the HIV infected population by examining 
whether individuals infected with HIV are more likely to engage in potentially problematic 
benzodiazepine use than their uninfected counterparts. In these two studies the inherent risk 
when medication therapy is indicated aspect of the medication misadventure definition will be 
addressed as the administration of benzodiazepines in the HIV infected population is 
controversial due to the abuse potential of the medication coupled with the high prevalence of 
SUDs in this population. In Chapter 5 the impact of a PDMP is evaluated using the example of 
South Carolina’s program implementation and the subsequent effect on benzodiazepine 
dispensing. Chapter 6 will further elaborate on the topic of PDMPs by assessing their impact on 
benzodiazepine dispensing using a nationwide sample. These chapters will address a policy that 
has been implemented by states to curtail problems associated with prescription drug abuse, 
which can lead to negative health outcomes that are always unexpected or undesirable to the 
patient and healthcare professional. Examples of unexpected or undesirable health outcomes as 
they pertain to prescription drug abuse include: tolerance and/or addiction, overdose, and 
fatality. At the same time, these studies evaluate the possibility that PDMPs may induce a 
‘chilling effect’ by limiting access to benzodiazepine therapy among patients who have a 
legitimate need for the medication. The inability of patients who have a legitimate need for a 
benzodiazepine to acquire it can lead to an iatrogenic hazard or incident that is created through 
the omission of a medication during which the patient may be harmed, another component of 
medication misadventures. 
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Table 1.1. List of benzodiazepines marketed in the United States as of January 2013. 
Generic Name 
Trade 
Names 
Dosage 
Forms 
Year on 
Market Indications 
Diazepam 
Milligram 
Equivalent 
(DME)7,151 
Alprazolam 
Niravam®;  
Xanax XR®; 
Xanax®   
Solution, 
Tablet 1981 
Treatment of generalized anxiety 
disorder (GAD); short-term relief 
of symptoms of anxiety; panic 
disorder, with or without 
agoraphobia; anxiety associated 
with depression 1 
Chlordiazepoxide 
Hydrochloride 
Librax®; 
Librium®; 
Limbitrol®; 
Limbitrol® 
DS  Capsule 1960 
Management of anxiety disorder 
or for the short-term relief of 
symptoms of anxiety; 
withdrawal symptoms of acute 
alcoholism; preoperative 
apprehension and anxiety 50 
Clobazam Onfi®  Tablet 2011 
Adjunctive treatment of seizures 
associated with Lennox-Gastaut 
syndrome 20 
Clonazepam 
Klonopin®; 
Klonopin® 
Wafers Tablet 1975 
Alone or as an adjunct in the 
treatment of petit mal variant 
(Lennox-Gastaut), akinetic, and 
myoclonic seizures; petit mal 
(absence) seizures unresponsive 
to succimides; panic disorder 
with or without agoraphobia 0.5 
Clorazepate 
Dipotassium 
GenXene®; 
Tranxene®  
T-TAB®  
Capsule, 
Tablet 1972 
Treatment of generalized anxiety 
disorder; management of 
ethanol withdrawal; adjunct 
anticonvulsant in management 
of partial seizures 15 
Diazepam 
Diastat® 
Rectal 
Delivery 
System; 
Valium®  
Gel, 
Injection, 
Solution, 
Tablet 1963 
Management of anxiety 
disorders; ethanol withdrawal 
symptoms; skeletal muscle 
relaxant; treatment of 
convulsive disorders; 
preoperative or preprocedural 
sedation and amnesia 
Rectal gel: management of 
selected, refractory epilepsy 
patients on stable regimens of 
antiepileptic drugs requiring 
intermittent use of diazepam to 
control episodes of increased 
seizure activity 10 
Estazolam ProSom® Tablet 1990 
Short-term management of 
insomnia 2 
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Table 1.1. List of benzodiazepines marketed in the United States as of January 2013 (cont’d). 
Flurazepam 
Hydrochloride Dalmane® Capsule 1970 
Short-term treatment of 
insomnia 30 
Lorazepam Ativan® 
Injection, 
Solution, 
Tablet 1977 
Oral: management of anxiety 
disorders or short-term (≤4 
months) relief of the symptoms 
of anxiety, anxiety associated 
with depressive symptoms, or 
insomnia due to anxiety or 
transient stress 
IV: status epileptics, anterograde 
amnesia, sedation 2 
Midazolam 
Hydrochloride Versed® Injection 1985 
Preoperative sedation; moderate 
sedation prior to diagnostic or 
radiographic procedures; ICU 
sedation (continuous infusion); 
induction and maintenance of 
general anesthesia 15 
Oxazepam Serax®  
Capsule, 
Tablet 1965 
Treatment of anxiety; 
management of ethanol 
withdrawal 30 
Quazepam Doral® Tablet 1985 Treatment of insomnia 15 
Temazepam Ristoril® Capsule 1981 
Short-term treatment of 
insomnia 20 
Triazolam Halcion® Tablet 1982 
Short-term generally (7-10 days) 
treatment of insomnia 0.25 
 
 
Table 1.2. Characteristics of benzodiazepine therapy and individual patients that influence 
withdrawal severity and inability to taper off the medication.44-46 
Characteristics of benzodiazepine therapy 
 Short half-life benzodiazepine 
 Higher benzodiazepine dosage 
 Longer duration of benzodiazepine therapy 
 Rapid taper 
Characteristics of individual patients 
 Female 
 Higher baseline levels of anxiety and depression 
 Higher level personality pathology 
 History of mild to moderate alcohol or drug abuse 
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Table 1.3. United States Schedule of controlled substances.55 
Schedule 
Definition of 
Controlled Substance Schedules Examples 
Schedule I 
No currently accepted medical use in the 
United States; lack of accepted safety for 
medical use; high potential for abuse 
Heroin; lysergic acid diethylamide 
(LSD); marijuana 
Schedule II 
High potential for abuse potentially leading 
to severe psychological or physical 
dependence 
Oxycodone; morphine; 
methamphetamine 
Schedule III 
Abuse potential is below that of Schedule I 
and II; abuse can lead to low to moderate 
physical dependence or high psychological 
dependence 
Combination products containing 
<15mg of hydrocodone per dosage 
unit; products containing <90mg 
codeine per dosage unit; 
buprenorphine 
Schedule IV 
Low potential for abuse compared to 
Schedule III All benzodiazepines; carisoprodol 
Schedule V 
Low potential for abuse compared to 
Schedule IV; primarily consists of 
substances containing limited quantities of 
certain narcotics 
Cough medications with ≤ 200mg 
codeine per 100ml/100g 
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Table 1.4. States with an operational prescription drug monitoring program and controlled 
substance Schedules monitored as of December 2014.80,83  
State 
Schedules Monitored 
 
 
Schedules Monitored 
II III IV V State II III IV V 
Alabama X X X X 
 
Nebraska X X X X 
Alaska X X X X 
 
Nevada X X X  
Arizona X X X 
  
New Hampshire X X X  
Arkansas X X X X 
 
New Jersey X X X X 
California X X X 
  
New Mexico X X X X 
Colorado X X X X 
 
New York X X X X 
Connecticut X X X X 
 
North Carolina X X X X 
Delaware X X X X 
 
North Dakota X X X X 
Florida X X X 
  
Ohio X X X X 
Georgia X X X X 
 
Oklahoma X X X X 
Hawaii X X X X 
 
Oregon X X X 
 Idaho X X X X 
 
Pennsylvania X 
   Illinois X X X X 
 
Rhode Island X X X 
 Indiana X X X X 
 
South Carolina X X X 
 Iowa X X X 
  
South Dakota X X X 
 Kansas X X X 
  
Tennessee X X X X 
Kentucky X X X X 
 
Texas X X X X 
Louisiana X X X X 
 
Utah X X X X 
Maine X X X 
  
Vermont X X X 
 Maryland X X X X 
 
Virginia X X X 
 Massachusetts X X X X 
 
Washington X X X X 
Michigan X X X X 
 
West Virginia X X X X 
Minnesota X X X 
  
Wisconsin X X X X 
Mississippi X X X X 
 
Wyoming X X X 
 Montana X X X X       
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CHAPTER 2: BENZODIAZEPINE USE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE AND THE RISK OF ACTUE EXACERBATIONS. 
INTRODUCTION 
 Chronic obstructive pulmonary disease (COPD) refers to lung diseases, mainly 
emphysema and chronic bronchitis, which obstruct air flow and interfere with normal patterns 
of breathing.152-154 Prevalence estimates suggest that 12.7 million adults in the US are afflicted 
with the disease.153 Currently, COPD results in more than 800,000 hospitalizations annually155 
and is the third leading cause of death in the United States.152,153 One of the trademarks of COPD 
is exacerbation, which is a sudden worsening of symptoms including shortness of breath or 
changes in the quantity and color of phlegm. Exacerbations typically occur in patients with COPD 
two to three times per year and their cause in largely unknown.155 
 Patients who suffer from COPD commonly experience symptoms related to insomnia,156-
159 anxiety and depression. Budhiraja et al.159 estimated the prevalence of chronic insomnia in 
the COPD population to be approximately 27%, greater than the 10% prevalence in the general 
population. Symptoms related to insomnia frequently reported by patients with COPD include 
difficulty falling asleep, trouble staying asleep, and an increased feeling of sleepiness during the 
day.156,160 Results from the Tucson Epidemiologic Study157 found more than 50% of patients with 
COPD experience sleep related difficulties and 25% an excessive feeling of daytime sleepiness. 
Additionally, studies have found a higher prevalence of anxiety and depression in patients 
diagnosed with COPD compared to the general population. Utilizing a case-control study design, 
Di Marco et al.161 estimated patients with COPD had a higher prevalence of anxiety (28% vs. 6%) 
and depression (19% vs. 6%) than controls without the disease. Kunik et al.162 found a 51% 
prevalence of anxiety and a 39% prevalence of depression in patients diagnosed with COPD 
 
 36 
receiving care through the Veteran’s Affairs system. These estimates exceed those of the 
general population: 18% for anxiety101 and 7% for depression.163 
Benzodiazepines are generally an effective pharmacological treatment option and are 
widely prescribed for the management of symptoms related to anxiety disorders and 
insomnia.11,103 Studies examining patients with COPD have found evidence of a link between 
benzodiazepine use and several adverse respiratory outcomes such as decreased minute 
ventilation,118,119 low levels of oxygen and high levels of carbon dioxide in the blood,119,120 and a 
decrease in respiratory muscle strength.118 Moreover, joint American Thoracic Society/European 
Respiratory Society guidelines recommend that hypnotics such as benzodiazepines not be used 
in patients with severe COPD.121  
To date there is little understanding regarding the impact benzodiazepine use on the 
risk of adverse respiratory outcomes among patients with COPD in the US. The current literature 
evaluating benzodiazepine use in this population relies on studies employing small sample sizes 
and patients with greater COPD severity. As a result, studies evaluating benzodiazepine use and 
their association with adverse respiratory outcomes at a population level are warranted. The 
goal of this research is to better understand how patients in the US with COPD are being treated 
when they have a psychiatric comorbid condition including anxiety, depression, and insomnia. 
This study will also provide clarity to concerns that the use of benzodiazepines in the COPD 
population may be associated with an elevated risk of adverse respiratory outcomes and thus 
impact the clinical care of these patients. The aims of this study are to estimate the prevalence 
of new benzodiazepine use among patients with COPD in the US and evaluate differences in the 
risk of acute exacerbations among patients with COPD who are identified as new users and 
nonusers of benzodiazepines. 
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METHODS 
This study employs a new user, retrospective cohort using medical and pharmacy claims 
obtained from a large private insurer for beneficiaries in all 50 states and Washington DC 
between January 1, 2007 and December 31, 2009. This claims database includes de-identified 
information regarding beneficiary socio-demographics and codes related to interactions with 
the healthcare system. Beneficiaries were considered for inclusion if they had continuous 
medical and pharmacy benefits coverage for the duration of the study period, had a diagnosis 
code in the medical claims data for chronic bronchitis (ICD-9 code: 491.xx) emphysema (492.xx), 
or chronic airway obstruction, not elsewhere classified (496.xx), did not have a diagnosis of 
asthma (493.xx excluding 493.2), were at least 40 years of age, and did not have a prescription 
drug claim for a benzodiazepine during the 180 days prior to the index date. 
Ascertainment of benzodiazepine use 
Benzodiazepine exposure was evaluated using dispensing records from a pharmacy 
claims database and identified through the use of national drug codes. Beneficiaries were 
considered to be an incident benzodiazepine user if they had a prescription drug claim for the 
medications consisting of alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, 
estazolam, flurazepam, lorazepam, midazolam, oxazepam, quazepam, temazepam, and trizolam 
following 180 days without a prescription drug claim for a benzodiazepine prior to the index 
date. The index date was defined as the date of the first prescription drug claim for a 
benzodiazepine following 180 days without a benzodiazepine prescription drug claim. Incident 
benzodiazepine use was only considered once during the study period, at the first occurrence, 
regardless if the beneficiary met the definition for incident benzodiazepine use multiple times.  
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Nonusers of benzodiazepines were identified based on not having a prescription drug 
claim for any of the benzodiazepine medications listed above. For these beneficiaries, index 
dates were randomly assigned based on the distribution of time to the first prescription drug 
claim for a benzodiazepine in those identified as incident benzodiazepine users. 
The follow-up time for each beneficiary started on the index date and was extended 
until the earliest of an acute COPD exacerbation, 30 days after the index date, or the end of the 
study period. This approach was intended to emulate an intention-to-treat analysis similar to 
that employed by randomized controlled trials. 
Propensity score matching 
To account for baseline differences in the severity of COPD and to estimate the effect of 
incident benzodiazepine use on the risk of acute exacerbations in the COPD population, users 
and non-users of benzodiazepines were matched using propensity score matching methods. The 
propensity score for each patient in the study population was estimated through logistic 
regression as the probability of initiating benzodiazepine therapy during the study period, based 
on demographic characteristics, index date, measures of general health, and healthcare 
utilization intensity. Matching was performed using the Greedy Matching algorithm164 without 
replacement and one-to-one and one-to-many matching methods were explored. 
Ascertainment of acute exacerbation 
 The outcome of interest was the occurrence of an acute COPD exacerbation within 30 
days following the index date. Acute exacerbations were identified in the medical claims 
database where the primary or admission diagnostic ICD-9 code was 491.21. Only the date of 
the first acute exacerbation within the 30-day follow-up timeframe after the index date was 
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utilized. The 30-day follow-up period was chosen as acute exacerbations related to 
benzodiazepine use were expected to occur relatively soon after their initiation. 
Statistical analysis 
 Baseline characteristics of benzodiazepine users and nonusers were compared before 
and after propensity score matching. Standardized differences were calculated to compare users 
and nonusers on all covariates before and after propensity score matching. The rates of 
experiencing an acute exacerbation within 30 days after the index date were estimated and 
compared using cumulative incidence function curves. Tests of equality of the cumulative 
function curves were performed using Gray’s method.165 Cox proportional hazard models 
estimated the hazard ratio (HR) and accompanying 95% confidence interval (CI) of experiencing 
an acute exacerbation associated with incident benzodiazepine use within 30 days after 
initiation. Sensitivity analyses were conducted to test the robustness of the results. For 
beneficiaries who did fill a benzodiazepine prescription during the study period, those whose 
prescription was for seven days or less were excluded to examine if the restriction of non-acute 
benzodiazepine use was associated with an increased risk in an acute exacerbation. Additionally, 
a second sensitivity analysis was conducted where beneficiaries were also matched on the 
number of claims for an acute exacerbation in the database. Data use was approved by the 
Institutional Review Board at the University of Kentucky. All statistical analyses were conducted 
using SAS 9.4 (SAS Institute Inc., Cary, NC). The a priori level of significance was set at 0.05. 
RESULTS 
 A total of 92,461 beneficiaries with COPD met the inclusion criteria (Figure 2.1). Of these 
15,723 (17.1%) were identified as incident benzodiazepine users. After propensity score 
matching 13,265 incident benzodiazepine users were matched to at least one benzodiazepine 
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nonuser. No propensity score match was found for 2,458 (15.6%) incident benzodiazepine users. 
Kernel density estimates of the propensity score distributions between the user and nonuser 
groups are shown in Figure 2.2a and Figure 2.2b. The distribution for the non-matched sample is 
depicted in Figure 2.2a while Figure 2.2b presents the matched sample. A comparison of 
baseline demographic and health characteristics between incident benzodiazepine users and 
nonusers is presented in Table 2.1. After matching incident benzodiazepine users and nonusers 
were well matched on all baseline characteristics with the exception of psychiatric disorders 
where the prevalence was greater among benzodiazepine users. Benzodiazepines are indicated 
and commonly prescribed for these conditions and to account for these observed differences 
the psychiatric disorders of anxiety, depression, and insomnia were considered in the hazard 
ratio calculation.  
 The logistic regression model used to derive propensity scores for the likelihood of 
initiating benzodiazepine therapy is presented in Table 2.2. The results indicate that among 
beneficiaries with COPD incident benzodiazepine use was more likely among females (AOR: 
1.34; 95% CI: 1.24, 1.39) and those diagnosed with anxiety (AOR: 5.21; 95% CI: 4.94, 5.49), 
depression (AOR: 1.61; 95% CI: 1.53, 1.70), or insomnia (AOR: 3.18; 95% CI: 2.97, 3.40). Those 
taking oral corticosteroids also had increased odds of incident benzodiazepine use (AOR: 1.28; 
95% CI: 1.20, 1.36). Beneficiaries were also more likely to be incident benzodiazepine users if 
they had a diagnosis for the comorbidities of other ischemic heart disease (AOR: 1.13; 95% CI: 
1.08, 1.19), cerebrovascular disease (AOR: 1.14; 95% CI: 1.08, 1.20), lung cancer (AOR: 1.67; 95% 
CI: 1.50, 1.85), cancers excluding lung cancer (AOR: 1.17; 95% CI: 1.12, 1.22), weight loss (AOR: 
1.12; 95% CI: 1.04, 1.22) or essential hypertension (AOR: 1.20; 95% CI: 1.02, 1.43). Beneficiaries 
with COPD who were black were less likely to be incident benzodiazepine users (AOR: 0.56; 95% 
CI: 0.52, 0.61). Additionally, increasing age was associated with a decreased likelihood of 
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incident benzodiazepine use (AOR: 0.98; 95% CI: 0.98, 0.98) as was a lower overall general 
health status as depicted by the Charlson Comorbidity Index (AOR: 0.69; 95% CI: 0.62, 0.71). 
 Prior to matching 148 (0.9%) of incident benzodiazepine users and 473 (0.4%) of 
nonusers had a claim for an acute exacerbation within 30 days of the index date. After matching 
127 (1.0%) of incident benzodiazepine users and 272 (0.6%) of nonusers had an acute 
exacerbation claim within 30 days of the index date. Results of the Cox proportional hazard 
model are shown in Table 2.3. Compared to nonusers, incident benzodiazepine users with COPD 
were at a 26% higher risk (HR: 1.26; 95% CI: 1.01, 1.57) for having a claim for an acute 
exacerbation within the 30 days following the index date. The cumulative incidence of acute 
exacerbations during the 30-day follow-up was determined to be greater for incident 
benzodiazepine users versus nonusers (p<0.01) beginning immediately after benzodiazepine 
initiation and continuing onwards (Figure 2.3).  
 The findings from the sensitivity analyses are presented in Table 2.3. The finding from 
the model only examining non-acute benzodiazepine use supported the findings of this study. 
When compared to nonusers, non-acute incident benzodiazepine users were at a statistically 
higher risk (HR: 1.28; 95% CI: 1.01, 1.63) of having a claim for an acute exacerbation within 30 
days of the index date. When all incident benzodiazepine users were considered but also 
matched on the number of claims for an acute exacerbation prior to the index date the 
association between incident benzodiazepine use and an acute exacerbation within 30 days was 
no longer statistically significant, however, the HR and most of the 95% CI were greater than 1 
(HR: 1.11; 95% CI: 0.89, 1.39). 
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DISCUSSIONS 
 This study of a nationally representative sample of privately insured adults in the US 
with COPD showed that incident benzodiazepine use was associated with an increased risk of an 
acute exacerbation within 30 days of initiation. Findings from the sensitivity analyses supported 
this finding. However, the point estimates were attenuated and were no longer statistically 
significant suggesting the presence of confounding and selection bias related to these factors. 
This observed association is consistent with previous finding that have reported a relationship 
between benzodiazepine use and adverse respiratory outcomes in the COPD population. Vozoris 
et al.123 recently evaluated the association between new benzodiazepine use and the risk of 
adverse health outcomes among older patients in Ontario with COPD. Their findings suggested 
that new benzodiazepine use is associated with a greater risk of outpatient respiratory 
exacerbations and emergency department visits for COPD or pneumonia. 
 An important finding in the present study was the observation that incident 
benzodiazepine use in the COPD population is common as we found it to occur in 17% of the 
study cohort despite American Thoracic Society/European Respiratory Society guidelines 
cautioning against their use.121 While this finding is less than that reported by Vozoris et al.122 
where new benzodiazepine use was found in roughly one-third of COPD patients, that study 
examined older patients with COPD and existing evidence demonstrates than benzodiazepines 
are more likely to be prescribed to older individuals.166  
 The results of the logistic regression model indicate that receipt of an oral corticosteroid 
prescription was associated with an increase in the odds of new benzodiazepine use. It is 
possible that receipt of an oral corticosteroid prescription may be related to an acute 
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exacerbation167 experienced in the outpatient setting where the patient did not utilize the 
healthcare system for treatment.   
This study found that new benzodiazepine use was associated with an increased risk of 
experiencing an acute exacerbation within 30 days of benzodiazepine initiation; however, the 
absolute risk was small, occurring in 0.9% of new benzodiazepine users and 0.4% of nonusers. 
Furthermore, the sensitivity analyses revealed selection and confounding by factors related to 
benzodiazepine use. Due to the high prevalence of COPD in the US, especially in states such as 
Kentucky and Alabama where the prevalence is estimated to be greater than 9%, this small risk 
is clinically important at the population level.   
 Limitations to this study exist. Due to the observational nature of this study an 
association between variables does not imply causality as unmeasured difference between the 
benzodiazepine user and nonuser groups may have influenced the findings. Secondly, as this 
study employs data for a privately insured, continuously enrolled cohort the overall COPD 
population may not be accurately represented. This study also could not account for 
benzodiazepine medications acquired outside the healthcare system of paid for out of pocket. 
Another potential limitation is that dispensed benzodiazepine prescriptions may not be 
equivalent to benzodiazepines consumed. Not all patients who experienced an acute 
exacerbation may have sought treatment from a healthcare provider and thus were not 
documented in the data, however, it is expected that no systematic differences existed between 
the user and nonuser groups in their propensity to access the healthcare system for this event 
and thus the results would not be influenced.  
 The findings of this study identify benzodiazepines as a potential risk factor associated 
with the occurrence of an acute exacerbation in a large sample of privately insured adults with 
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COPD. This highlights concerns regarding the potential misuse of benzodiazepines in clinically 
vulnerable populations, including those with COPD. Given that patients with COPD are often 
afflicted with symptoms related to anxiety, depression, and insomnia, which are commonly 
managed with benzodiazepines, the potential of experiencing an acute exacerbation should be 
considered in treatment decisions. Inappropriate benzodiazepine use, especially in clinically 
vulnerable populations, can lead to adverse drug event and adverse drug reactions, which are 
potentially avoidable. These can result in a dramatic negative effect on a patient’s health 
outcomes and quality of life. Based on the findings from this study further research is warranted 
regarding the relationship between benzodiazepine use in the COPD population, especially is it 
pertains to other COPD related health outcomes. 
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Table 2.1. Characteristics of benzodiazepine users and nonusers with COPD. 
 Before Matching  After Matching  
 Benzodiazepine users 
Benzodiazepine 
nonusers 
Std. 
Diffd 
Benzodiazepine 
users 
Benzodiazepine 
nonusers 
Std. 
Diffd 
Beneficiariesa 15,723 76,738  13,265 37,828  
COPD Exacerbation           
Acute exacerbation 
within 30 days of index 
date 
148 (0.9) 473 (0.4) 0.07 127 (1.0) 272 (0.7) 0.03 
Sex           
Male 7,294 (46.4) 43,594 (56.8)  6,273 (47.5) 19,133 (50.4) 0.00 
Female 8,429 (53.6) 33,142 (43.2) 0.21 6,992 (52.5) 18,695 (49.6) 0.00 
Age           
Median ageb (IQRc) 71 (66-77) 72 (67-78) -0.13 72 (67-78) 73 (68-78) -0.06 
Race           
White 12,806 (81.4) 59,790 (77.9) 0.11 11,932 (90.0) 33,871 (89.4) 0.01 
Black 877 (5.6) 7,069 (9.2) -0.15 847 (6.4) 2,598 (6.9) -0.02 
Other 523 (3.3) 2,191 (2.9) 0.03 486 (3.7) 1,359 (3.7) 0.00 
Psychiatric Disorder           
Anxiety 4,954 (31.5) 4,403 (5.7) 0.70 3,581 (27.0) 4,025 (10.6) 0.43 
Depression 4,516 (28.7) 8,177 (10.7) 0.47 3,439 (26.0) 6,588 (17.4) 0.21 
Insomnia 2,309 (14.7) 2,709 (3.5) 0.40 1,645 (12.5) 2,427 (6.4) 0.21 
Comorbidities           
Acute myocardial 
infarction 687 (4.4) 2,598 (3.4) 0.05 581 (4.4) 1,470 (3.9) 0.02 
Other ischemic heart 
disease 6,475 (41.2) 25,928 (33.8) 0.15 5,575 (42.0) 15,293 (40.0) 0.03 
Congestive heart failure 3,417 (21.7) 13,447 (17.5) 0.11 2,975 (22.5) 8,031 (21.0) 0.03 
Cerebrovascular disease 3,788 (24.1) 13,427 (17.5) 0.16 3,212 (24.3) 8,373 (22.2) 0.05 
Diabetes 5,724 (36.4) 25,533 (33.3) 0.07 4,970 (37.4) 13,994 (37.3) 0.01 
Lung cancer 750 (4.8) 1,885 (2.5) 0.12 587 (4.4) 1,468 (3.9) 0.03 
Cancers excluding lung 
cancer 6,371 (40.5) 25,129 (32.7) 0.16 5,310 (39.9) 14,662 (38.7) 0.03 
Cardiac arrhythmia 4,397 (28.0) 17,527 (22.8) 0.12 3,745 (28.4) 10,140 (26.7) 0.03 
Pulmonary circulation 
disorder 1,273 (8.1) 4,504 (5.9) 0.09 1,086 (8.1) 2,787 (7.4) 0.03 
Weight loss 1,187 (7.5) 3,783 (4.9) 0.11 954 (7.2) 2,296 (6.1) 0.05 
Essential hypertension 12,131 (77.2) 53,806 (70.1) 0.16 10,349 (78.1) 28,838 (76.0) 0.04 
Any hypertension 12,322 (78.4) 54,946 (71.6) 0.16 10,522 (79.4) 29,387 (77.4) 0.04 
Tobacco user 4,665 (30.0) 17,287 (22.5) 0.16 3,756 (28.2) 9,657 (25.7) 0.06 
Medications used           
Short/long acting β-
agonists 2,663 (16.9) 11,193 (14.6) 0.06 2,253 (17.0) 6,128 (16.4) 0.02 
Inhaled corticosteroids 2,373 (15.1) 9,388 (12.2) 0.08 1,957 (14.9) 5,386 (14.3) 0.01 
Oral corticosteroids 3,179 (20.2) 11,473 (15.0) 0.14 2,605 (19.8) 7,023 (18.7) 0.03 
Theophylline 103 (0.7) 347 (0.5) 0.03 90 (0.7) 234 (0.6) 0.01 
Healthcare utilization           
Median number of 
healthcare claims (IQRc) 26 (14-49) 22 (11-43) 0.11 27 (14-50) 26 (13-49) 0.01 
Median number of 
prescription claims 
(IQRc) 
51 (24-94) 44 (16-89) 0.11 53 (26-98) 53 (22-102) 0.00 
a Data are presented at n(%) unless otherwise noted 
b Median age assessed at index date 
c Interquartile range 
d A standardized difference of >0.10 is considered a potentially meaningful difference 
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Table 2.2. Propensity score model of incident benzodiazepine use. 
Variable Odds Ratio 95% Confidence Interval 
Year   
Index year1 1.05 1.02 1.09 
Sex   
Male Ref.  
Female 1.34 1.28 1.39 
Race   
White Ref.  
Black 0.56 0.52 0.61 
Other 1.04 0.93 1.15 
Age   
Age 0.98 0.98 0.98 
Psychiatric Disorder   
Anxiety 5.21 4.94 5.49 
Depression 1.61 1.53 1.70 
Insomnia 3.18 2.97 3.40 
COPD Medications   
Beta-agonists 0.96 0.90 1.03 
Inhaled corticosteroids 1.03 0.97 1.11 
Oral corticosteroids 1.28 1.20 1.36 
Theophylline 1.19 0.93 1.54 
Comorbidities   
Acute myocardial infarction 0.93 0.84 1.03 
Other ischemic heart disease 1.13 1.08 1.19 
Congestive heart failure 1.02 0.96 1.08 
Cerebrovascular disease 1.14 1.08 1.20 
Diabetes 0.99 0.94 1.03 
Lung cancer 1.67 1.50 1.85 
Cancers excluding lung cancer 1.17 1.12 1.22 
Cardiac arrhythmia 1.02 0.97 1.07 
Pulmonary circulation disorder 1.06 0.98 1.15 
Weight loss 1.12 1.04 1.22 
Essential hypertension 1.20 1.02 1.43 
Any hypertension 0.88 0.74 1.05 
Tobacco user 1.05 1.00 1.10 
Healthcare Utilization   
Total number of medical claims 1.00 1.00 1.00 
Total number of prescription claims 1.00 1.00 1.00 
General Health State   
Charlson Comorbidity Index 0.69 0.62 0.77 
1 Reference year is 2007    
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Table 2.3. Comparison of hazard ratios. 
Model 
Number of incident 
benzodiazepine users 
Number of outcomes 
among incident 
benzodiazepine users 
Number of non 
benzodiazepine 
users 
Number of acute 
exacerbation among non 
benzodiazepine users 
Hazard 
ratio 95% CI 
Study model 13,265 127 37,828 272 1.26 (1.01, 1.57) 
Matching on acute 
exacerbation 13,265 125  37,763 288 1.11 (0.89, 1.39) 
Elimination of acute 
benzodiazepine use 10,757 105 30,878 222 1.28 (1.01, 1.63) 
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Figure 2.1. Sample selection flow chart. 
 
 
 
 
 
 
 
 
Beneficiaries continuously enrolled between January 1, 2007 and December 31, 2009 
1,080,141 
Excluded: 
 1. Did not have COPD diagnosis 
  927,604 
 2. Had an asthma diagnosis 
  42,232 
 3. Under 40 years of age 
  1,436 
4. Prescription drug claim for benzodiazepine 
during 180 days prior to index date 
  16,284 
5. Acute exacerbation occurred on index date 
  124 
Study population before propensity score matching 
92,461 
Incident benzodiazepine users 
15,723 
Benzodiazepine nonusers 
76,738 
Incident benzodiazepine users after 
matching 
13,265 
Benzodiazepine nonusers after matching 
37,828 
Study population after propensity score matching 
51,093 
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Figure 2.2a. Propensity score distributions for incident benzodiazepine users and nonusers 
before propensity score matching. 
 
Figure 2.2b. Propensity score distributions for incident benzodiazepine users and nonusers 
after propensity score matching. 
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Figure 2.3. Cumulative incidence function curves for acute exacerbations among incident 
benzodiazepine users and nonusers occurring within 30 days of the index date.  
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CHAPTER 3: SEX DIFFERENCES IN BENZODIAZEPINE USE IN THE HIV-INFECTED POPULATION. 
INTRODUCTION 
The burden of psychiatric disorders in the HIV-infected population exceeds that of the 
general US population116,168 and the 12-month prevalence of psychiatric disorders is estimated 
at 48%.116 This estimate is nearly two times greater than the 26% prevalence rate estimated in 
the general population.101 The most commonly detected psychiatric disorders in the HIV-
infected population include major depression, dysthymia, and generalized anxiety disorder.116 
Additionally, patients who suffer from psychiatric disorders are likely afflicted with symptoms of 
insomnia.102 The estimated prevalence rate for anxiety disorders may be as high as 38%,169 32% 
for depression,116 and 78% for insomnia,170 in the HIV-infected population. Each of these 
estimates exceeds those of the general population: 18% for anxiety,101 7% for depression,163 and 
30% for insomnia.171 Managing symptoms of these comorbidities is especially important in HIV-
infected patients as they are associated with suboptimal adherence to antiretrovirals.117,168 High 
levels of adherence are necessary to achieve optimal viral load suppression and mitigate the 
development of drug-resistant HIV infection.172,173 
Benzodiazepines are the most frequently used psychotropic drug class,11 and are widely 
prescribed for the management of symptoms related to anxiety, insomnia, and depression.103,174 
Concerns exist regarding benzodiazepine use in the HIV-infected population due to potential 
interactions with antiretroviral therapy175,176. Moreover, due to their abuse/misuse potential, 
benzodiazepines are not recommended for patients with a substance abuse history, a common 
problem among the HIV-infected population.116 To date, few studies have compared the 
prevalence of benzodiazepine use in the HIV-infected and uninfected populations. Furthermore, 
no studies have examined benzodiazepine usage by sex despite evidence suggesting prevalence 
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rates of psychiatric disorders differ between males and females in the general and HIV-infected 
populations.163,177,178 The current study uses insurance claims data to examine whether HIV-
infected patients are more likely to fill a benzodiazepine prescription than uninfected patients 
and, investigate sex differences in the likelihood of filling a benzodiazepine prescription among 
HIV-infected and uninfected patients. 
METHODS 
We established a four state nationally representative, population-based cohort using 
data from a large private insurance claims database from January 2007 to December 2009. This 
claims database includes patient socio-demographics and codes related to interactions with the 
healthcare system. Beneficiaries were included if they resided in Kentucky, Maryland, North 
Carolina, or Washington, were between 19 and 64 years of age, and had at least one healthcare 
claim in 2007 followed by a subsequent claim in either 2008 or 2009. Beneficiaries were 
identified as HIV-positive if they had at least one healthcare claim in 2007 with the ICD-9 code 
‘042’ (Human Immunodeficiency Virus (HIV) disease). The outcome of interest was filling a 
benzodiazepine prescription. Benzodiazepine fills during the study period were represented by a 
claim for any benzodiazepine identified using national drug codes. We considered the following 
covariates assessed in the year 2007: sex, age, race, education, state of residence, continuous 
insurance enrollment, substance abuse treatment (e.g. residential or non-residential treatment 
facility), and psychiatric disorders. Bivariate analysis examined the association between HIV-
infection and benzodiazepine use. Multivariate logistic regression models adjusted for 
covariates identified above were used to estimate the adjusted odds ratio (AOR) of filling a 
benzodiazepine prescription for HIV-infected patients. We examined the presence of interaction 
between HIV-infection and the covariates using backwards elimination. Statistical significance 
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was considered using the Wald χ2 p-value associated with the interaction term as well as 
clinically meaningful differences by comparing stratum specific odds ratios. Data use was 
approved by the XXXXX Institutional Review Board. Statistical analysis was conducted using 
Stata 12.0 (StataCorp., College Station, TX). 
RESULTS 
A total of 323,902 beneficiaries met the inclusion criteria for this study. Of these 
beneficiaries 106 were excluded due to duplicate or conflicting information. Overall, our study 
cohort consisted of 323,796 beneficiaries, 723 were identified as HIV-infected. Baseline 
characteristics and benzodiazepine utilization for HIV-infected and uninfected patients are 
shown in Table 1. Compared to the uninfected population the HIV-infected population had a 
greater proportion of men (80% versus 44%) and blacks (21% versus 7%). The HIV-infected 
population also had a greater proportion of patients with a diagnosis of depression (12% versus 
8%) or insomnia (6% versus 3%). We observed a greater proportion of HIV-infected patients 
filled a benzodiazepine prescription during the study period (24% versus 19%) with alprazolam, 
diazepam, and lorazepam being the most commonly filled benzodiazepines. 
Figure 1 shows the AOR of filling a benzodiazepine prescription for HIV-infected patients 
stratified by sex relative to the overall estimate of HIV-infected patients. The overall AOR 
demonstrates that without stratifying by sex, HIV-infected patients have 1.68 times greater odds 
of filling a benzodiazepine prescription than uninfected patients (95% CI: 1.39, 2.02). When 
stratified by sex, results from the multivariate regression showed HIV-infected males are 1.68 
times more likely to fill a benzodiazepine prescription than uninfected males, adjusting for 
covariates (95% CI: 1.05, 2.67), while no statistical difference was observed between HIV-
infected and uninfected females (AOR: 1.12, 95% CI: 0.73, 1.70). Interaction between HIV-
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infection and age, race, education, substance abuse treatment, and psychiatric disorders was 
considered but statistical significance was not achieved at the 0.05 level nor were there any 
clinically meaningful differences between the strata. 
In the overall population the likelihood of filing a benzodiazepine prescription is 
influenced by the patient’s age, sex, and race, along with treatment for substance abuse and 
psychiatric disorder diagnosis. With each additional ten years patients age, their odds of filling a 
benzodiazepine prescription increase 21% (AOR: 1.21, 95% CI: 1.20, 1.22). Additionally, males 
are less likely than females (AOR: 0.62, 95% CI: 0.61, 0.63) and nonwhite patients are less likely 
than white patients to fill a benzodiazepine prescription (AOR: 0.72, 95% CI: 0.70, 0.74). 
Furthermore, treatment for substance abuse (AOR: 1.27, 95% CI: 1.14, 1.42), or having a 
diagnosis of anxiety (AOR: 5.99, 95% CI: 5.81, 6.18), depression (AOR: 2.48, 95% CI: 2.42, 2.56), 
or insomnia (AOR: 2.78, 95% CI: 2.65, 2.90) increase the odds of filling a benzodiazepine 
prescription. 
DISCUSSIONS 
This study demonstrates that HIV-infected patients are more likely to fill a 
benzodiazepine prescription than uninfected patients.  Furthermore, we show HIV-infected 
males are more likely than uninfected males to fill a benzodiazepine prescription, with no 
observed difference between HIV-infected and uninfected females. This difference is notable as 
concerns exist regarding benzodiazepine use in the HIV-infected population due to their high 
abuse/misuse potential and the link between substance abuse and poor medication 
adherence.179,180 
The overall difference in the odds of filling a benzodiazepine prescription between HIV-
infected and uninfected patients may be related to the high prevalence of psychiatric disorders 
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in this population.116 However, we adjusted for these conditions in our models suggesting 
additional factors shown to be associated with benzodiazepine use in this population and not 
captured within claims data, such as exposure to stressful events related to HIV serostatus and 
disclosure,181 may explain the differences in benzodiazepine use between the HIV-infected and 
uninfected populations. The high prevalence of substance abuse and dependence in the HIV-
infected population116 should also be considered as an explanation of the observed differences 
in benzodiazepine use. Few studies have compared benzodiazepine use in the HIV-infected and 
uninfected populations and to our knowledge, this study is the first to examine differences in 
receipt of benzodiazepines by sex. Roux et al.181 investigated factors associated with regular 
benzodiazepine use in HIV-infected patients but as this study included HIV-infected patients 
only, comparisons to the uninfected population were not made.  
Reasons for observed differences between males and females in our study may be 
related to underlying differences in the prevalence of psychiatric disorders, differences in 
stigmatization, as well as differences in overall health care utilization between HIV-infected men 
and women. Lopes et al.177 showed HIV-infected men were more likely than uninfected men to 
have a specific DSM-IV diagnosis with no observed differences among women. Our results 
support these findings as we found HIV-infected men more likely than uninfected men to fill a 
benzodiazepine prescription, with no observable differences between women. Additionally, 
Roux et al.181 found that individuals belonging to the injecting drug use (IDU) and men who have 
sex with men (MSM) HIV-transmission groups were more likely than their heterosexual HIV-
transmission group counterparts to report regular benzodiazepine use. This finding is likely 
associated with IDUs and MSM group members perceiving and facing greater discrimination and 
stigmatization.182 Evidence exists of differences in healthcare utilization between HIV-infected 
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men and women. Hellinger and Encinosager183 found HIV-infected men were more likely than 
HIV-infected women to receive antiretroviral therapy and costlier medications. 
Limitations to this study exist. First, this study uses data from a private insurance claims 
database for four states, and may not accurately represent the overall HIV-infected or 
uninfected populations. Also, this study does not account for the number of benzodiazepine 
prescriptions filled or the quantity and dosages of those prescriptions. Additionally, we cannot 
account for prescriptions acquired through family and friends or paid for using cash. Finally, 
while our results show HIV-infected patients are more likely to fill a benzodiazepine 
prescription, we did not differentiate between appropriate and inappropriate use.  
Despite these limitations, our findings demonstrate HIV-infected patients, especially 
HIV-infected males, are more likely to use benzodiazepines. Our findings, in combination with 
evidence demonstrating sex differences in psychiatric disorders, show the need for further 
research evaluating reasons for observed differences. Furthermore, intervention studies 
targeting this at-risk population to reduce the risk of substance abuse and improve HIV clinical 
care are warranted. 
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Table 3.1. Comparison of demographics of HIV-infected and HIV-uninfected patients. 
 
 
HIV 
N=723 
HIV-uninfected 
N = 323,073 
 
p-value 
Variables n % n %  
Benzodiazepine Usage      
 Filled Benzodiazepine Prescription 174 24% 60,420 19% < 0.001 
State of Residence      
 Kentucky 67 9% 36,698 11% 0.077 
 Maryland 193 27% 59,635 18% < 0.001 
 North Carolina 339 47% 177,680 55% < 0.001 
 Washington 124 17% 49,060 15% 0.141 
Sex      
 Male 578 80% 140,605 44% < 0.001 
Age      
 Mean Age (for year 2007), SDa 43.02 8.83 41.98 11.46 0.015 
Race      
 White 483 67% 255,735 79% < 0.001 
 Black 155 21% 23,085 7% < 0.001 
 Hispanic 32 4% 11,501 4% 0.209 
 Other 49 7% 29,917 9% 0.021 
Education      
 Less than High School 6 1% 2,023 1% 0.488 
 High School Graduate 237 33% 112,330 35% 0.262 
 Some College 345 48% 139,963 43% 0.017 
 College Graduate 118 16% 60,340 19% 0.104 
Psychiatric Diagnosis      
 Anxiety 47 7% 21,386 7% 0.989 
 Depression 84 12% 26,026 8% < 0.001 
 Insomnia 44 6% 9,973 3% < 0.001 
Substance Abuse Treatment      
 Receiving Substance Abuse 
Treatment 
5 1% 1,941 1% 0.752 
Enrollment Eligibility      
 Continuously Eligible 284 39% 145,518 45% 0.002 
 Gaps in Coverage 439 61% 177,555 55% 0.002 
aSD: Standard Deviation    
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Figure 3.1. Likelihood of filling a benzodiazepine prescription among HIV-infected individuals compared to HIV-uninfected individuals 
stratified by sex. 
 
aAdjusted for state of residence, age, race, education, and enrollment eligibility (e.g. continuous insurance coverage, gaps in insurance 
coverage).  
bCI: Confidence Interval.  
Copyright © Sarah Elizabeth Wixson 2015 
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CHAPTER 4: PROBLEMATIC BENZODIAZEPINE USE AMONG COMMERCIALLY INSURED HIV-
INFECTED INDIVIDUALS IN THE UNITED STATES.  
INTRODUCTION 
The misuse of prescription medications is a growing public health concern in the United 
States. Results from the 2013 National Survey on Drug Use and Health184 found that prescription 
drug misuse is the second most prevalent drug problem in the United States trailing only 
marijuana. Prescription medications, including benzodiazepines, prescribed for the management 
of symptoms related to anxiety, depression, and insomnia, are increasingly being misused by 
patients who take them long-term or in larger than prescribed doses. National estimates of 
drug-related visits to emergency departments collected by the Drug Abuse Warning Network105 
(DAWN) for the year 2011 reported that between 2004 and 2011 the number of emergency 
department visits for the non-medical use of benzodiazepines increased 149% from 143,500 to 
357,800 visits. The DAWN report also identified benzodiazepines as being involved in 29% of all 
emergency department visits concerning the nonmedical use of pharmaceuticals, trailing only 
opioids analgesics. These estimates suggest that benzodiazepine misuse can lead to serious 
adverse effects and caution must be exercised regarding their prescribing and use. 
Existing evidence suggests that HIV-infected individuals are often afflicted with 
psychiatric comorbidities that are associated with prescription drug misuse.53,185,186 A screening 
of a nationally representative sample of HIV-infected patients in the United States estimated 
approximately one-half have a diagnosable psychiatric disorder.116 Managing symptoms of these 
conditions is important as they are associated with a lower quality of life and suboptimal 
adherence to antiretroviral therapy.117,187 Symptom management is frequently accomplished 
through the prescribing and use of benzodiazepines. In the HIV-infected population the use of 
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benzodiazepines is controversial due to the high prevalence of substance use disorders in this 
population coupled with the abuse potential of benzodiazepines. Despite this, benzodiazepine 
use is highly prevalent among HIV-infected individuals. Vitello et al.188 utilized the HIV Cost and 
Services Utilization Study (HCSUS) and found nearly one-quarter of HIV-infected patients with a 
co-occurring mental disorder reported benzodiazepine use. Wixson and Brouwer115 found that 
in a privately insured population HIV infection was associated with a 68% increase in the odds of 
filling a benzodiazepine prescription relative to those uninfected. In a survey of HIV-infected 
patients conducted in France, Roux et al.181 found regular benzodiazepine use in 16% of 
patients. Furthermore, results from this study determined that psychosocial factors, including 
disclosure of HIV status, are predictors of regular benzodiazepine use.  
Prescription drug misuse is a common problem in the HIV-infected population. A survey 
conducted by Newville, Roley and Sorensen189 of HIV-infected patients receiving antiretroviral 
therapy at a San Francisco hospital found 11% of patients acknowledged misuse of prescription 
medications. Most of the literature examining prescription drug misuse in the HIV-infected 
population has primarily focused on opioid analgesics. Hansen et al.190 found a high prevalence 
of opioid analgesic misuse in a homeless and marginally housed sample of HIV-infected adults in 
San Francisco. Silverberg et al.191 determined that long-term prevalent prescription opioid use, 
defined as longer than 90 days and associated with a greater than 120 total days’ supply, or ten 
or more dispensed prescriptions in a year, was more common among individuals infected with 
HIV compared to those uninfected. An analysis of the HCSUS database by Tsao et al.192 showed 
increased rates of opioid misuse in patients having a history of problematic substance use. 
Likewise, Robinson-Papp et al.193 found an association between problematic opioid use and 
having a history of a substance use or dependence disorder. This study also demonstrated that a 
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current psychiatric disorder and poor antiretroviral adherence were linked to problematic opioid 
use.  
 While previous studies examining prescription drug misuse in the HIV-infected 
population have concentrated on opioid analgesics, this study focuses on the potentially 
problematic use of benzodiazepine medications. Potentially problematic benzodiazepine use 
describes instances when the medication may be used in a manner that has not been proven 
effective or may lead to patient harm. One measure of potentially problematic benzodiazepine 
use involves long-term continuous use exceeding 120 days duration. As their long-term (> 120 
days) anxiolytic efficacy has not been evaluated, benzodiazepines are only recommended for 
short-term use, with the exception of managing symptoms related to panic or seizure disorders 
in some patients.2 Additionally, long-term benzodiazepine use carries the risk of increasing 
tolerance to the drug’s effects and the development of dependence.28,35 Another measure of 
potentially problematic benzodiazepine use involves excessive daily dosages that are greater 
than 40 diazepam milligram equivalents (DME) per day. Current guidelines regarding the dosing 
of benzodiazepines in adults under 65 years of age recommend 20 DME per day as the 
maximum daily dose.194 An expert panel has defined high daily dosage of benzodiazepines 
indicating potentially problematic benzodiazepine use as doses greater than two-times the 
recommended daily maximum (i.e. 40 DME).65 Concurrent use of prescription benzodiazepine 
and prescription opioid medications for non-acute purposes also constitutes potentially 
problematic benzodiazepine use. Rarely are benzodiazepines the preferred or sole drug of 
abuse; instead abuse commonly occurs in conjunction with another substance, often opioids.16 
Clinical evidence shows that benzodiazepines and opioids, when used concurrently exert a 
synergistic effect by increasing the rewarding and reinforcing effects of opioids.17-23 Other 
measures of potentially problematic benzodiazepine use include doctor shopping and pharmacy 
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hopping. Doctor shopping depicts a pattern of visiting multiple prescribers to obtain 
prescriptions for a controlled substance (CS) medication95,195 and pharmacy hopping describes a 
pattern of having CS prescriptions filled at multiple pharmacies.196 Each of these measures has 
previously been found to be associated with problematic prescription drug use.197 
The aims of this study are to estimate the prevalence of potentially problematic 
benzodiazepine use in a commercially insured population of HIV-infected adults and, determine 
if HIV-infection is associated with an increased risk of potentially problematic benzodiazepine 
use. In addition, this study evaluated differences in patient characteristics including sex, age, 
race, education, presence of a psychiatric disorder, and substance use history on the likelihood 
of potentially problematic benzodiazepine use among HIV-infected and uninfected patients. 
METHODS 
 This study utilized data from a population-based cohort of privately insured 
beneficiaries from all 50 states and the District of Columbia from January 2007 through 
December 2009. Beneficiaries were included in the study cohort if they were between the ages 
of 19 and 64 throughout the study period, resided in the same state the entire duration of the 
study period, had at least one healthcare claim in 2007 followed by a subsequent claim in either 
2008 or 2009, and had a claim for a least one benzodiazepine prescription during the study 
period regardless of quantity, days’ supply, or dosage form. Benzodiazepine fills during the study 
period were identified using national drug codes for the medications consisting of alprazolam, 
chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, 
midazolam, oxazepam, quazepam, temazepam, and triazolam. HIV-infection among 
beneficiaries was identified if they had at least one healthcare claim in 2007 in any position for 
HIV-infection (ICD-9 code: ‘042’). The outcome of interest was potentially problematic 
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benzodiazepine use. The following covariates were assessed during the first year of observation: 
sex, age, race, education, state of residence, substance abuse treatment (e.g. residential or 
nonresidential treatment facility), psychiatric disorders, and alcohol abuse.  
 Measures of potentially problematic benzodiazepine use were identified through 
reviews of the literature65 and discussions with academic pharmacists. The measures employed 
in this study include: duration of benzodiazepine use exceeding 120 consecutive days, daily 
dosages greater than 40 DMEs, having filled a prescription for an opioid medication for a 
duration exceeding seven days during a benzodiazepine episode, having a benzodiazepine 
prescription written by a minimum of four different prescribers during the study period, and 
filling a benzodiazepine prescription at a minimum of four different pharmacies during the study 
period. The duration of a benzodiazepine episode was defined as a chronological sequence of 
benzodiazepine dispensing with a break of no more than seven days between the end date of 
the prescription and the subsequent benzodiazepine prescription fill. The end date of a 
prescription was calculated by taking the fill date of the prescription and adding to it the days’ 
supply of that prescription. For each benzodiazepine prescription DMEs per day were calculated 
based on equivalency rates proposed by Shader et al.7 and The American Pharmacists 
Association.151 Conversion to DME dosages allowed for therapeutic comparisons between each 
benzodiazepine dispensed. To calculate the per day dosage the equivalency rates were 
multiplied by the quantity and strength of the prescribed benzodiazepine and then divided by 
the total days’ supply. Prescription opioid fills were identified through the use of national drug 
codes. The dispensing of an opioid medication where the days supply was less than or equal to 
seven days were not considered as short-term concurrent benzodiazepine and opioid use may 
be appropriate (i.e. opioid use for the management of acute pain in a person taking 
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benzodiazepines to manage symptoms of a psychiatric disorder). Individual prescribers and 
pharmacies were identified using unique identifiers within the database. 
The distributions of baseline covariates between the HIV-infected and uninfected 
samples were examined. Bivariate analyses tested the association between HIV-infection and 
potentially problematic benzodiazepine use defined by the measures above. Multivariate logistic 
regression models adjusted for covariates were used to estimate the adjusted odds ratio (AOR) 
of potentially problematic benzodiazepine use for HIV-infected patients. The covariates 
described previously were added to the multivariate model based on their bivariate association 
with potentially problematic benzodiazepine use and were operationalized as categorical 
variables. Age was segregated into two categories, ages 19 to 44 years and 45 to 64 years, based 
on the mean age of the study population years. Race was divided into two categories, white and 
nonwhite. The nonwhite category was comprised of beneficiaries identified in the claims data as 
black, Hispanic, or other. Education was separated into two categories: high school graduate or 
less and more than high school education. Effect modification between HIV and the covariates 
was examined using the Breslow-Day test and added to the model based on clinically 
meaningful differences between the stratums. Data use was approved by the University of 
Kentucky Institutional Review Board. Statistical analyses were conducted using SAS 9.4 (SAS 
Institute, Cary, NC). Statistical significance was set a priori at the 0.05 level. 
RESULTS 
 A total of 835,025 beneficiaries met the inclusion criteria for this study. Of these 
beneficiaries, 3,555 were excluded due to duplicate information (i.e., multiple states of 
residence, conflicting years of birth), 181 were excluded because they resided outside the US at 
some point during the study period, and eight were excluded due to incomplete benzodiazepine 
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dispensing information. Overall, the study cohort consisted of 831,281 beneficiaries with 3,447 
identified as HIV-infected. Baseline characteristics of the HIV-infected and uninfected 
populations are presented in Table 4.1. Compared to the uninfected population the HIV-infected 
population had a greater proportion of males (84% vs. 32%) blacks (8% vs. 4%) Hispanics (11% 
vs. 7%). The HIV-infected population also had a greater proportion of beneficiaries with a 
diagnosis of depression (24% vs. 20%) and insomnia (11% vs. 8%) compared to those uninfected 
with HIV.  
 At least one indicator of potentially problematic benzodiazepine use was found in 45% 
of HIV-infected patients and 31% of uninfected patients (Figure 4.1). Of these indicators, long-
term continuous use exceeding 120 days duration was the most common measure of potentially 
problematic benzodiazepine use and was observed in 28% of HIV-infected patients compared to 
16% of uninfected patients. Patients infected with HIV also were more likely than their 
uninfected counterparts to have benzodiazepine prescriptions written by at least four different 
providers (10% vs. 7%), filled by at least four different pharmacies (6% vs. 3%), have the daily 
dosage exceed 40 DMEs (7% vs. 5%), and have non-acute opioid use during a benzodiazepine 
episode (25% vs. 19%). 
Results from the multivariate model suggest differences in the likelihood of potentially 
problematic benzodiazepine use by any measure between the HIV-infected and uninfected 
populations stratified by level of education and the presence of a depression or insomnia 
diagnosis (Figure 4.2). In this model HIV-infection alone was associated with a significant 
increase in the odds of potentially problematic benzodiazepine use by any measure (AOR: 1.32; 
95% CI: 1.20, 1.45). Stratum-specific results show that HIV-infected patients with less education 
(i.e. high school graduate or less) were 1.37 times more likely (95% CI: 1.20, 1.56) to have 
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potentially problematic benzodiazepine use compared to HIV-infected patients who had more 
than a high school education while in the uninfected population those with less education were 
less likely to have potentially problematic benzodiazepine use (AOR: 0.76; 95% CI: 0.76, 0.77). 
Results show that in both the HIV-infected and uninfected populations having received a 
diagnosis of depression was associated with an increased likelihood of potentially problematic 
benzodiazepine use, however, in the HIV-infected population the likelihood was greater than 
that observed in the uninfected population. HIV-infected patients who had received a 
depression diagnosis were twice as likely (AOR: 1.99; 95% CI: 1.71, 2.32) to have potentially 
problematic benzodiazepine use than HIV-infected patients without a depression diagnosis 
while in the uninfected population those who received a diagnosis of depression, compared to 
those without, were only 20% more likely (AOR: 1.20; 95% CI: 1.18, 1.21) to have potentially 
problematic benzodiazepine use. Having been diagnosed with insomnia was also found to 
increase the likelihood of potentially problematic benzodiazepine use in the HIV-infected and 
uninfected populations. In the HIV-infected population a diagnosis of insomnia was associated 
with an 87% increase (AOR: 1.87; 95% CI: 1.49, 2.35) in the likelihood of potentially problematic 
benzodiazepine use but in the uninfected population a diagnosis of insomnia was only 
associated with a 23% increase in the odds (AOR: 1.23; 95% CI: 1.21, 1.25). 
DISCUSSIONS 
 To our knowledge this is the first study to examine potentially problematic 
benzodiazepine use in the HIV-infected population. The present study demonstrates that HIV 
infection is associated with an increase in the likelihood of potentially problematic 
benzodiazepine use. Furthermore, among the HIV-infected population those with less education 
or who were diagnosed with depression or insomnia were more likely to display signs of 
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potentially problematic benzodiazepine use compared to those with more education or absent a 
depression diagnosis. In the uninfected population lower education was associated with a 
decrease in the odds of potentially problematic benzodiazepine use, and even though having 
received a diagnosis of depression or insomnia was associated with an increase in the likelihood 
of potentially problematic benzodiazepine use it was not as great as the association observed in 
the HIV-infected population. The observed findings are notable as concerns exist regarding 
benzodiazepine use in the HIV-infected population due to their high abuse/misuse potential. 
Substance abuse has been linked to poor adherence of antiretroviral therapy179,180 and 
problematic benzodiazepine use may lead to increases in the cost of treating the HIV-infected 
population and poor clinical outcomes. 
 Reasons for the observed finding of HIV-infection being a risk factor of potentially 
problematic benzodiazepine use may be related to the high prevalence of substance abuse in 
this population. Evidence also suggests that chronic pain is undertreated among HIV-infected 
patients as physicians may have a difficult time managing chronic pain in HIV-infected patients 
due to the high prevalence of substance abuse concerns.198-200 As a result of undertreated pain, 
HIV-infected patients may seek pain relief by concurrently taking benzodiazepines with opioid 
analgesics in an effort to enhance the pain relieving effects of opioids. Our finding that one 
quarter of HIV-infected patients had evidence of non-acute opioid use during a benzodiazepine 
episode lends support to this explanation; however, it is not possible to ascertain the reasons 
for the concurrent use. 
 This study also found that HIV-infected patients with less education were more likely 
that their more educated counterparts to have potentially problematic benzodiazepine use 
while the reverse was found in the uninfected population where less educated patients had a 
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decreased likelihood of potentially problematic benzodiazepine use. Lower educational 
attainment has been shown to be associated with both prescription drug misuse201 and HIV-
infection.202 The increased odds of potentially problematic benzodiazepine use among those 
with less education in the HIV-infected population may be explained by links that have been 
shown to exist between education and health related quality of life. Murri et al.203 showed that 
lower education levels were associated with poorer mental health where symptom 
management may involve benzodiazepine use. Lower education levels may also lead to 
difficulties in understanding complex HIV treatment regimens that may cause additional stress 
and anxiety for the patient.203 
 The differences in the odds of potentially problematic benzodiazepine use between the 
HIV-infected and uninfected populations based on the presences of depression may be related 
to demographic or behavioral factors that are unable to be captured in the claims data (i.e., HIV-
related stigmas, psychosocial burdens, and the overall encumbrance of being HIV-infected). 
Surveys using a sample of the general US population found that men who have sex with men 
and injecting drug users perceive and face a greater degree of discrimination and stigmatization 
associated with their HIV serostatus.182 The level of social support has also been found to be 
directly related to depressive symptoms experienced by patients infected with HIV.204 Another 
possible explanation is HIV-infected patients with depression may be more concerned about 
their health status and life expectancy thus making them more likely to engage with treatment 
providers who monitor their medications205 leading to increased opportunities to acquire a 
benzodiazepine prescription. Benzodiazepines are not specifically indicated for the management 
of depression however, anxiety, a condition for which benzodiazepines are indicated, is 
associated with depressive symptoms.116 
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 In the HIV-infected population managing symptoms related to insomnia is important as 
they have been linked with adverse effects on the immune system206 and medication 
adherence,207,208 both which can impact disease outcomes. This may offer explanation to the 
finding that among HIV-infected individuals those diagnosed with insomnia were more likely 
than those without to have at least one indicator of potentially problematic benzodiazepine use. 
Estimates of the rate of sleep disturbances in the HIV-infected population vary widely (29-
97%)209 but mostly exceed that estimated in the general population (33%).210 Existing evidences 
also points to a direct relationship between sleep disturbances and advanced HIV disease 
stage211-213 and longer duration of HIV-infection.206,209,214 Furthermore, a relationship between 
antiretroviral therapy, specifically nonnucleoside reverse transcriptase inhibitor (NNRTI), and 
sleep disturbances has been shown in several studies.215-217 These previous studies may provide 
explanation for the finding that in the HIV-infected population the likelihood of potentially 
problematic benzodiazepine use among those diagnosed with insomnia is greater than the odds 
observed in the uninfected population. 
 Limitations to this study should be recognized. First, as this study employs data from a 
private insurance claims database the overall HIV-infected and uninfected populations may not 
be accurately represented. Additionally, we are unable to account for medications acquired 
from family or friends or prescriptions paid for with cash. Due to the observational nature of this 
study an association between variables does not imply causality. Another potential limitation is 
that dispensed medications may not be equivalent to medications consumed. More generous 
definitions of continuous benzodiazepine use have been employed elsewhere in the literature65 
however, when applied results from the present study were unchanged. 
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 Despite these limitations the findings presented provide valuable information on 
potentially problematic benzodiazepine use in the HIV-infected population. This study supports 
the idea that caution should be exercised in the prescribing of benzodiazepines and other 
potentially abused medications in this population. Additionally, these findings highlight the need 
to adequately manage symptoms of depression and insomnia among this clinically vulnerable 
population. Furthermore, social factors including perceived stigmas and social support systems 
may have a valuable role in the management of HIV related symptoms. Future research should 
highlight HIV related health outcomes associated with potentially problematic benzodiazepine 
use. Interventions designed to reduce potentially problematic benzodiazepine use in this 
population are also warranted. Healthcare providers should take care in an effort to adequately 
manage symptoms of pain in the HIV-infected population while also being mindful of concerns 
regarding the risk of prescription drug misuse. Additionally, decreasing stigmas associated with 
HIV infection and mitigating daily stressors for HIV-infected patients may also reduce potentially 
problematic benzodiazepine use in this population. As the lifespan of the HIV-infected 
population continues to approach that of the uninfected population adequately managing 
symptoms associated with HIV and curtailing prescription drug misuse would benefit patients, 
payers, and society. 
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Table 4.1. Comparison of demographics of HIV-infected and uninfected patients. 
 HIV-infected HIV-uninfected 
 n = 3,447 n = 827,834 
Variable n % n % 
Sex     
Male 2,886 84% 267,077 32% 
Race     
White 2,463 71% 657,722 79% 
Black 292 8% 31,526 4% 
Hispanic 389 11% 56,018 7% 
Other 289 8% 75,404 9% 
Age     
Mean age (for year 2007), SDa 44.1 (8.4) 43.9 (11.0) 
Education     
High school graduate or less 1,044 30% 282,203 34% 
Some college or college graduate 2,304 67% 520,314 63% 
Location     
Northeast 419 12% 84,623 10% 
Midwest 494 14% 198,531 24% 
South 1,943 56% 423,821 51% 
West 590 17% 120,822 15% 
Psychiatric disorders     
Anxiety 676 20% 178,947 22% 
Depression 844 24% 169,143 20% 
Insomnia 375 11% 68,739 8% 
Substance abuse     
Alcohol abuse 120 3% 15,802 2% 
Substance abuse treatment 35 1% 7,396 1% 
a Standard deviation     
Percentage values presented may not add to 100% due to rounding or missing values. 
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Figure 4.1. Measures of potentially problematic benzodiazepine use in the HIV-infected and 
uninfected samples. 
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Figure 4.2. Likelihood of potentially problematic benzodiazepine use among HIV-infected patients 
compared to HIV-uninfected patients stratified by presence of anxiety diagnosis and age. 
 
a Adjusted for sex, education, race, psychiatric disorder diagnosis, substance use disorder (e.g., alcohol abuse diagnosis, treatment for substance 
use). 
b CI: Confidence interval. 
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HIV  1.32 (1.20, 1.45) 
High school or less 0.76 (0.76, 0.77) 
HIV*High school or less 1.37 (1.20, 1.56) 
Depression 1.20 (1.18, 1.21) 
HIV*Depression 1.99 (1.71, 2.32) 
Insomnia 1.23 (1.21, 1.25) 
HIV*Insomnia 1.87 (1.49, 2.35) 
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CHAPTER 5: IMPACT OF SOUTH CAROLINA’S PRESCRIPTION DRUG MONITORING PROGRAM 
ON THE USE OF BENZODIAZEPINES IN A COMMERCIALLY INSURED POPULATION. 
INTRODUCTION 
For patients afflicted with symptoms of anxiety and insomnia, benzodiazepines are a 
generally safe and effective pharmacological treatment option. Benzodiazepines are indicated 
for use as anxiolytics, sedatives, hypnotics, anticonvulsants, and/or skeletal muscle relaxants2,103 
and are the most frequently prescribed psychotropic drug class.11 In 2012 benzodiazepines were 
the 10th most prescribed drug class in the United States with approximately 94 million 
prescriptions dispensed.12 Alprazolam was the most commonly dispensed benzodiazepine with 
49 million prescriptions dispensed in 2012 and ranked as the 13th most commonly dispensed 
medication in the United States.13  
Although considered safer than other sedative-hypnotics drugs, such as barbiturates 
and meprobamate,2,3,6 the potential exists for benzodiazepines to be abused and are therefore 
classified as a Schedule IV controlled substance (CS). According to the 2012 National Survey of 
Drug Use and Health, the estimated number of incident benzodiazepine abusers was 166,000.104 
National estimates of drug-related visits to emergency departments collected by the Drug Abuse 
Warning Network (DAWN) for the year 2011 reported that between 2004 and 2011 the number 
of emergency department visits for the non-medical use of benzodiazepines increased 149% 
from 143,500 to 357,800.105 Additionally, this report identified benzodiazepines as the second 
leading cause of all emergency department visits concerning nonmedical use of pharmaceuticals 
as they were involved in 28.7% of all emergency department visits for this cause.105 Another 
recent study examining data from DAWN between 2004 and 2008 reported that 
benzodiazepines were identified in approximately 26% of all opioid-related emergency 
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department visits.106 These estimates suggest that inappropriate benzodiazepine use can lead to 
serious adverse effects and caution must be exercised regarding their prescribing and use. 
Concerns about the growing trend of prescription drug abuse and diversion have 
prompted states to enact legislation to track the prescribing and dispensing of targeted CS. In 
1989, New York became the first state to monitor the prescribing and dispensing of 
benzodiazepines through the state’s triplicate prescribing program (TPP).63-65 Several studies 
have since evaluated the effectiveness of the New York TPP on the state’s Medicaid population 
and discovered that following implementation there was an immediate, significant, and 
sustained reduction in overall benzodiazepine use.65,73,74 Other studies of the New York TPP 
highlighted concerns that policies monitoring benzodiazepine prescribing and dispensing may 
result in a chilling effect where patients with a chronic psychiatric disorder and/or a legitimate 
need for benzodiazepine therapy are unable to acquire the medication.73 Patients may be 
unable to obtain appropriate CS medications either due to a physician’s unwillingness to 
prescribe or a pharmacist being unwilling to dispense the CS. The unwillingness to prescribe or 
dispense a CS may be due to fear of legal investigations, fear of confidentiality violations, 
increased administrative burden, or confusion between the patterns of addiction and 
pseudoaddiction, where patients who are not being adequately treated for their condition 
appear, on paper, to be addicts.76-79 
More recently, states have relied on electronic data transfer systems, more commonly 
referred to as prescription drug monitoring programs (PDMPs), to track the prescribing, 
dispensing, and utilization of targeted medications in an effort to mitigate prescription drug 
abuse and diversion. Reports detailing a patient’s CS prescription history can be accessed upon 
request by healthcare providers, allowing for treatment decisions to be made at the point of 
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care. Additionally, because many PDMPs allow healthcare providers nearly instantaneous access 
to a patient’s CS prescription history, use of PDMPs can alert them to possible cases of 
prescription drug abuse and diversion by patients. As of December 2014, 49 states have an 
operational PDMP.80  
In 2006, the South Carolina state legislature signed into law legislation authorizing the 
state’s Department of Health and Environmental Control (DHEC) Bureau of Drug Control to 
establish and maintain a PDMP with the intent of improving the ability to identify and prevent 
prescription drug diversion in an efficient and cost effective manner without impeding access to 
licit CS medications for patients with a legitimate need.218 The South Carolina Reporting and 
Identification Tracking System (SCRIPTS) started collecting data from CS dispensers on January 1, 
2008, and reporting began on February 1, 2008.219  
All dispensing of Schedule II-IV CS in community pharmacy and outpatient settings are 
maintained in the SCRIPTS electronic database.218 Dispensers, including pharmacists, physicians, 
and veterinarians, are required to submit their CS dispensing data for Schedule II-IV at least 
every 30 days, between the 1st and 15th of the month.218 Controlled substance prescription data 
submitted to SCRIPTS follows a standard format and includes patient’s name, address, and date 
of birth, prescriber’s Drug Enforcement Administration (DEA) number, dispenser’s (i.e., 
pharmacy’s) DEA number, date the prescription was issued, date the drug was dispensed, 
National Drug Code (NDC), quantity, and approximate number of days supply of the CS 
medication dispensed.218 Physicians and pharmacists may request a patient’s CS prescription 
history report from SCRIPTS, which is usually available within minutes,219 in order to make 
treatment decisions at the point of care; however, physicians and pharmacists are not required 
to do so.218 Prior to accessing the SCRIPTS database, physicians and pharmacists are required to 
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complete an online training course and granted access by the DHEC.220,221 Law enforcement and 
prosecutorial officials may also request reports from the SCRIPTS database as long as they are 
officially engaged in a drug-related investigation.218,221 However, these parties cannot access the 
database directly. Instead, they must mail a request form to the DHEC who must approve the 
request before reports will be mailed via certified U.S. Mail to the requesting official.222 In the 
first complete fiscal year following the implementation of SCRIPTS (July 1, 2008 – June 30, 2009) 
more than nine million prescription records were collected and more than 51 thousand SCRIPTS 
reports were produced.223 
Policies designed to curtail the abuse, misuse, and diversion of prescription drugs (i.e., 
PDMPs) should be evaluated to determine if they are effectively meeting their objectives. 
Assessments of these policies are also necessary to ensure patient safety (i.e., permitting access 
to CS medication for appropriate medical care). To date, studies regarding current PDMP 
legislation have focused primarily on the impact concerning opioid analgesic prescribing and 
use. Focus on this medication class is understandable as opioid analgesics are the primary 
contributor to the increasing trend of drug overdose deaths in the United States.92-94 However, 
other CS, specifically benzodiazepines, have been found to be a factor contributing to the 
substantial rise in unintentional poisoning deaths.92,95-97 Despite the role of benzodiazepines in 
the US prescription drug abuse epidemic, no studies have evaluated the impact of current PDMP 
legislation on benzodiazepine use. Of the 49 operational PDMPs, as of December 2014, 48 have 
the authority to monitor the prescribing and dispensing of Schedule IV CS which includes 
benzodiazepines.224  
The aim of this study is to evaluate the effect of South Carolina PDMP implementation 
on the dispensing of benzodiazepines. This will be accomplished by testing the following 
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hypotheses: 1.) Implementation of the PDMP in South Carolina will not result in a change in the 
rate of benzodiazepine use 2.) Implementation of the PDMP in South Carolina will not result in a 
chilling effect, defined as a reduction in the likelihood of filling a benzodiazepine prescription 
among patients with a legitimate need for the medication. Results of this study will expand the 
literature on PDMPs and their influence on benzodiazepine utilization. 
METHODS 
 Using data from a large private insurance claims database containing beneficiary socio-
demographic information and codes related to interactions with the healthcare system, two 
identically defined cohorts, one from South Carolina (study), the other from Tennessee 
(control), were extracted for the time period between January 2007 and December 2009. This 
time period constitutes the 12 months prior to and 24 months after the South Carolina PDMP 
was implemented. Tennessee was selected as a control state because had a PDMP in place 
during the entire study period and, with the exception of race, is it similar demographically to 
South Carolina225 (Table 5.1). Beneficiaries were included in the analyses if they resided in South 
Carolina or Tennessee, were between 19 and 64 years of age during the entire study period, and 
were continuously enrolled (≥1090 days) during the study period. Beneficiaries under the age of 
19 were excluded because the prescribing of benzodiazepines in children is an uncommon 
practice65 while those 65 and older were excluded because benzodiazepines are not 
recommended for use in this population due to an increased risk of cognitive impairment, falls, 
and fractures.52,53 Psychiatric disorders for which benzodiazepines are commonly prescribed 
including anxiety103 (ICD-9 codes: 300.xx, excluding 300.4), insomnia103 (307.41, 307.42, and 
780.52), and depression174 (296.2x, 296.3x, 300.4, and 311) were also identified in the database. 
These conditions were used as an indicator of legitimate benzodiazepine use to test for the 
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presence of a chilling effect. Beneficiaries were considered to have a specific psychiatric disorder 
if they had a claim at any time during the study period with a diagnosis including one of the ICD-
9 diagnostic codes listed above. Benzodiazepine dispensing during the study period was 
represented by a claim for any benzodiazepine during a given month of the study period and 
identified using national drug codes. 
 To evaluate whether or not the implementation of the South Carolina PDMP had a 
greater impact on the rate of benzodiazepine use than any underlying secular trend, interrupted 
time series methods were employed. Time series analyses using autoregressive integrated 
moving average (ARIMA) models estimated changes in the level and trend of the percent of 
beneficiaries in each state who filled a benzodiazepine prescription during each of the 12 
months prior to and 24 months after the South Carolina PDMP was implemented. According to 
Wagner, Soumarai, Zhang, and Ross-Degnan (2002), a change in level is described as the jump or 
drop in the outcome after an intervention, while a change in the trend is defined by an increase 
or decrease in the slope of the trend line after the intervention compared to the trend line prior 
to the intervention.226 Because some prescriptions written in 2007 may not have been filled 
immediately and because reporting did not begin until February 1, 2008, January 2008 was 
excluded from this analysis. The exclusion of this time period is consistent with the methods 
used by Ross-Degnan et al. (2004) to evaluate the impact of the New York TPP on 
benzodiazepine use.65 Moreover, a sensitivity analysis was performed to test the robustness of 
the results using the proportion of the continuously eligible sample who filled an opioid 
prescription during each of the 12 months prior to and 24 months after the South Carolina 
PDMP was implemented. 
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 Panel data methods were employed to examine the effect that South Carolina PDMP 
implementation had on the likelihood of filling a benzodiazepine prescription. Multivariate 
logistic regression models using random effects and adjusted for presence of a PDMP, sex, age, 
race, presence of psychiatric disorders, state and month specific unemployment rates, time in 
months, and state of residence were used to estimate the adjusted odds ratio (AOR) and 
associated 95% confidence intervals (CI) of filling a benzodiazepine prescription. The covariates, 
with the exception of the monthly unemployment rates and the time trend variable, were 
operationalized as categorical variables. Age was calculated based on the beneficiary’s year of 
birth and segregated into two categories based on the median age of the study sample, age 19 
to 44 and 45 to 64. Race was divided into three categories: white, black, and other. The other 
race category was comprised primarily of beneficiaries identified in the database as Hispanic, or 
other. These beneficiaries were considered together due to their individually small 
representation in the study population. State and month specific unemployment rates acquired 
from the US Bureau of Labor Statistics were used to adjust for the economic climate that was 
especially volatile during the study period.227 The unemployment variable was operationalized 
as a continuous variable representing the percentage of the states’ workforce who were without 
a job, actively seeking employment, and available for work during a given month. The monthly 
time trend variable was operationalized as an ordinal variable taking the values 1 through 36 
and included in the analysis to capture the effects that trend in one direction over time.  
 The first multivariate logistic regression model takes a linear form to determine factors 
that influence the likelihood of filling a benzodiazepine prescription among beneficiaries in the 
study population. This model takes the form of 
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Where        is the odds of filling a benzodiazepine prescription for beneficiary   residing in 
state   in month  . The variable        indicates the presence of an operational PDMP in state 
  in month  .        represents the state of residence for beneficiary  . The matrix   identifies 
demographic characteristics for beneficiary   including sex, race, and age, and the matrix   
represents the presence of a psychiatric disorder diagnosis including anxiety, depression, and 
insomnia for beneficiary  . The variable           is the unemployment rate for state   in 
month   and       is the monthly time trend variable. Finally,   is a normal independent 
identically distributed (i.i.d.) error term. 
A difference in difference (DD) estimator, obtained by interacting the variables 
indicating the beneficiary’s state of residence and the presence of a PDMP, estimated the effect 
the South Carolina PDMP had on the odds of filling a benzodiazepine prescription among South 
Carolina beneficiaries compared to their counterparts in Tennessee. To evaluate if the South 
Carolina PDMP implementation had a differential impact on specific subgroups in the 
population, difference in difference in difference (DDD) estimators were employed. These 
second order interactions were obtained by interacting the DD estimator with each of the 
demographic and psychiatric disorder covariates listed previously. This model takes the form of  
                                                            
                                                          
Linear combinations of coefficients estimated the odds of filling a benzodiazepine prescription 
among subgroups in South Carolina during the two years after the PDMP implementation 
compared to the odds in the year preceding the program. Statistical significance was considered 
using the Wald χ2 p-value associated with the interaction term. The a priori level of significance 
for all analyses was set at 0.05. Data use was approved by the University of Kentucky 
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Institutional Review Board. Statistical analyses was conducted using Stata 13.0 (StataCorp., 
College Station, TX). 
RESULTS 
 A total of 69,738 beneficiaries met the inclusion criteria of this study. Of these, 19,034 
(27.3%) resided in South Carolina and 50,965 (72.7%) in Tennessee. Baseline characteristics and 
benzodiazepine utilization by state of residence are shown in Table 5.2. Due to the large sample 
sizes, differences in the demographic characteristics between the states are statistically 
significant but the proportions in the distributions are similar for most characteristics. A sizable 
difference exists between the individual state cohorts with regards to race, with the South 
Carolina cohort having a higher proportion of nonwhite beneficiaries, particularly black 
beneficiaries (11.85% vs. 6.57%), compared to the Tennessee cohort. The South Carolina cohort, 
compared to the Tennessee cohort, also had a greater proportion of beneficiaries with at least 
some college education or a college degree (52.1% vs. 48.5%). 
 Overall, 18% of the South Carolina cohort and 17% of the Tennessee cohort filled a 
benzodiazepine prescription between January 2007 and December 2009. During this timeframe 
12,297 unique beneficiaries filled a total of 101,036 benzodiazepine prescriptions. Alprazolam 
(47,501 unique prescriptions filled), clonazepam (19,612), lorazepam (13,624), and diazepam 
(11,836) were the most commonly filled benzodiazepine prescriptions. The number of 
beneficiaries who filled a benzodiazepine prescription in each month of the study period is 
presented in Appendix 5.1. 
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Interrupted Time Series Analysis 
 Throughout 2007, the percentage of South Carolina beneficiaries who filled a 
prescription for a benzodiazepine was increasing monthly by a rate 5% (0.05; 95% CI: 0.03, 0.07; 
p<0.01; Table 5.3). After the PDMP was implemented in South Carolina in January 2008, the 
percentage of beneficiaries filling a benzodiazepine prescription increased at a rate of 4% (0.04; 
95% CI: 0.03, 0.07; p<0.01). This change in trend of the percent of South Carolina beneficiaries 
filling a benzodiazepine prescription each month was not significant (-0.01; 95% CI: -0.03, 0.02; 
p=0.46). Additionally, there was no change observed in the level (0.10; 95% CI: -0.33, 0.12; 
p=0.38) of the percent of South Carolina beneficiaries who filled a benzodiazepine prescription 
immediately after the PDMP was implemented (Figure 5.1). In the control state of Tennessee, 
no change was observed in the slope of the trend line of the percentage of beneficiaries filling a 
benzodiazepine prescription each month (-0.01; 95% CI: -0.03, 0.01; p=0.25). There was also no 
change observed in the level of filled benzodiazepine prescriptions (0.13; 95% CI: -0.30, 0.04; 
p=0.13) among Tennessee beneficiaries at the time of the South Carolina PDMP 
implementation.  
The relative effect of the South Carolina PDMP based on 2007 predicted values initially 
after the program was implemented was 3.1% (95% CI: -8.92%, 3.58%; p=0.36) reduction in the 
percent of beneficiaries who filled a benzodiazepine prescription and not statistically significant 
(Figure 5.2). In January 2009, one year after the program began, the relative effect was a 5.3% 
(95% CI: -13.91%, 5.41%; p=0.31) reduction in the percent of beneficiaries who filled a 
benzodiazepine prescription and also not determine to be significant. By the end of 2009 the 
relative effect of the PDMP implementation was a 7% (95% CI: -18.44, 8.33%; p=0.34) reduction 
 
 84 
in the percent of beneficiaries who were predicted to fill a benzodiazepine prescription and not 
statistically significant.  
The results from the sensitivity analysis performed determined that there was no 
change in trend or level of the percentage of South Carolina beneficiaries who filled an opioid 
prescription after the PDMP was implemented in January 2008 (Appendix 5.2). Similar findings 
were observed in Tennessee where there was no change in trend or the level of the percent of 
beneficiaries who filled an opioid prescription. Furthermore, the relative effect of the South 
Carolina PDMP on the percentage of beneficiaries who filled an opioid prescription was not 
significant throughout the follow-up period (Appendix 5.3). 
Multivariate Logistic Regression Analysis 
 In the overall study population, the odds of filling a benzodiazepine prescription were 
influenced by sex, race, age, presence of a psychiatric disorder, state of residence, 
unemployment rate, and time (Table 5.4). The odds of filling a benzodiazepine prescription were 
greater for beneficiaries residing in South Carolina compared to those in Tennessee (AOR: 1.29; 
95% CI: 1.18, 1.40; p<0.01), females compared to males (AOR: 2.45; 95% CI: 2.26, 2.66; p<0.01) 
and beneficiaries between the ages of 45 and 64 compared to those 19 to 44 (AOR: 1.64; 95% 
CI: 1.54, 1.73; p<0.01). Having a diagnosis of anxiety (AOR: 31.39; 95% CI: 28.58, 34.48; p<0.01), 
depression (AOR: 4.68; 95% CI: 4,27, 5.13; p<0.01), or insomnia (AOR: 5.65; 95% CI: 5.09, 6.28; 
p<0.01) also increased the odds of filling a benzodiazepine prescription during the study period. 
Furthermore, the time trend variable included in the regression suggests that as time 
progressed during the study period the odds of a beneficiary filling a benzodiazepine 
prescription also increased (AOR: 1.02; 95% CI: 1.02, 1.03; p<0.01). Conversely, beneficiaries 
identified as black (AOR: 0.35; 95% CI: 0.30, 0.42; p<0.01) or other race (AOR: 0.55; 95% CI: 0.49, 
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0.67; p<0.01) were less likely than white beneficiaries to have filled a benzodiazepine 
prescription. The unemployment rate was also inversely related to the odds of filling a 
benzodiazepine prescription (AOR: 0.98; 95% CI: 0.97, 0.99; <0.01). Results also suggest the 
presence of a PDMP did not have an effect on the odds of beneficiaries filling a benzodiazepine 
prescription during the study period (AOR: 0.98; 95% CI: 0.94, 1.02; p=0.37). 
Table 5.5 presents results from the DDD model evaluating whether the South Carolina 
PDMP implementation had a differential impact on the likelihood of having a benzodiazepine 
prescription filled among specific subgroups in South Carolina. The DD estimator was omitted 
from the final interaction model due to collinearity as the correlation between the DD estimator 
and the state of residence variable was determined to be 76 percent.  
Adjusted for the covariates described previously, results from the DDD model suggested 
the implementation of the PDMP in South Carolina differentially impacted the likelihood that 
certain subgroups in the population would fill a benzodiazepine prescription. Linear 
combinations of effect estimates (Table 5.6) demonstrated that in the 24 months after the 
PDMP in South Carolina went into effect females and beneficiaries 45 and older experienced a 
significant reduction in the odds of filling a benzodiazepine prescription compared to the 12 
months prior to the program. The South Carolina PDMP implementation resulted in females 
only having 85% (AOR: 0.85; 95% CI: 0.77, 0.91; p<0.01) of the odds of filling a benzodiazepine 
prescription while beneficiaries 45 and older only had 87% (AOR: 0.87; 95% CI: 0.80, 0.95; 
p<0.01) of the odds of filling a benzodiazepine prescription in 2008 and 2009 than they did prior 
to the program in 2007.  
Conversely, beneficiaries in South Carolina with a diagnosis of insomnia during the study 
period had greater odds of filling a benzodiazepine prescription in the two years after the PDMP 
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was implemented than they did in the year prior. South Carolina beneficiaries diagnosed with 
insomnia during the study period experienced a 16% increase (AOR: 1.16; 95% CI: 1.03, 1.30; 
p=0.02) in their odds of filling a benzodiazepine prescription after the PDMP was implemented. 
DISCUSSIONS 
 In this sample of continuously eligible, privately insured beneficiaries in South Carolina 
the implementation of SCRIPTS did not impact the rate of benzodiazepine use or create a chilling 
effect by decreasing the likelihood of filing a benzodiazepine prescription during the two years 
following the program’s implementation for beneficiaries having a diagnosis of insomnia, a 
condition for which benzodiazepines are indicated. This finding is a contrast from previous 
findings in New York,65 which suggested that benzodiazepine monitoring programs cause a 
sudden and sustained decrease in the rate of benzodiazepine use. The findings of the present 
study show that in the two years after SCRIPTS was implemented there was no change in the in 
the level nor the trend of benzodiazepine dispensing when compared to the year prior to the 
program. One possible explanation for this finding is that during the study period use of SCRIPTS 
was voluntary among physicians and pharmacists. Physicians may not have accessed the 
SCRIPTS database due to time constraints often present with evaluating patients. Another 
deterrent to SCRIPTS use by physicians may be the perception that the information contained in 
the report is incomplete and would therefore not impact their CS prescribing decisions. The 
perception of the report being incomplete may be based on the knowledge that CS dispensers 
were only required to submit their CS dispensing data once every 30 days. Of note, in June 2014 
legislation passed the South Carolina General Assembly requiring daily reporting of CS 
dispensing data by dispensers.228 Pharmacists may not have accessed the SCRIPTS database to 
request a patient’s CS prescription history due to workflow issues and limited access to the 
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Internet, especially in chain pharmacy settings. Pharmacists may have also assumed that 
physicians were accessing the SCRIPTS database and therefore there was no reason for them to 
do so. 
 Findings from this study did show that the presence of SCRIPTS differentially impacted 
certain subgroups of the population. Results show that among South Carolina beneficiaries the 
likelihood of filling a benzodiazepine prescription after SCRIPTS went into effect were 
significantly decreased for females and beneficiaries 45 and older. However, even after SCRIPTS 
was implemented females remained nearly three times more likely than males to fill a 
benzodiazepine prescription and those 45 and older were nearly twice as likely to fill a 
benzodiazepine prescription as their younger counterparts. As this study evaluated the impact 
of SCRIPTS on the dispensing of benzodiazepines it cannot be determined if the discontinuation 
of benzodiazepine therapy among female beneficiaries in South Carolina was appropriate or if 
there were any adverse outcomes experienced as a result.  
 This study also demonstrated that having received a diagnosis of insomnia during the 
study period significantly increased the likelihood of filling a prescription for a benzodiazepine 
after the PDMP was implemented compared to beneficiaries without a diagnosis. As 
benzodiazepines are indicated to manage symptoms associated with this condition, the finding 
suggests that PDMPs, as they pertain to benzodiazepines, do not induce a chilling effect by 
restricting access to pharmacotherapy options among those with a diagnosis of insomnia, a 
condition where benzodiazepine therapy is appropriate. 
 Limitations to this study exist. First, this study does not distinguish between appropriate 
or potentially inappropriate benzodiazepine dispensing to beneficiaries. However, the use of 
diagnostic codes for conditions for which benzodiazepines are indicated and/or commonly 
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prescribed can be used as a proxy for appropriate dispensing. Also, even though 
benzodiazepines are often prescribed for the treatment of seizure disorders, they are generally 
not the first-line therapy option. Because of this and the necessity of tailoring seizure disorder 
treatments to individual patients seizure disorder conditions were not assessed. This study does 
not account for the number of benzodiazepine prescriptions filled or the quantity and dosage of 
these prescriptions. As this study utilized prescription drug claims from a private insurance 
claims database, prescriptions acquired from family and friends or paid for using cash cannot be 
accounted for. Additionally, this study could not account for utilization of the SCRIPTS program 
by physicians and pharmacists who make treatment decisions. Finally, this a sample of 
continuously enrolled, privately insured beneficiaries may not adequately represent the 
populations of South Carolina or Tennessee as a whole and may not be generalizable to other 
populations. 
 Findings from this study demonstrate that the presence of SCRIPTS did not induce a 
chilling effect with regards to benzodiazepines in the overall sample of continuously enrolled, 
privately insured beneficiaries in South Carolina with a diagnosis of insomnia. However, 
benzodiazepine dispensing to females and beneficiaries 45 and older in South Carolina were 
more impacted by the presence of the program than they were to males and younger adults. As 
this study did not explicitly differentiate between appropriate and potentially inappropriate 
benzodiazepine dispensing it cannot be determined if the reduction in benzodiazepine 
dispensing to females and beneficiaries 45 and older was focused on those who may have been 
misusing or diverting benzodiazepines or if discontinuation occurred in those who were using 
the medication appropriately. Future research focusing on PDMPs and their impact on 
benzodiazepine utilization should consider employing methods to identify appropriate and 
potentially inappropriate benzodiazepine use in claims databases in order to evaluate if PDMPs 
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are achieving their goal of reducing prescription drug abuse and diversion without impeding 
access for those with a legitimate need. Additionally, exploring clinical outcomes among 
patients who have had their benzodiazepine therapy discontinued can assist in evaluating costs 
associated with the presence of a PDMP. Finally, future studies should explore the impact of 
PDMPs on benzodiazepine use by expanding the number of states to allow for specific 
characteristics of PDMPs to be analyzed and understand how they impact benzodiazepine use. 
In addition, the time period analyzed should be expanded in order to observe the long-term 
impact of PDMPs on benzodiazepine utilization. Considerable potential exists for PDMPs to 
become a powerful tool to combat prescription drug abuse and diversion heightening the need 
for more research to understand their clinical utility and ensure they do no obstruct access to 
legitimate pharmacotherapies. 
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Table 5.1. United States Census demographic information for South Carolina and Tennessee.225 
 South Carolina Tennessee 
2010 Population 4,625,364 6,346,105 
Sex   
Male 48.7% 48.8% 
Female 51.3% 51.2% 
Age   
Under 18 years of age 22.6% 23.0% 
Age 65 and older 15.2% 14.7% 
Race   
White 63.9% 74.9% 
Black 27.9% 17.0% 
Hispanic 5.3% 4.9% 
Education   
High School or more 84.5% 84.4% 
Bachelor’s or more 25.1% 23.8% 
   
 
Table 5.2. Demographic characteristics of continuously enrolleda adult beneficiaries in South 
Carolina and Tennessee. 
 South Carolina Tennessee  
Sample Size 19,043 50,695 p-value 
Benzodiazepine use 
Filled benzodiazepine 
prescription 
3,515 18.46% 8,782 17.32% <0.01 
Sex 
Female 9,727 51.08% 25,738 50.77% 0.47 
Ageb 
Median age (IQRc) 44 (35 – 53) 44 (34 – 52) <0.01 
Race 
White 15,165 79.64% 42,875 84.57% <0.01 
Black 2,257 11.85% 3,332 6.57% <0.01 
Hispanic 421 2.21% 1,199 2.37% 0.23 
Other 1,053 5.53% 2,987 5.89% 0.07 
Education 
High school diploma or 
less 
8,422 44.23% 25,003 49.32% <0.01 
Some college or college 
degree 
9,911 52.05% 24,604 48.53% <0.01 
ICD-9 Diagnosis 
Anxiety 2,205 11.58% 6,310 12.45% <0.01 
Depression 2,165 11.37% 6,559 12.94% <0.01 
Insomnia 1,489 7.82% 3,854 7.60% 0.34 
a Continuously enrolled defined as ≥1090 days eligibility between Jan 1, 2007 & Dec 31, 2009 
b Median age was evaluated for the year 2007 
c Interquartile range 
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Table 5.3. Interrupted time series analysis examining the percentage of South Carolina and 
Tennessee beneficiaries filling a benzodiazepine prescription by month. 
 South Carolina Tennessee 
 
Coefficient p-value 
95% 
Confidence 
Interval Coefficient p-value 
95% 
Confidence 
Interval 
Monthly rate of increase 
in benzodiazepine in 
2007 0.05 <0.01 0.03, 0.07 0.04 <0.01 0.03, 0.06 
Monthly rate of increase 
in benzodiazepine in 
2008 & 2009 0.04 <0.01 0.02, 0.05 0.03 <0.01 0.03, 0.04 
Change in the rate of 
increase of 
benzodiazepine use -0.01 0.43 -0.03, 0.01 -0.01 0.25 -0.03, 0.01 
Change in the level one 
month after PDMP 
implementation -0.11 0.35 -0.34, 0.12 -0.13 0.13 -0.30, 0.04 
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Table 5.4. Odds of filling a benzodiazepine prescription between January 2007 and December 
2009 among continuously enrolled adult beneficiaries in South Carolina and Tennessee. 
Variable Odds Ratio p-value 95% Confidence Interval 
PDMP    
No operational PDMP Ref.   
PDMP operational 0.98 0.37 0.94 – 1.02 
State of Residence    
Tennessee Ref.   
South Carolina 1.29 <0.01 1.18 – 1.40 
Sex    
Male Ref.   
Female 2.45 <0.01 2.26 – 2.66 
Race    
White Ref.   
Black 0.35 <0.01 0.30 – 0.42 
Other 0.58 <0.01 0.49 – 0.67 
Age    
Age 44 and under Ref.   
Age 45 and over 1.64 <0.01 1.54 – 1.73 
Diagnosis of a Psychiatric Disorder    
No psychiatric disorder diagnosis Ref.   
Anxiety 31.39 <0.01 28.58 – 34.48 
Depression 4.68 <0.01 4.27 – 5.13 
Insomnia 5.65 <0.01 5.09 – 6.28 
Economic Climate    
Unemployment ratea 0.98 <0.01 0.97 – 0.99 
Time Trend    
Monthb 1.02 <0.01 1.02 – 1.03 
a Unemployment rate interpretation is the effect of a one percentage point increase in the 
unemployment rate 
b Month interpretation is  the effect of time progressing forward one additional month 
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Table 5.5. Odds of South Carolina adult beneficiaries filling a benzodiazepine prescription 
after the implementation of the state’s PDMP. 
Variable Odds Ratio p-value 95% Confidence Interval 
Presence of PDMP 
No operational PDMP Ref.   
PDMP operational 0.92 0.09 0.83 – 1.01 
State of Residence 
Tennessee Ref.   
South Carolina 1.26 <0.01 1.12 – 1.41 
Sex 
Male Ref.   
Female 2.49 <0.01 2.29 – 2.71 
Race 
White Ref.   
Black 0.35  0.29 – 0.42 
Other 0.57 <0.01 0.48 – 0.66 
Age 
Age 44 and under Ref.   
Age 45 and over 1.65 <0.01 1.55 – 1.75 
Diagnosis of a Psychiatric Disorder 
No psychiatric disorder diagnosis Ref.   
Anxiety 30.55 <0.01 27.78 – 33.60 
Depression 4.64 <0.01 4.23 – 5.10 
Insomnia 5.40 <0.01 4.85 – 6.00 
Economic Climate 
Unemployment ratea 0.98 <0.01 0.97 – 0.99 
Time Trend 
Monthb 1.02 <0.01 1.02 – 1.03 
DDDc Estimators    
PDMP * SC * Female 0.92 0.04 0.85 – 0.99 
PDMP * SC * Black 1.03 0.73 0.89 – 1.18 
PDMP * SC * Other  1.08 0.34 0.92 – 1.26 
PDMP * SC * Over 45 0.95 0.19 0.88 – 1.03 
PDMP * SC * Anxiety 1.15 <0.01 1.06 – 1.25 
PDMP * SC * Depression 1.05 0.25 0.97 – 1.14 
PDMP * SC * Insomnia 1.26 <0.01 1.15 – 1.37 
a Unemployment rate interpretation is the effect of a one percentage point increase in the 
unemployment rate 
b Month interpretation is  the effect of time progressing forward one additional month 
c Difference in difference in difference estimators 
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Table 5.6. Linear combinations of effect estimates comparing odds of subgroups of South 
Carolina adult beneficiaries filling a benzodiazepine prescription before and after PDMP 
implementation. 
Variable 
Odds of filling a 
benzodiazepine 
prescription before 
South Carolina PDMP 
p-value 
(95% CI) 
Odds of filling a 
benzodiazepine 
prescription after South 
Carolina PDMP 
p-value 
(95% CI) 
Comparison of odds 
after the South Carolina 
PDMP implementation 
to before 
p-value 
(95% CI) 
Female 
3.13 2.65 0.85 
<0.01 <0.01 <0.01 
(2.70, 3.64) (2.19, 3.20) (0.77, 0.92) 
Black 
0.44 0.41 0.94 
<0.01 <0.01 0.47 
(0.36, 0.54) (0.32, 0.54) (0.80, 1.11) 
Other 
0.71 0.70 0.99 
<0.01 0.01 0.92 
(0.58, 0.87) (0.54, 0.92) (0.83, 1.18) 
Age 45 and over 
2.07 1.81 0.87 
<0.01 <0.01 <0.01 
(1.81, 2.37) (1.51, 2.16) (0.80, 0.95) 
Anxiety 
38.40 40.64 1.06 
<0.01 <0.01 0.28 
(32.90, 44.83) (32.99, 50.05) (0.95, 1.17) 
Depression 
5.84 5.63 0.96 
<0.01 <0.01 0.57 
(5.02, 6.80) (4.51, 7.03) (0.85, 1.09) 
Insomnia 
6.79 7.85 1.16 
<0.01 <0.01 0.02 
(5.79, 7.96) (6.29, 9.80) (1.03, 1.30) 
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Figure 5.1. Percent of sample who filled a benzodiazepine prescription each month during the 
study period among continuously enrolled, privately insured beneficiaries in South Carolina 
and Tennessee. 
 
Figure 5.2. Relative effect of South Carolina PDMP on percentage of sample population filling 
a benzodiazepine prescription. 
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Appendix 5.1. Number and percentage of continuously enrolled beneficiaries in South 
Carolina and Tennessee who filled a benzodiazepine prescription by month. 
 South Carolina Tennessee 
Sample Size 19,043 50,695 
2007 January 578 3.04% 1545 3.05% 
 February 527 2.77% 1458 2.88% 
 March 613 3.22% 1597 3.15% 
 April 585 3.07% 1569 3.09% 
 May 625 3.28% 1608 3.17% 
 June 626 3.29% 1600 3.16% 
 July 638 3.35% 1693 3.34% 
 August 649 3.41% 1710 3.37% 
 September 616 3.23% 1647 3.25% 
 October 683 3.59% 1771 3.49% 
 November 644 3.38% 1715 3.38% 
 December 641 3.37% 1730 3.41% 
2008 January 680 3.57% 1770 3.49% 
 February 649 3.41% 1723 3.40% 
 March 675 3.54% 1739 3.43% 
 April 704 3.70% 1788 3.53% 
 May 696 3.65% 1804 3.56% 
 June 676 3.55% 1771 3.49% 
 July 681 3.58% 1898 3.74% 
 August 718 3.77% 1860 3.67% 
 September 698 3.67% 1901 3.75% 
 October 740 3.89% 1919 3.79% 
 November 678 3.56% 1857 3.66% 
 December 740 3.89% 1926 3.80% 
2009 January 743 3.90% 1926 3.80% 
 February 693 3.64% 1851 3.65% 
 March 795 4.17% 2009 3.96% 
 April 739 3.88% 1943 3.83% 
 May 777 4.08% 1969 3.88% 
 June 787 4.13% 1992 3.93% 
 July 785 4.12% 2028 4.00% 
 August 760 3.99% 2079 4.10% 
 September 810 4.25% 2042 4.03% 
 October 810 4.25% 2160 4.26% 
 November 785 4.12% 2062 4.07% 
 December 837 4.40% 2180 4.30% 
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Appendix 5.2. Interrupted time series analysis examining the percentage of South Carolina 
and Tennessee beneficiaries filling an opioid prescription by month. 
  South Carolina Tennessee 
 
Coefficient p-value 
95% 
Confidence 
Interval Coefficient p-value 
95% 
Confidence 
Interval 
Monthly rate of increase 
in benzodiazepine in 
2007 0.04 0.03 0.00a, 0.08 0.02 0.25 -0.02, 0.07 
Monthly rate of increase 
in benzodiazepine in 
2008 & 2009 0.03 <0.01 0.02, 0.04 0.03 <0.01 0.02, 0.05 
Change in the rate of 
increase of 
benzodiazepine use -0.01 0.73 -0.04, 0.03 0.01 0.68 -0.03, 0.05 
Change in the level one 
month after PDMP 
implementation -0.08 0.67 -0.45, 0.03 0.11 0.55 -0.25, 0.48 
 
 
Appendix 5.3. Relative effect of South Carolina PDMP on percentage of sample population 
filling an opioid prescription. 
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CHAPTER 6: A NATIONWIDE STUDY OF THE IMPACT OF PRESCRIPTION DRUG MONITORING 
PROGRAMS ON THE DISPENSING OF BENZODIAZEPINES AMONG COMMERCIALLY INSURED 
ADULTS. 
INTRODUCTION 
For the millions of American afflicted with symptoms of anxiety and insomnia 
benzodiazepines are a generally safe and effective pharmacologic treatment option. 
Benzodiazepines are the most frequently prescribed psychotropic drug class.11 In 2012 they 
were the 10th most prescribed drug class in the United States with approximately 94 million 
prescriptions dispensed.12 Benzodiazepines are considered a safer alternative compared to 
other sedative-hypnotics drugs, such as barbiturates and meprobamate,2,3,6 however the 
potential remains for benzodiazepines to be abused due to their addictive nature. Due to 
evidence regarding the abuse potential of benzodiazepines they are classified as a Schedule IV 
controlled substance (CS). 
The role of benzodiazepines in the United States prescription drug abuse epidemic is 
prominent. National estimates of drug-related visits to emergency departments collected by the 
Drug Abuse Warning Network105 (DAWN) for the year 2011 reported that between 2004 and 
2011 the number of emergency department visits for the non-medical use of benzodiazepines 
increased 149% from 143,500 to 357,800. Additionally, this report identified benzodiazepines as 
the second leading cause of all emergency department visits concerning nonmedical use of 
pharmaceuticals, as they were involved in 28.7% of all emergency department visits for this 
cause. Another recent study by Cai et al.106 examining data from DAWN between 2004 and 2008 
reported that benzodiazepines were identified in approximately 26% of all opioid related 
emergency department visits. These estimates suggest that benzodiazepine misuse and abuse 
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can lead to serious adverse effects on individuals and caution must be exercised with their 
prescribing and use. 
To address the prescription drug abuse epidemic in the United States, individual states 
have taken the lead in creating and implementing prescription drug monitoring programs 
(PDMPs) with the purpose of identifying and mitigating prescription drug abuse and diversion. 
These programs permit healthcare providers, including prescribers and pharmacists, the ability 
to request and receive a patient’s controlled substance (CS) prescription history with quick 
turnaround, allowing treatment decisions to be made at the point of care. Reports detailing a 
patient’s CS prescription history can be accessed upon request, or proactively distributed to 
authorized PDMP users, depending upon the regulations of the individual state’s program. 
Pharmacies, along with dispensing physician and veterinarian offices submit CS dispensing data 
to the PDMP on a regular basis as mandated by state law. The majority of states require CS 
dispensing data to be submitted at least every seven days with some states requiring daily or 
“real-time” reporting.80 Prescription data submitted to PDMPs follows a standard format and 
includes patient name, prescriber name, date of dispensing, and name, strength, and quantity of 
the CS medication dispensed. As of December 2014, 49 states have an operational PDMP. 
Missouri and Washington DC do not currently have a PDMP, however, Washington DC does 
have pending legislation.80 
 While all PDMPs were designed to facilitate collection, analysis, and reporting of 
prescription CS use, in practice they take several different forms based upon individual state 
legislation and differ in terms of objectives, design, and operations.229 Housing agencies of 
PDMPs vary between states with the majority of PDMPs housed within and agency having 
primarily a public health mission (e.g. health professional boards, departments of health); 
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however some states house their PDMP within a law enforcement agency and while others are 
part of another housing authority.80 The housing agency of the PDMP may have an effect on the 
overall mission of the program and how authorized PDMP users interact with the system. For 
example, states that house their PDMP within a law enforcement agency may perceive 
prescription drug abuse as a safety concern and those who abuse and divert CS as criminals 
while a state that houses their PDMP in a public health department may view prescription drug 
abuse and diversion as a condition for which people need programs and treatment options to 
help them overcome their problem. Variation also exists across states in terms of groups 
authorized to access the PDMP system and subsequent reports. In most states healthcare 
professionals including prescribers and pharmacists are authorized to receive the information 
contained within PDMP reports, however, access among law enforcement personnel is less 
uniform.80 States also differ in the CS Schedules monitored. While all state PDMPs track the 
dispensing of Schedule II CS, some states also monitor Schedules III, IV, and V. Some state 
PDMPs also have the authority to monitor non-CS under certain circumstances.82 The frequency 
with which CS prescription dispensing data is transmitted to the PDMP is another source of 
variation between programs with the majority of states require CS dispensing data to be 
submitted at least every seven days, however, some states require daily or “real-time” 
reporting.80 
 Policies designed to curtail the abuse, misuse, and diversion of prescription drugs (i.e., 
PDMPs) should be evaluated to determine if they are effectively meeting their objectives. 
Assessments of these policies are also necessary to ensure patient safety (i.e., permitting access 
to CS medication for appropriate medical care). To date, studies regarding current PDMP 
legislation have primarily focused on the impact concerning opioid analgesic prescribing and 
use. Emphasis on this medication class is understandable as opioid analgesics are the primary 
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contributor to the increasing trend of drug overdose deaths in the US.92-94 The role of other CS 
medications, specifically benzodiazepines, has also been found to contribute substantially to the 
rise in unintentional poisoning deaths.92,95-97  
Previous studies assessing the impact of benzodiazepine monitoring have concentrated 
on the New York triplicate prescription program (TPP) from the early 1990s. In 1989, New York 
became the first state the track the prescribing, dispensing, and utilization of benzodiazepines 
when they were added to the list of medications to be targeted by the state’s TPP with the goal 
of reducing diversion for illicit use and inappropriate prescribing.63-65 Evaluations of the 
effectiveness of the New York TPP policy change suggested that immediately following 
implementation there was a significant and sustained reduction in overall benzodiazepine 
use.65,73,74 There were also concerns that this policy change may have induced a ‘chilling effect’ 
by restricting access to benzodiazepine therapy among patients with chronic psychiatric 
disorders, and/or a legitimate need for the medication were also highlighted. A 2003 evaluation 
by Wagner and colleagues72 examined new benzodiazepine use among patients recently 
discharged from the hospital for either an acute cardiac event or cancer. Benzodiazepines are 
often prescribed to relieve anxiety associated with acute myocardial infarction and in cancer 
patients to reduce anticipatory anxiety and anxiety related effects associated with the 
administration of chemotherapy.2 The study found new benzodiazepine use among New York 
Medicaid beneficiaries recently discharged from the hospital for acute cardiac events and cancer 
declined 72.5% and 69.4%, respectively during the two-year observation period after the 
benzodiazepine triplicate regulation was implemented. Additionally, Simoni-Wastila et al.73 
studied patients who had a diagnosis of schizophrenia, epilepsy, or bipolar disorder, where 
benzodiazepines represent an effective first-line or adjunct treatment option, and demonstrated 
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a nearly 50% decline in benzodiazepine use six months after the policy change. Patients with a 
seizure disorder experienced a 60% decline, the largest among the conditions assessed. 
 Despite the prominent role of benzodiazepines in the US prescription drug epidemic, 
there is a notable absence of the studies evaluating how current PDMP legislation impacts 
benzodiazepine behaviors. Of the 49 operational PDMPs as of December 2014, 48 have the 
authority to monitor Schedule IV CS which includes benzodiazepines.80,83 The aim of this study is 
to understand the impact of PDMPs on the dispensing of benzodiazepines by quantifying the 
impact of having a PDMP become operational on the percentage of beneficiaries who fill a 
benzodiazepine prescription, estimating the relationship between the presence of a PDMP 
monitoring Schedule IV CS an the likelihood of filling a benzodiazepine prescription, testing for 
evidence of a chilling effect in the presence of a PDMP, and identifying the association between 
the presence of a PDMP monitoring Schedule IV CS and potentially inappropriate 
benzodiazepine dispensing.  
METHODS 
 Data were extracted from a large private insurance claims database for the time period 
between January 2007 and December 2009 for continuously eligible beneficiaries (≥1090 days) 
from all 50 states and the District of Columbia who were between 19 and 64 years of age 
throughout the duration of the study period. The claims database includes patient socio-
demographic information and codes related to interactions with the healthcare system. 
Benzodiazepine dispensing during the study period was represented by a claim for any 
benzodiazepine during a given month of the study period and identified using national drug 
codes. Psychiatric disorders for which benzodiazepines are indicated or commonly prescribed 
including anxiety103 (ICD-9 codes: 300.xx, excluding 300.4), insomnia103 (307.41, 307.42, and 
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780.52), and depression174 (296.2x, 296.3x, 300.4, and 311) were also identified in the database. 
These conditions were used as a proxy for legitimate benzodiazepine use to test of the presence 
of a chilling effect. Beneficiaries were considered to have a specific psychiatric disorder if they 
had a claim in any position at any time during the study period with a diagnosis including one of 
the ICD-9 diagnostic codes listed above.  
 The operational status of PDMPs was considered monthly. The monthly time period was 
chosen because PDMP implementations take immediate effect (i.e., beginning on a specified 
date all dispensing of monitored CS must be reported to the system). The use of monthly time 
periods also allowed for the observation of short-term (<12 months) and long-term (≥12 
months) trends related to the dispensing of benzodiazepines associated with the 
implementation of a PDMP. To be considered operational PDMPs had to be actively collecting 
CS dispensing data and authorized users able to generate CS dispensing reports. For the purpose 
of this study, states were divided into categories based on their PDMP status during the study 
period. States that had an operational PDMP and also monitored Schedule IV CS the entire 
duration of the study were grouped together as were states that did not have an operational 
PDMP or did not monitor Schedule IV CS throughout the study period. States that had a PDMP 
become operational or started monitoring Schedule IV CS during the study period were 
considered individually as the dates the PDMPs became operational varied. The month each 
state’s PDMP became operational was excluded from all analyses as some benzodiazepine 
prescriptions written prior to the PDMP becoming operational may not have been filled 
immediately. The exclusion of this time period is consistent with the methods applied by Ross-
Degnan et al.65 to evaluate the impact of the New York TPP on benzodiazepine use. 
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 To evaluate if having a PDMP monitoring Schedule IV CS become operational impacted 
the proportion of beneficiaries who filled a benzodiazepine prescription, interrupted time series 
methods were employed. States were considered for individual analysis if they had a PDMP 
become operational during the study period, had a minimum observation period of 12 months 
before and after PDMP implementation to allow for adequate trend analysis and, on average, 
had more than 30 beneficiaries fill a benzodiazepine prescription each month. Time series 
analyses using autoregressive integrated moving average (ARIMA) models estimated changes in 
the level and trend, in addition to 95% confidence intervals (CI), of the percent of beneficiaries 
in each state who filled a benzodiazepine prescription during each of the months prior to and 
after the PDMP became operational. A change in level is described by Ramsay et al.230 as the 
difference between the observed level at the first intervention time point and that predicted by 
the pre-intervention time trend, and a change in trend as the difference between post- and pre-
intervention slopes. States that did not have the operational status of their PDMP change 
throughout the study period were used as controls to account for any underlying secular trends 
that may have concurrently affected the dispensing of benzodiazepines. States that did not have 
a PDMP monitoring Schedule IV CS in place throughout the study and those states that did were 
evaluated separately to determine if other underlying and unobserved factors related to either 
having or not having an operational PDMP monitoring Schedule IV CS may have partially 
accounted for the results observed in the state implementing the PDMP. 
 Panel data methods using random effects were employed to examine the effect PDMPs 
monitoring Schedule IV CS had on the likelihood of beneficiaries filling a benzodiazepine 
prescription during the study period. Random effects models were used to control for factors 
unobserved in the data that may have impacted the dispensing of benzodiazepines (i.e., 
alternate prescription drug abuse policies, changes in news coverage surrounding prescription 
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drug abuse, changing attitudes towards treatments for anxiety, depression, and insomnia). 
Multivariate logistic regression models adjusted for presence of a PDMP, sex, age, race, 
presence of psychiatric disorders, state and month specific unemployment rates, and time in 
months were used to estimate the adjusted odds ratio (AOR) and associated 95% CI of filling a 
benzodiazepine prescription. The covariates, with the exception of the monthly unemployment 
rates and the time trend variable, were operationalized as indicator variables. Age was 
segregated into two categories based on the study population’s median age, 19 to 44 and 45 to 
64, and was calculated based on the beneficiary’s year of birth. Race was divided into four 
categories: white, black, Hispanic, and other race. State and month specific unemployment rates 
acquired from the US Bureau of Labor Statistics227 were used to adjust for the economic climate 
that was especially volatile during the study period and included in the model because 
unemployment has previously been shown to be associated with benzodiazepine use.164 The 
unemployment variable was operationalized as a continuous variable representing the 
percentage of the states’ workforce who were without a job, actively seeking employment, and 
available for work during a given month. The monthly time trend variable was operationalized 
as an ordinal variable taking the values 1 through 36, with 1 representing January 2007 and 36 
representing December 2009, and included to capture the effects that trend in one direction 
over time.  
 The first multivariate logistic regression model used a linear form to determine factors 
that influence the likelihood of filling a benzodiazepine prescription among beneficiaries in the 
study population. This model took the form of 
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Where        is the odds of filling a benzodiazepine prescription for beneficiary   residing in 
state   in month  . The variable        indicates the presence of an operational PDMP in state 
  in month  . The matrix   identifies demographic characteristics for beneficiary   including sex, 
race, and age, and the matrix   represents the presence of a psychiatric disorder diagnosis 
including anxiety, depression, and insomnia for beneficiary   and the occurrence of a 
combination of these psychiatric disorders. The variable            is the unemployment rate 
for state   in month   and       is the monthly time trend variable. Finally,   is a normal 
independent identically distributed (i.i.d.) error term. 
 To better understand the effect of PDMPs on the likelihood of filling a benzodiazepine 
prescription an interaction model was estimated. This model estimated the effect of PDMPs in 
conjunction with the beneficiary specific predictor variables to understand how subgroups 
within the population are potentially differentially impacted by the presence of a PDMP. The 
interaction model utilized took the form of  
                                                              
               
Linear combinations of coefficients estimated the likelihood of filling a benzodiazepine 
prescription among subgroups within the population in the presence of an operational PDMP 
monitoring Schedule IV CS. The odds of filling a benzodiazepine prescription in the presence of a 
PDMP monitoring Schedule IV CS was compared to the likelihood of doing so in the absence of 
such a program.  
A third multivariate regression model was estimated to determine if the presence of a 
PDMP alone, or if instead, individual program characteristics has the greatest impact on 
benzodiazepine dispensing. This model analyzing PDMP characteristics took the form of  
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In this model        represents the presence of an operational PDMP monitoring Schedule IV 
CS in state   in month  . The matrix     denotes the housing agency of the PDMP in state   in 
month  . Housing agencies were grouped together based on the primary focus of the agency in 
which the PDMP was housed. For the purpose of this analysis housing agencies were 
categorized as “health focused” (e.g., departments of public health), “safety focused” (e.g., law 
enforcement agencies or agencies with a safety focused mission), and “licensing boards” (e.g., 
Boards of Pharmacy). Health focused agencies were identified by observing if the work ‘health’ 
was in the name of the housing agency. Likewise, safety focused agencies were identified if the 
word ‘safety’ or ‘protection’ was present in the housing agency’s name. Law enforcement 
housing agencies were initially considered separately from safety focused agencies. Due to lack 
of variation between states housed in law enforcement agencies the variable was dropped from 
the model. The decision was made to combine safety focused agencies and law enforcement 
agencies as their primary mission is to protect and serve the public. Licensing boards were 
evaluated separately because even though they may be health centric their primary purpose is 
to serve the profession they represent. Controlled substance Schedules monitored by the PDMP 
are represented by the matrix  . The authority to monitor non-controlled substances are 
denoted in matrix . Groups authorized to access the PDMP and obtain information from the 
system are represented by the matrix  . Groups of authorized users included in this analysis are 
pharmacists and law enforcement agents who were able to access the system without requiring 
a warrant. Physicians were not included to avoid the issue of collinearity as all states with a 
PDMP monitoring Schedule IV CS also allowed physician access to the system. Finally, the  
matrix characterizes the frequency with which CS dispensing was required to be reported to the 
PDMP and includes monthly, bi-monthly, weekly, and daily reporting frequencies.  
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Statistical significance was considered using the Wald χ2 p-value associated with the 
interaction term. The a priori level of significance for all analyses was set at 0.05. Data use was 
approved by the University of Kentucky Institutional Review Board. Statistical analyses was 
conducted using Stata 13.0 (StataCorp., College Station, TX). 
RESULTS 
 A total of 2,827,874 beneficiaries met the inclusion criteria of this study. Baseline 
characteristics and benzodiazepine utilization are described in Table 6.1. The population was 
divided evenly between males and females (48% vs. 52%) and the median age assessed in 2007 
was 44 years (interquartile range (IQR) 35-52). Nearly two-thirds (63%) of the population had 
received at least some college education or had earned a college degree. The study population 
was also predominately white (74%) with blacks (5%) Hispanics (8%) and beneficiaries of other 
races (12%) comprising only one-quarter of the sample. Anxiety and depression diagnoses were 
each found in 12% of the study population with 6% of beneficiaries having had received an 
insomnia diagnosis during this timeframe. Throughout the study period the proportion of 
beneficiaries who filled a benzodiazepine prescription in each month increased steadily (Figure 
6.1) with a total of 443,380 (16%) unique beneficiaries having filled at least one prescription for 
a benzodiazepine.  
 Overall, 19 states had an operational PDMP monitoring Schedule IV CS during the entire 
study period. Eighteen states did not have an operational PDMP throughout the study duration. 
Four states had an operational PDMP in place during the study period but did not monitor 
Schedule IV CS. An additional nine states had a PDMP become operational during the study, and 
one state had a PDMP in place during the entire study period but began monitoring Schedule IV 
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CS during the study period. A description of the states and their PDMP status from January 2007 
through December 2009 are presented in Table 6.2. 
Interrupted Time Series Analysis 
 Tables 6.3a-6.3f present results from the interrupted time series analyses. All values in 
the tables are interpreted as percentages. The first column of results in each of the tables shows 
the rate of increase in the trend of benzodiazepine dispensing before and after the PDMP was 
implemented in the state of interest, the change in the rate of benzodiazepine dispensing after 
the PDMP was implemented compared to before, and the change in the level of benzodiazepine 
dispensing in the month immediately following the implementation of the PDMP compared to 
the month immediately preceding the PDMP implementation. The second column of the results 
shows the results of the interrupted time series analysis for states without an operational PDMP 
monitoring Schedule IV CS throughout the duration of the study period. The last column shows 
the results for states that did have a PDMP in place monitoring Schedule IV CS during the entire 
study period. These last two columns were analyzed and included to determine if other 
underlying and unobserved factors related to either having or not having an operational PDMP 
monitoring Schedule IV CS may have partially accounted for the results observed in the state of 
interest.  
Among the states that had a PDMP become operational during the study period, six 
(Arizona, Connecticut, Illinois, Iowa, Louisiana, and South Carolina) met the requirements for 
individual trend analysis. Of these states only Iowa experienced a changed in the trend of 
beneficiaries who filled a benzodiazepine prescription after their PDMP became operational. 
Prior to January 2009 when the PDMP was implemented in Iowa, the percentage of beneficiaries 
in that state who filled a benzodiazepine prescription was increasing by a rate of 3% (0.03; 95% 
 
 110 
CI: 0.02, 0.04; p<0.01; Table 6.3d) each month. After the PDMP was implemented the 
percentage of beneficiaries who filled a benzodiazepine prescription increased at a rate of 6% 
each month (0.06; 95% CI: 0.04, 0.08; p<0.01). The observed increase in the slope of the trend 
line of Iowa beneficiaries filling a benzodiazepine prescription after the PDMP became 
operational was determined to be statistically significant (0.03, 95% CI: 0.01, 0.05; p<0.01). At 
the same time there was no change observed in the percent of beneficiaries who filled a 
benzodiazepine prescription in states with an operational PDMP monitoring Schedule IV CS 
throughout the study period (0.00; 95% CI: 0.00, 0.01; p=0.31) or without an operational PDMP 
monitoring Schedule IV CS throughout the study period (-0.01; 95% CI: -0.03, 0.00; p=0.12). 
 A change in the level of beneficiaries who filled a benzodiazepine prescription was 
observed in Connecticut and Iowa. In the August 2008, the first month after the Connecticut 
PDMP became operational, there was a statistically significant decrease the proportion of 
beneficiaries who filled a benzodiazepine prescription (-0.15; 95% CI: -0.30, -0.01; p=0.04). At 
the same time, no change in the level was observed in states that throughout the study period 
monitored Schedule IV CS (-0.01; 95% CI: -0.13, 0.11; p=0.89) or did not monitor Schedule IV CS 
(-0.02; 95% CI: -0.18, 0.15; p=0.84). A similar finding was observed in Iowa where in February 
2009, the first month after the PDMP became operational, there was a statistically significant 
decrease in the proportion of beneficiaries who filled a benzodiazepine prescription (-0.28; 95% 
CI: -0.48, -0.08; p=0.01). Additionally, there was no observed change in the level of beneficiaries 
who filled a benzodiazepine prescription among states that throughout the duration of the 
study period monitored Schedule IV CS (-0.04, 95% CI: -0.12, 0.05; p=0.39) or did not monitor 
Schedule IV CS (-0.12; 95% CI: -0.25, 0.01; p=0.08).  
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 Results from the interrupted time series analyses also suggest that while the beginning 
of Schedule IV monitoring in Illinois and PDMP implementation in South Carolina occurring in 
January 2008 did not have a direct effect on the trend or level of the proportion of beneficiaries 
who filled a benzodiazepine prescription (Tables 6.3c and 6.3f), states that did not have a PDMP 
monitoring Schedule IV CS throughout the study period had a statistically significant increase in 
the level of the proportion of beneficiaries who filled a benzodiazepine prescription during this 
timeframe (0.26; 95% CI: 0.16, 0.37; p<0.01). Also of note was that states that did not monitor 
Schedule IV CS throughout the study period experienced a decline in the rate of increase of the 
proportion of beneficiaries who filled a benzodiazepine prescription during the same timeframe 
when the PDMPs in Arizona, Connecticut, and Louisiana became operational, however, a similar 
change in these states was not observed (Tables 6.3a, 6.3b, and 6.3e). 
 In most states that implemented a PDMP monitoring Schedule IV CS during the study 
period the relative effect of the program, based on pre-PDMP predicted values, was not 
statistically significant (Figures 6.3a-6.3f). Two states, Connecticut (Figure 6.2b) and Iowa (Figure 
6.2d), had significant reductions in the proportion of beneficiaries who filled a benzodiazepine 
prescription. In each instance the significance of this effect was negated after only three 
months. In Connecticut the PDMP resulted in a 5.26% (95% CI: -9.71%, -0.35%; p=0.04) 
reduction in the proportion of beneficiaries who filled a benzodiazepine prescription in the first 
month after implementation based on pre-PDMP predicted values. This was followed by a 5.22% 
(95% CI: -9.93%, 0.00%; p=0.04) and 5.17% (95% CI: 10.11%, 0.00%; p=0.05) reduction in the 
second and third months before becoming insignificantly different from pre-PDMP predicted 
values. In Iowa the relative effect of the PDMP in the first month based on pre-PDMP predicted 
values was a 9.74% (95% CI: -15.96%, -2.11%; p=0.01) reduction in the proportion of 
beneficiaries who filled a benzodiazepine prescription. This was followed by a 7.96% (95% CI: -
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14.14%, -1.22%; p=0.02) and 6.74% (95% CI: 12.63%, 0.00%; p=0.05) reduction in the 
subsequent months before the relative effect of the PDMP was no longer significant.  
Multivariate Logistic Regression Analysis 
 In the overall study population, the odds of filling a benzodiazepine prescription were 
influenced by the presence of an operational PDMP monitoring Schedule IV CS, sex, race, age, 
presence of a psychiatric disorder, the unemployment rate, and time (Table 6.4). The odds of 
filling a benzodiazepine prescription were two times greater for females compared to males 
(AOR: 2.07; 95% CI: 2.04-2.10) and 2.5 times higher for beneficiaries 45-64 years of age than 
beneficiaries 19-44 (AOR 2.52; 95% CI: 2.49-2.55). Having received a diagnosis for a psychiatric 
disorder during the study period also significantly increased the likelihood of filling a 
benzodiazepine prescription during the study period. Among beneficiaries having received a 
diagnosis of anxiety, the odds of filling a benzodiazepine prescription were 48 times greater 
(AOR: 47.92; 95% CI: 46.84-49.02) compared to beneficiaries without a diagnosis. Having 
received a diagnosis for insomnia increased the likelihood of filling a benzodiazepine 
prescription 10 times (AOR: 10.23; 95% CI: 10.00-10.46) and among those with depression the 
odds of filling a benzodiazepine prescription were nearly 10 times greater than those without a 
diagnosis (AOR: 9.91; 95% CI: 9.70-10.13). Additionally, the time trend variable included in the 
model suggests that as time progressed during the study period, the odds of a beneficiary filling 
a benzodiazepine prescription in a given month were also increasing (AOR: 1.02; 95% CI: 1.02-
1.02).  
Conversely, beneficiaries identified and black, Hispanic, or other race were less likely 
than white beneficiaries to have filled a benzodiazepine prescription during the study period. 
The odds of Hispanic (AOR: 0.63; 95% CI: 0.61-0.64) and beneficiaries of other race (AOR: 0.64; 
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95% CI: 0.63-0.65) filling a benzodiazepine prescription were only about 60% of that of white 
beneficiaries while black beneficiaries were only half as likely to fill a benzodiazepine 
prescription compared to their white counterparts (AOR: 0.49; 95% CI: 0.48-0.51). Beneficiaries 
diagnosed with multiple psychiatric comorbidities were significantly less likely to fill a 
benzodiazepine prescription than beneficiaries without any diagnosis of a psychiatric disorder 
(AOR: 0.22; 95% CI: 0.21-0.22). Also, the presence of an operational PDMP monitoring Schedule 
IV CS lowered the odds of filling a benzodiazepine prescription. When such a PDMP was present 
the odds of filling a benzodiazepine prescription were only 92% (AOR: 0.92; 95% CI: 0.92-0.93) of 
that compared to instances where one was not. 
 Results from the interaction model determining whether PDMPs have a differential 
impact on specific subgroups of beneficiaries by interacting the PDMP indicator variable with 
beneficiary specific predictor variables are presented in Table 6.4. Adjusted for the covariates 
described previously, results from the interaction model infer that the presence of a PDMP 
monitoring Schedule IV CS differentially impacts the likelihood that specific subgroups within 
the population fill a prescription for a benzodiazepine. For the reference group of white males, 
between the ages of 19 and 44, and absent a diagnosis of anxiety, depression or insomnia, the 
presence of a PDMP monitoring schedule IV CS decreased the likelihood of filling a 
benzodiazepine prescription to 97% (AOR: 0.97; 95% CI: 0.95-0.98) of what they were when one 
is not present or monitoring Schedule IV CS. For females, non-white beneficiaries, and those 
between 45 and 64 years of age, the odds were further decreased. When a PDMP was 
operational and monitoring Schedule IV CS females were only 95% (AOR: 0.95; 0.94-0.97) as 
likely to fill a benzodiazepine prescription compared to the reference group, blacks 93% (AOR: 
0.93; 95% CI: 0.90-0.97), Hispanics 91% (AOR: 0.91; 95% CI: 0.88-0.94), beneficiaries of another 
race 92% (AOR: 0.92; 95% CI: 0.89-0.94), and those between 45 and 64 years of age 90% (AOR: 
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0.90; 95% CI: 0.88-0.91). Conversely, those beneficiaries who had received an anxiety diagnosis 
were 12% more likely (AOR: 1.12; 95% CI: 1.10-1.14) to fill a benzodiazepine prescription when 
there was an operational PDMP monitoring Schedule IV CS than the reference group. 
Beneficiaries who had been diagnosed with insomnia had 11% (AOR: 1.11; 95% CI: 1.08-1.13) 
greater odds of filling a benzodiazepine prescription in the presence of a PDMP monitoring 
Schedule IV CD than the reference group, and beneficiaries diagnosed with depression were 2% 
more likely (AOR: 1.02; 95% CI: 1.00-1.05) to fill a benzodiazepine prescription. 
Linear combinations of effect estimates (Table 6.5) demonstrate that in the presence of 
a PDMP monitoring Schedule IV CS, females, beneficiaries identified as black, Hispanic, or other 
race, those 45 and older, and who had multiple psychiatric disorder diagnoses experienced 
reduced odds of filling a benzodiazepine prescription. In the presence of a PDMP monitoring 
Schedule IV CS the odds of filling a benzodiazepine prescription for females was 92% (AOR: 0.92; 
95% CI: 0.90-0.94) what they were when no program was operational. For blacks the odds were 
reduced to 90% (AOR: 0.90; 95% CI: 0.86-0.94), Hispanics 88% (AOR: 0.88; 95% CI: 0.85-0.91), 
beneficiaries of other races 89% (AOR: 0.89; 95% CI: 0.86-0.91), and those 45 and older only had 
87% (AOR: 0.87; 95% CI: 0.85, 0.88) of the odds of filling a benzodiazepine prescription in the 
presence of PDMP monitoring Schedule IV CS compared to when no program was operational. 
Of note, females (AOR: 1.94; 95% CI: 1.90-1.98) and those 45 and older (AOR: 2.27; 95% CI: 2.22-
2.31) were still approximately two times more likely to fill a benzodiazepine prescription in the 
presence of a PDMP monitoring Schedule IV CS than their male and younger counterparts. 
However, the presence of a PDMP monitoring Schedule IV CS further reduced the odds of black 
(AOR: 0.45; 95% CI: 0.43-0.47), Hispanic (AOR: 0.57; 95% CI: 0.55-0.59), and beneficiaries of 
other race (AOR: 0.59; 95% CI: 0.57-0.60) filling a benzodiazepine prescription to nearly half that 
of white beneficiaries. Likewise, those with multiple psychiatric disorder diagnoses were only 
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94% (AOR: 0.94; 95% CI: 0.91-0.98) as likely to fill a benzodiazepine prescription when there was 
a PDMP monitoring Schedule IV CS further reducing the odds of filling a benzodiazepine 
prescription to only 20% (AOR: 0.21; 95% CI: 0.20-0.22) of those absent any psychiatric disorder 
diagnosis. 
 In the presence of a PDMP monitoring Schedule IV CS, beneficiaries who had received 
an anxiety or insomnia diagnosis during the study period experienced greater odds of filling a 
benzodiazepine prescription compared to when no program was operational. Beneficiaries who 
had received an anxiety diagnosis were 8% (AOR: 1.08; 95% CI; 1.06–1.11) more likely to fill a 
benzodiazepine prescription. Likewise, those who had been diagnosed with insomnia 
experienced a 7% increase (AOR: 1.07; 95% CI: 1.04–1.10) increase in their odds of filling a 
benzodiazepine prescription.  
 Characteristics of PDMPs during the study period between January 2007 and December 
2009 are presented in Table 6.7. Results from the model testing whether the presence of a 
PDMP alone or instead individual characteristics of the program affect benzodiazepine 
dispensing are reported in Table 6.8. The findings indicate that it is individual characteristics of 
the PDMP, and not the presence of the PDMP alone, that have an effect on the likelihood of 
filling a benzodiazepine prescription. The model found that beneficiaries residing in a state 
where the PDMP was housed in a safety focused agency were less likely (AOR: 0.70; 95% CI: 
0.68, 0.73) to fill a benzodiazepine prescription. There was no observed effect on the likelihood 
of filling a benzodiazepine prescription in states were the PDMP was housed in a health focused 
agency (AOR: 0.97; 95% CI: 0.93, 1.01) or a licensing board (AOR: 1.00; 95% CI: 0.97, 1.04). 
Authorized access to a beneficiary’s CS history report by pharmacists and law enforcement 
officials resulted in an increase in the odds of filling a benzodiazepine prescription. When 
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pharmacists were allowed to access CS history reports, in addition to submitting CS dispensing 
records, there was a 24% increase (AOR: 1.24; 95% CI: 1.21, 1.27) in the odds of filling a 
benzodiazepine prescription. When law enforcement officials hand the ability to access a 
beneficiary’s CS history report there was a 3% increase (AOR: 1.03; 95% CI: 1.01, 1.05) in the 
odds of filling a benzodiazepine prescription. Regarding the CS Schedules monitored by the 
PDMP, there was no effect observed on the odds of filling a benzodiazepine prescription when 
the program only monitored Schedule II & III CS (AOR: 1.03; 95% CI: 0.99, 1.06) or Schedule II-IV 
CS (AOR: 1.01; 95% CI: 0.95, 1.07) compared to Schedule II CS monitoring only. When the CS 
Schedules monitored included Schedule II-V there was a 17% increase (AOR: 1.17; 95% CI: 1.12, 
1.24) in the likelihood of filling a benzodiazepine prescription. The addition of the authority to 
monitor non-controlled substances, however, resulted in a decrease in the odds of filling a 
benzodiazepine prescription (AOR: 0.91; 95% CI: 0.89, 0.93). When compared beneficiaries in 
states with PDMPs that only required CS dispensing to be reported monthly, those residing in 
states that mandated bi-monthly (AOR: 0.87; 95% CI: 0.85, 0.88) or daily (AOR: 0.74; 95% CI: 
0.66, 0.83) experienced decreased odds of filling a benzodiazepine prescription. However, a 10% 
increase in the odds (AOR: 1.10; 95% CI: 1.07, 1.13) of filling a benzodiazepine prescription was 
found among those residing in states where weekly reporting of CS dispensing to the PDMP was 
required. 
DISCUSSIONS 
 In this sample of continuously eligible adult beneficiaries in the United States, PDMPs 
monitoring Schedule IV CS impacted benzodiazepine dispensing. The findings of the interrupted 
time series analyses suggested that in the month following the PDMP implementations in 
Connecticut and Iowa there was a significant decrease in the level of the percentage of each 
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states’ beneficiaries who filled a benzodiazepine prescription. Results also indicated that in the 
year after the PDMP in Iowa became operational the proportion of beneficiaries who filled a 
benzodiazepine prescription each month was increasing at a faster rate than it was prior to the 
PDMP going into effect. This finding was at least partially negated by the decrease in the level of 
the proportion of beneficiaries who filled a benzodiazepine prescription which resulted in the 
relative effect of the PDMP being a significant reduction in the proportion of beneficiaries who 
filled a benzodiazepine prescription in the first three months following implementation with no 
significant difference detected thereafter.   
The PDMP implementation in Connecticut and Iowa created a shock to the system and 
the trend of benzodiazepine dispensing to beneficiaries as the percentage of the population 
who filled a benzodiazepine prescription was significantly lower in the month following the 
PDMP implementation compare to the month prior to the program. The relative effect of these 
shocks in each of these two states were only observed for three months before the observed 
percentage of the population who filled a benzodiazepine prescription approached their 
predicted values as no PDMP been implemented. These results from Connecticut and Iowa in 
conjunction with the other states that had a PDMP implemented during the study period 
suggest that with regards to benzodiazepine dispensing PDMP implementation may have a 
modest short-term effect on the percentage of the beneficiaries who fill a prescription, however 
there is not significant long-term impact as healthcare providers and patients will adjust to the 
new policy and the proportion of beneficiaries who fill a benzodiazepine prescription will 
approach their pre-PDMP predicted values. 
Furthermore, benzodiazepine dispensing was indirectly impacted in some states by the 
implementation of a PDMP monitoring Schedule IV CS. In Illinois and South Carolina, two states 
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that began monitoring Schedule IV CS in January 2008, having the PDMP become operational 
may have prevented the rate of benzodiazepine dispensing from increasing at a faster rate. 
States that did not monitor Schedule IV CS during 2008 and 2009 experienced an increase in the 
trend of the proportion of beneficiaries who filled a benzodiazepine prescription in each month 
whereas there was no evidence of a change in the trends observed in Illinois and South Carolina. 
This result suggests that there may have been an unobserved factor occurring at this time that 
was associated with an increasing proportion of beneficiaries who filled a benzodiazepine 
prescription but the effect of this factor was mitigated by the presence of a PDMP as states that 
had a PDMP throughout the study period, in addition to Illinois and South Carolina, did not have 
a significant change in the trend of the proportion of beneficiaries who filled a benzodiazepine 
prescription between January 2008 and December 2009 compared to January through 
December of 2007.  
Of interest is the finding after PDMPs were implemented in Arizona, Connecticut, and 
Louisiana there was no evidence of a change in the trend regarding the proportion of 
beneficiaries who filled a benzodiazepine prescription each month, however, in states that did 
not have a PDMP monitoring Schedule IV CS during this time experienced a decline in the trend. 
One explanation is that there was an alternative intervention occurring concurrently that 
targeted states without Schedule IV CS monitoring, as states that had a PDMP in place 
throughout also did not experience a decline in the trend of benzodiazepine dispensing.  
 Results from the linear logistic regression model found an association between an 
operational PDMP monitoring Schedule IV CS and a reduction in the odds of filling a 
benzodiazepine prescription. Furthermore, the interaction model provided evidence that PDMPs 
may differentially influence the likelihood of filling a benzodiazepine prescription among certain 
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subgroups within the population. Females, blacks, Hispanics, beneficiaries of other races, those 
between the ages of 45 and 64, and those with more than one psychiatric condition were 
significantly less likely to fill a benzodiazepine prescription during the study period when 
Schedule IV CS were being monitored by a PDMP. Even with having an operational PDMP, 
females and beneficiaries between 45 and 64 remained more likely to fill a benzodiazepine 
prescription than their male and younger counterparts, a finding that is in line with existing 
evidence demonstrating that in the general US population, benzodiazepines are more likely to 
be prescribed to females and older individuals.166 The finding that having an operational PDMP 
was associated with black, Hispanic, and beneficiaries of other races being even less like to fill a 
benzodiazepine prescription is consistent with findings reported by Pearson et al.74 who found 
Medicaid beneficiaries residing in predominately black, Hispanic, or mixed race neighborhoods 
were consistently more likely to have their benzodiazepine therapy discontinued after they 
were added to the list of medications monitored by the New York TPP. 
 No evidence of a chilling effect was detected among beneficiaries who received a 
diagnosis of anxiety or insomnia during the study period. Moreover, the odds of beneficiaries 
with these diagnoses filling a benzodiazepine prescription were greater when a PDMP 
monitoring Schedule IV CS was operational. As benzodiazepines are indicated to manage 
symptoms associated with these conditions, this suggests that PDMPs, as they pertain to 
benzodiazepines, do not induce a chilling effect by restricting access to pharmacotherapy 
options among those with a diagnosis of anxiety or insomnia, two conditions where 
benzodiazepine therapy is appropriate. An explanation for this finding is that prescribers and 
dispensers may have felt more confident in their decisions surrounding benzodiazepine use in a 
patient with these conditions in the presence of a PDMP. This potential increase in confidence 
may be because the information contained within a patient’s CS history report could give a more 
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comprehensive depiction of the patient’s CS use history and allow for a quick determination of 
the appropriateness of benzodiazepine in the patient ad their propensity to abuse or divert the 
medication. 
 Of interest was the result that patients with multiple psychiatric diagnoses were 
significantly less likely to fill a benzodiazepine prescription than those without any psychiatric 
diagnoses, and furthermore, the presences of a PDMP monitoring Schedule IV CS further 
depressed these odds. This finding indicates that benzodiazepines are not prescribed and 
dispensed to patients with more severe and complex psychiatric illness. This could be because 
alternate therapeutic options are being utilized in these patients as severe psychiatric disorders 
have been acknowledged as a risk factor for substance use disorders.231 The finding that PDMPs 
monitoring Schedule IV CS further reduces the likelihood of filling a benzodiazepine prescription 
indicates that prescribers and dispensers may be using a patient’s CS history report to identify 
those most at risk of inappropriate benzodiazepine use.  
 After adjusting for individual characteristics of PDMPs, it was determined that it is 
individual characteristics of these programs, and not the presence of the program itself, that 
impact the likelihood of filling a benzodiazepine prescription. An interesting finding was that 
safety focused housing agencies of PDMPs were associated with a significant decrease in the 
likelihood of filling a benzodiazepine prescription. This finding may be due to increased 
reluctances of prescribing and dispensing benzodiazepines, and other CS, by healthcare 
providers due to fears of investigations and prosecutions related to CS prescribing and 
dispensing behaviors. Also of interest was that more frequent reporting requirements, with the 
exception of weekly reporting, was associated with lower odds of filling a benzodiazepine 
prescription. During the timeframe of this study only North Dakota had a mandate requiring 
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dispensers to report daily their CS dispensing records. Therefore, the finding of weekly reporting 
of CS dispensing requirements being associated with an increase in the odds of filling a 
benzodiazepine prescription may be related to healthcare providers feeling they had a 
comprehensive insight into the patient’s history of CS behaviors and thus an increase confidence 
in the prescribing and dispensing of benzodiazepines to their patients. 
 Of note is the result that law enforcement access to PDMPs was associated with a slight 
increase in the odds of filling a benzodiazepine prescription. This categorization does not take 
into account the types of law enforcement officials who have access to information from the 
PDMP or the process necessary for them to acquire that information. For example, in some 
states law enforcement officials may be required to be pursuing an active investigation in order 
to obtain a CS history report while in other states only a select few law enforcement officials are 
allowed to directly access and obtain CS history reports from the PDMP. These officials are then 
responsible for disseminating that report or the information contained within to other law 
enforcement officials as needed. These variations in laws pertaining to law enforcement access 
should be considered when evaluating the meaningfulness of this particular finding. 
 Limitations to this study exist. First, this study employs data for a nationally 
representative sample extracted from private insurance claims database and may not accurately 
represent the overall US population. Due to the utilization of a claims database this study could 
not account for prescription medications acquired from sources outside the healthcare system 
or paid for using cash. Additionally, this study utilized diagnostic codes for psychiatric 
comorbidities for which benzodiazepines are indicated and/or commonly prescribed as proxies 
for appropriate benzodiazepines use. While these proxies may not encompass all facets of 
appropriate benzodiazepine use they are consistent with the goals of PDMPs in mitigating 
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prescription drug abuse and its consequences while maintaining access to those with a 
legitimate need for CS medications. Also, this study did not account for the number of 
benzodiazepine prescriptions filled or the quantity and dosage of these prescriptions. However, 
as the aim of this study was to understand the impact of PDMPs on the likelihood of filling a 
benzodiazepine prescription among privately insured beneficiaries this information was not 
required. Differences may exist between what was written in PDMP legislation and what was 
practiced. For example, even though some states had the authority to monitor non-controlled 
substances they may not have been actively doing so. Additionally, variability in the 
operationalization of PDMPs housed within the same type of housing agency is possible, (e.g., 
types of PDMP requestor accounts, requirements for determining the necessity of requesting a 
report) and may impact the observed findings, however, decisions on how individual PDMPs are 
operationalized are made in order to achieve the overall goals and mission of the program, 
which are likely similar among programs housed within the same type of agency. 
 The findings presented in this study indicated that PDMPs monitoring Schedule IV CS 
have an impact on the dispensing of benzodiazepines. Using an interrupted time series model 
evidence was provided that indicated having a PDMP monitoring Schedule IV CS become 
operational directly and indirectly impacted benzodiazepine dispensing trends. The presence of 
a PDMP monitoring Schedule IV CS was found to decrease the likelihood of filling a 
benzodiazepine prescription, especially for those beneficiaries who were female, black, 
Hispanic, of another race, between 45 and 64 years of age, or who had multiple psychiatric 
disorders. On the other hand, beneficiaries diagnosed with only anxiety or insomnia during the 
study period experienced an increase in their odds of filling a benzodiazepine prescription 
suggesting that for beneficiaries diagnosed with these conditions there was no “chilling effect” 
induced by a PDMP. Furthermore, specific characteristics of PDMPs were found to have a 
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significant effect on the odds of filling a benzodiazepine prescription, and should be considered 
when amending current PDMPs laws in order to assist effort of mitigating the prescription drug 
abuse crisis. 
The findings in this study provide support for PDMPs as an effective tool to address the 
prescription drug abuse epidemic in the US as it pertains to benzodiazepines. Future studies 
regarding the relationship between PDMPs and benzodiazepines should explore clinical 
outcomes experienced by those who have their benzodiazepine therapy discontinued to better 
understand the economic and societal costs associated with PDMPs. Future policy amendments 
should focus on reducing the potential for disparities in benzodiazepine access among 
vulnerable groups within the population. As PDMPs become a more widely utilized tool to 
combat prescription drug abuse and diversion more research is needed to understand their 
clinical utility and ensure they do no obstruct access to legitimate pharmacotherapies. 
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Table 6.1. Demographic characteristics of continuously enrolled, commercially insured adults 
in the United States. 
  Number of beneficiaries (%) 
Sample size 2,827,874 
Benzodiazepine utilization  
Filled benzodiazepine prescription 443,380 (16%) 
Gender  
Male 1,354,884 (48%) 
Female 1,472,990 (52%) 
Age  
Mediana (IQR) 44 (35-52) 
Education  
High school diploma or less 955,281 (34%) 
Some college or college degree 1,787,429 (63%) 
Race  
White 2,085,190 (74%) 
Black 146,165 (5%) 
Hispanic 240,090 (8%) 
Other 331,325 (12%) 
Psychiatric disorder diagnosis  
Anxiety 325,107 (12%) 
Depression 352,750 (12%) 
Insomnia 175,090 (6%) 
Multiple psychiatric disorder diagnoses 206,112 (7%) 
a Median age was evaluated for the year 2007  
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Table 6.2. Prescription drug monitoring programs tracking the dispensing of Schedule IV 
controlled substances for the period January 2007 – December 2009.31 
PDMP operational 
throughout study period 
No PDMP operational 
throughout study 
period 
PDMP operational but 
Schedule IV CS not 
monitored 
PDMP became 
operational during 
study period (date of 
PDMP implementation) 
Alabama Alaska Massachusetts Arizona 
California Arkansas Pennsylvania (October 2008) 
Hawaii Delaware Rhode Island Colorado 
Idaho District of Columbia Texas (July 2007) 
Indiana Florida  Connecticut 
Kentucky Georgia  (July 2008) 
Maine Kansas  Illinoisa 
Michigan Maryland  (January 2008) 
Mississippi Minnesota  Iowa 
Nevada Missouri  (January 2009) 
New Mexico Montana  Louisiana 
New York Nebraska  (November 2008) 
Ohio New Hampshire  North Carolina  
Oklahoma New Jersey  (July 2007) 
Tennessee Oregon  North Dakota 
Utah South Dakota  (September 2007) 
Virginia Washington  South Carolina 
West Virginia Wisconsin  (January 2008) 
Wyoming   Vermont 
   (January 2009) 
a Prior to Jan. 2008 Illinois had a PDMP in place but only electronically monitored Schedule II CS 
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Table 6.3a. Interrupted time series analysis examining the percentage of beneficiaries filling a 
benzodiazepine prescription by month (Arizona). 
 Arizona 
States with no PDMP 
throughout the study 
period 
States with a PDMP 
throughout the study 
period 
 
Coefficient 
p-value 
95% Confidence 
Interval 
Coefficient 
p-value 
95% Confidence 
Interval 
Coefficient 
p-value 
95% Confidence 
Interval 
Monthly rate of increase in 
beneficiaries filling a 
benzodiazepine 
prescription prior to PDMP  
0.02 
<0.01 
0.02, 0.03 
0.04 
<0.01 
0.04, 0.05 
0.02 
<0.01 
0.01, 0.03 
Monthly rate of increase in 
beneficiaries filling a 
benzodiazepine 
prescription after PDMP 
implementation 
0.03 
<0.01 
0.02, 0.03 
0.03 
<0.01 
0.03, 0.05 
0.02 
<0.01 
0.02, 0.03 
Change in the rate of 
increase of beneficiaries 
filling a benzodiazepine 
prescription pre/post 
PDMP 
0.00 
0.29 
0.00a, 0.01 
-0.01 
0.04 
-0.03, 0.00a 
0.00 
0.51 
-0.01, 0.01 
Change in the level one 
month after PDMP 
implementation 
-0.06 
0.17 
-0.14, 0.03 
-0.08 
0.11 
-0.17, 0.02 
-0.01 
0.43 
-0.30, 0.13 
a Confidence interval contains 0.00 due to rounding 
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Table 6.3b. Interrupted time series analysis examining the percentage of beneficiaries filling a 
benzodiazepine prescription by month (Connecticut). 
 Connecticut 
States with no PDMP 
throughout the study 
period 
States with a PDMP 
throughout the study 
period 
 
Coefficient 
p-value 
95% Confidence 
Interval 
Coefficient 
p-value 
95% Confidence 
Interval 
Coefficient 
p-value 
95% Confidence 
Interval 
Monthly rate of increase in 
beneficiaries filling a 
benzodiazepine 
prescription prior to PDMP  
0.03 
<0.01 
0.02, 0.04 
0.04 
<0.01 
0.03, 0.05 
0.02 
<0.01 
0.01, 0.03 
Monthly rate of increase in 
beneficiaries filling a 
benzodiazepine 
prescription after PDMP 
implementation 
0.03 
<0.01 
0.02, 0.04 
0.02 
<0.01 
0.01, 0.03 
0.02 
<0.01 
0.02, 0.03 
Change in the rate of 
increase of beneficiaries 
filling a benzodiazepine 
prescription pre/post 
PDMP 
0.00 
0.65 
-0.02, 0.01 
-0.02 
0.01 
-0.03, -0.01 
0.00 
0.70 
-0.01, 0.01 
Change in the level one 
month after PDMP 
implementation 
-0.15 
0.04 
-0.30, 0.01 
-0.03 
0.72 
-0.16, 0.11 
0.01 
0.82 
-0.11, 0.14 
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Table 6.3c. Interrupted time series analysis examining the percentage of beneficiaries filling a 
benzodiazepine prescription by month (Illinois). 
 Illinois 
States with no PDMP 
throughout the study 
period 
States with a PDMP 
throughout the study 
period 
 
Coefficient 
p-value 
95% Confidence 
Interval 
Coefficient 
p-value 
95% Confidence 
Interval 
Coefficient 
p-value 
95% Confidence 
Interval 
Monthly rate of increase in 
beneficiaries filling a 
benzodiazepine 
prescription prior to PDMP  
0.03 
<0.01 
0.02, 0.04 
0.03 
<0.01 
0.02, 0.03 
0.02 
<0.01 
0.01, 0.04 
Monthly rate of increase in 
beneficiaries filling a 
benzodiazepine 
prescription after PDMP 
implementation 
0.02 
<0.01 
0.01, 0.03 
0.02 
<0.01 
0.02, 0.03 
0.02 
<0.01 
0.02, 0.03 
Change in the rate of 
increase of beneficiaries 
filling a benzodiazepine 
prescription pre/post 
PDMP 
-0.01 
0.26 
-0.02, 0.01 
0.00 
0.59 
-0.02, 0.01 
0.00 
0.91 
-0.01, 0.01 
Change in the level one 
month after PDMP 
implementation 
-0.08 
0.30 
-0.22, 0.07 
0.20 
<0.01 
0.09, 0.31 
-0.03 
0.65 
-0.15, 0.10 
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Table 6.3d. Interrupted time series analysis examining the percentage of beneficiaries filling a 
benzodiazepine prescription by month (Iowa). 
 Iowa 
States with no PDMP 
throughout the study 
period 
States with a PDMP 
throughout the study 
period 
 
Coefficient 
p-value 
95% Confidence 
Interval 
Coefficient 
p-value 
95% Confidence 
Interval 
Coefficient 
p-value 
95% Confidence 
Interval 
Monthly rate of increase in 
beneficiaries filling a 
benzodiazepine 
prescription prior to PDMP  
0.03 
<0.01 
0.02, 0.04 
0.04 
<0.01 
0.03, 0.04 
0.02 
<0.01 
0.02, 0.02 
Monthly rate of increase in 
beneficiaries filling a 
benzodiazepine 
prescription after PDMP 
implementation 
0.06 
<0.01 
0.04, 0.08 
0.03 
<0.01 
0.02, 0.04 
0.03 
<0.01 
0.02, 0.03 
Change in the rate of 
increase of beneficiaries 
filling a benzodiazepine 
prescription pre/post 
PDMP 
0.03 
<0.01 
0.01, 0.05 
-0.01 
0.18 
-0.02, 0.01 
0.00 
0.38 
-0.01, 0.01 
Change in the level one 
month after PDMP 
implementation 
-0.28 
0.01 
-0.48, -0.08 
-0.11 
0.06 
-0.22, 0.01 
0.00 
0.95 
-0.08, 0.08 
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Table 6.3e. Interrupted time series analysis examining the percentage of beneficiaries filling a 
benzodiazepine prescription by month (Louisiana). 
 Louisiana 
States with no PDMP 
throughout the study 
period 
States with a PDMP 
throughout the study 
period 
 
Coefficient 
p-value 
95% Confidence 
Interval 
Coefficient 
p-value 
95% Confidence 
Interval 
Coefficient 
p-value 
95% Confidence 
Interval 
Monthly rate of increase in 
beneficiaries filling a 
benzodiazepine 
prescription prior to PDMP  
0.03 
<0.01 
0.02, 0.04 
0.04 
<0.01 
0.03, 0.05 
0.02 
<0.01 
0.01, 0.03 
Monthly rate of increase in 
beneficiaries filling a 
benzodiazepine 
prescription after PDMP 
implementation 
0.04 
<0.01 
0.04, 0.05 
0.03 
<0.01 
0.02, 0.04 
0.02 
<0.01 
0.02, 0.03 
Change in the rate of 
increase of beneficiaries 
filling a benzodiazepine 
prescription pre/post 
PDMP 
0.01 
0.45 
-0.01, 0.03 
-0.01 
0.04 
-0.03, 0.00a 
0.00 
0.51 
-0.01, 0.01 
Change in the level one 
month after PDMP 
implementation 
-0.13 
0.14 
-0.31, 0.04 
-0.11 
0.02 
-0.22, -0.02 
-0.03 
0.57 
-0.13, 0.07 
a Confidence interval contains 0.00 due to rounding 
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Table 6.3g. Interrupted time series analysis examining the percentage of beneficiaries filling a 
benzodiazepine prescription by month (South Carolina). 
 South Carolina 
States with no PDMP 
throughout the study 
period 
States with a PDMP 
throughout the study 
period 
 
Coefficient 
p-value 
95% Confidence 
Interval 
Coefficient 
p-value 
95% Confidence 
Interval 
Coefficient 
p-value 
95% Confidence 
Interval 
Monthly rate of increase in 
beneficiaries filling a 
benzodiazepine 
prescription prior to PDMP  
0.05 
<0.01 
0.03, 0.07 
0.03 
<0.01 
0.02, 0.03 
0.02 
<0.01 
0.01, 0.04 
Monthly rate of increase in 
beneficiaries filling a 
benzodiazepine 
prescription after PDMP 
implementation 
0.04 
<0.01 
0.02, 0.05 
0.02 
<0.01 
0.02, 0.03 
0.02 
<0.01 
0.02, 0.03 
Change in the rate of 
increase of beneficiaries 
filling a benzodiazepine 
prescription pre/post 
PDMP 
-0.01 
0.43 
-0.03, 0.01 
0.00 
0.59 
-0.02, 0.01 
0.00 
0.91 
-0.01, 0.01 
Change in the level one 
month after PDMP 
implementation 
-0.10 
0.38 
-0.33, 0.13 
0.20 
<0.01 
0.09, 0.31 
-0.03 
0.65 
-0.15, 0.10 
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Table 6.4. Odds of filling a benzodiazepine prescription between January 2007 and December 
2009 among continuously enrolled adult beneficiaries in the United States. 
Variable Odds Ratio p-value 95% Confidence Interval 
PDMP    
No operational PDMP monitoring 
Schedule IV CS Ref.   
PDMP operational and 
monitoring Schedule IV CS 0.92 <0.01 0.92 – 0.93 
Sex    
Male Ref.   
Female 2.07 <0.01 2.04 – 2.10 
Race    
White Ref.   
Black 0.49 <0.01 0.48 – 0.51 
Hispanic 0.63 <0.01 0.61 – 0.64 
Other 0.64 <0.01 0.63 – 0.65 
Age    
Age 44 and under Ref.   
Age 45 and over 2.52 <0.01 2.49 – 2.55 
Diagnosis of a Psychiatric Disorder    
No psychiatric disorder diagnosis Ref.   
Anxiety 47.92 <0.01 46.84 – 49.02 
Depression 9.91 <0.01 9.70 – 10.13 
Insomnia 10.23 <0.01 10.00 – 10.46 
Multiple psychiatric diagnoses 0.22 <0.01 0.21 – 0.22 
Economic Climate    
Unemployment ratea 1.00 0.03 1.00 – 1.00b 
Time Trend    
Additional monthc 1.02 <0.01 1.02 – 1.02 
a Unemployment rate interpretation is the effect of a one percentage point increase in the 
unemployment rate 
b Confidence interval includes 1.00 due to rounding 
c Month interpretation is  the effect of time progressing forward one additional month 
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Table 6.5. Odds of filling a benzodiazepine prescription among subgroups within a population 
of continuously enrolled adult beneficiaries in the United States between January 2007 and 
December 2009. 
Variable Odds Ratio p-value 95% Confidence Interval 
PDMP    
No operational PDMP monitoring 
Schedule IV CS Ref.   
PDMP operational and 
monitoring Schedule IV CS 0.97 <0.01 0.95 – 0.98 
Sex    
Male Ref.   
Female 2.11 <0.01 2.08 – 2.14 
Race    
White Ref.   
Black 0.50 <0.01 0.49 – 0.52 
Hispanic 0.64 <0.01 0.63 – 0.66 
Other 0.66 <0.01 0.65 – 0.68 
Age    
Age 44 and under Ref.   
Age 45 and over 2.62 <0.01 2.59 – 2.66 
Diagnosis of a Psychiatric Disorder    
No psychiatric disorder diagnosis Ref.   
Anxiety 45.99 <0.01 44.90 – 47.10 
Depression 9.83 <0.01 9.60 – 10.05 
Insomnia 9.85 <0.01 9.61 – 10.09 
Multiple psychiatric diagnoses 0.22 <0.01 0.21 – 0.23 
Economic Climate    
Unemployment rate 1.00 0.05 1.00 – 1.00a 
Time Trend    
Additional month 1.02 <0.01 1.02 – 1.02 
Interaction variables    
PDMP * Female 0.96 <0.01 0.94 – 0.97 
PDMP * Black 0.93 <0.01 0.90 – 0.97 
PDMP * Hispanic 0.91 <0.01 0.88 – 0.94 
PDMP * Other 0.92 <0.01 0.89 – 0.94 
PDMP * Age over 45 0.90 <0.01 0.88 – 0.91 
PDMP * Anxiety 1.12 <0.01 1.10 – 1.14 
PDMP * Depression 1.02 0.03 1.00a – 1.05 
PDMP * Insomnia 1.11 <0.01 1.08 – 1.13 
PDMP * Multiple psychiatric 
diagnoses 0.98 <0.01 0.94 – 1.01 
b Confidence interval includes 1.00 due to rounding 
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Table 6.6. Linear combinations of effect estimates comparing odds of subgroups within a 
population of continuously enrolled adult beneficiaries in the United States filling a 
benzodiazepine prescription with and without the presence of a PDMP monitoring Schedule 
IV controlled substances. 
Variable 
Odds of filling a 
benzodiazepine 
prescription when no 
PDMP monitoring 
Schedule IV CS is 
present 
(p-value) 
(95% CI) 
Odds of filling a 
benzodiazepine 
prescription when a 
PDMP monitoring 
Schedule IV CS is 
present 
(p-value) 
(95% CI) 
Comparison of odds of 
filling a benzodiazepine 
prescription when a 
PDMP monitoring 
Schedule IV CS is 
present to without 
(p-value) 
(95% CI) 
Female 
2.11 1.94 0.92 
<0.01 <0.01 <0.01 
(2.18 – 2.14) (1.90 – 1.98) (0.90 – 0.94) 
Black 
0.50 0.45 0.90 
<0.01 <0.01 <0.01 
(0.49 – 0.52) (0.43 – 0.47) (0.86 – 0.94) 
Hispanic 
0.64 0.57 0.88 
<0.01 <0.01 <0.01 
(0.63 – 0.66) (0.55 – 0.59) (0.85 – 0.91) 
Other 
0.66 0.59 0.89 
<0.01 <0.01 <0.01 
(0.65 – 0.68) (0.57 – 0.60) (0.86 – 0.91) 
Age 45 and over 
2.62 2.27 0.87 
<0.01 <0.01 <0.01 
(2.59 – 2.66) (2.22 – 2.31) (0.85 – 0.88) 
Anxiety 
45.99 49.74 1.08 
<0.01 <0.01 <0.01 
(44.90 – 47.10) (48.31 – 51.22) (1.06 – 1.11) 
Depression 
9.83 9.72 0.99 
<0.01 <0.01 0.15 
(9.60 – 10.05) (9.44 – 10.01) (0.96 – 1.01) 
Insomnia 
5.78 10.55 1.07 
<0.01 <0.01 <0.01 
(5.67 – 5.89) (10.23 – 10.88) (1.04 – 1.10) 
Multiple psychiatric 
disorder diagnoses 
0.22 0.21 0.94 
<0.01 <0.01 <0.01 
(0.21 – 0.23) (0.20 – 0.22) (0.91 – 0.98) 
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Table 6.7. Characteristics of prescription drug monitoring programs 2007-2009.31,32 
State Housing Agency Authorized Users Schedules Monitored 
Reporting 
Frequency 
Alabama Health Focused Prescribers Pharmacists II-V Weekly 
Arizona Licensing Board Prescribers Pharmacists II-IV Weekly 
California Safety Focused 
Prescribers 
Pharmacists 
Law Enforcement 
II-IV Monthly 
Colorado Licensing Board Prescribers Pharmacists II-V Bi-monthly 
Connecticut Safety Focused Prescribers Pharmacists II-V Weekly 
Hawaii Safety Focused Prescribers Pharmacists II-IV Monthly 
Idaho Licensing Board 
Prescribers 
Pharmacists 
Law Enforcement 
II-IV 
Non-controlled 
substances 
Monthly 
Illinois Health Focused 
Prescribers 
Pharmacists 
Law Enforcement 
II-III 
(until Dec 31, 2007) 
II-V 
(starting Jan 1, 2008) 
Bi-monthly 
Indiana Licensing Board Prescribers Law Enforcement II-IV Bi-monthly 
Iowa Licensing Board Prescribers Pharmacists II-IV Bi-monthly 
Kentucky Health Focused 
Prescribers 
Pharmacists 
Law Enforcement 
II-V Weekly 
Louisiana Licensing Board Prescribers Pharmacists II-IV Bi-monthly 
Maine Health Focused Prescribers Pharmacist II-IV Bi-monthly 
Massachusetts Health Focused Prescribers Pharmacists II Monthly 
Michigan Licensing Board 
Prescribers 
Pharmacists 
Law Enforcement 
II-V Monthly 
Mississippi Licensing Board Prescribers Pharmacists 
II-IV 
Non-controlled 
substances 
Monthly 
Nevada Licensing Board Prescribers Pharmacists 
II-V 
Non-controlled 
substances 
Monthly 
New Mexico Licensing Board 
Prescribers 
Pharmacists 
Law Enforcement 
II-IV Monthly 
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Table 6.7. Characteristics of prescription drug monitoring programs 2007-2009 (cont’d). 
New York Health Focused Prescribers II-V Monthly 
North Carolina Health Focused Prescribers Pharmacists II-V Monthly 
North Dakota Licensing Board 
Prescribers 
Pharmacists 
Law Enforcement 
II-V 
Non-controlled 
substances 
Daily 
Ohio Licensing Board Prescribers Pharmacists 
II-V 
Non-controlled 
substances 
Bi-monthly 
Oklahoma Safety Focused Prescribers Pharmacists II-V Monthly 
Tennessee Licensing Board 
Prescribers 
Pharmacists 
Licensing Boards 
II-V Weekly 
Pennsylvania Safety Focused Prescribers Pharmacists II Monthly 
Rhode Island Licensing Board Law Enforcement II-III Monthly 
South Carolina Health Focused 
Prescribers 
Pharmacists 
Law Enforcement 
II-IV Monthly 
Texas Safety Focused 
Prescribers 
Pharmacists 
Law Enforcement 
II Monthly 
Utah Licensing Board Prescribers Pharmacists II-V Monthly 
Vermont Health Focused Prescribers Pharmacists II-IV Weekly 
Virginia Licensing Board Prescribers Pharmacists II-IV Bi-monthly 
West Virginia Licensing Board Prescribers Pharmacists II-V Weekly 
Wyoming Licensing Board Prescribers Pharmacists 
II-V 
Non-controlled 
substances 
Monthly 
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Table 6.8. Characteristics of PDMPs that impact the dispensing of benzodiazepines. 
Variable Odds Ratio p-value 95% Confidence Interval 
PDMP    
No operational PDMP  Ref.   
Operational PDMP 0.96 0.21 0.91 – 1.02 
Housing Agency    
Licensing agency 1.00 0.83 0.97 – 1.04 
Health focused agency 0.97 0.06 0.93 – 1.01 
Safety focused agency 0.70 <0.01 0.68 – 0.73 
Groups Authorized to Access    
No pharmacist access Ref.   
Pharmacists 1.24 <0.01 1.21 – 1.27 
No law enforcement access Ref.   
Law Enforcement Officials 1.03 <0.01 1.01 – 1.05 
Schedules Monitored    
Schedule II only Ref.   
Schedule II & III 1.03 0.13 0.99 – 1.06 
Schedules II-IV 1.01 0.80 0.95 – 1.07 
Schedule II-V 1.17 <0.01 1.12 – 1.24 
Reporting Frequency    
Monthly Ref.   
Bi-monthly 0.87 <0.01 0.85 – 0.88 
Weekly 1.10 <0.01 1.07 – 1.13 
Daily 0.74 <0.01 0.66 – 0.83 
Authority to monitor non-controlled substances  
Non-controlled substance 
monitoring not authorized Ref.   
Authority to monitory non-
controlled substances 0.91 <0.01 0.89 – 0.93 
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Figure 6.1. Percentage of study population who filled a benzodiazepine prescription in each 
month between January 2007 and December 2009. 
 
 
 
Figure 6.2a. Relative effect of PDMP implementation on the proportion of beneficiaries filling 
a benzodiazepine prescription (Arizona).  
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Figure 6.2b. Relative effect of PDMP implementation on the proportion of beneficiaries filling 
a benzodiazepine prescription (Connecticut). 
 
 
Figure 6.2c. Relative effect of PDMP implementation on the proportion of beneficiaries filling 
a benzodiazepine prescription (Illinois). 
 
 
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
4.0%
Pe
rc
en
t o
f C
on
ne
ct
ic
ut
 b
en
ef
ic
ia
rie
s 
Months 
Pre-PDMP
Post-PDMP
Linear (Pre-PDMP)
Linear (Post-PDMP)Connecticut PDMP 
became operational 
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
Pe
rc
en
t o
f I
lli
no
is
 b
en
ef
ic
ia
rie
s 
Months 
Pre-PDMP
Post-PDMP
Linear (Pre-PDMP)
Linear (Post-PDMP)
Illinois PDMP became 
operational 
 
 140 
Figure 6.2d. Relative effect of PDMP implementation on the proportion of beneficiaries filling 
a benzodiazepine prescription (Iowa). 
 
 
Figure 6.2e. Relative effect of PDMP implementation on the proportion of beneficiaries filling 
a benzodiazepine prescription (Louisiana). 
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Figure 6.2g. Relative effect of PDMP implementation on the proportion of beneficiaries filling 
a benzodiazepine prescription (South Carolina). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Sarah Elizabeth Wixson 2015 
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
4.0%
4.5%
5.0%
Pre-PDMP
Post-PDMP
Linear (Pre-PDMP)
Linear (Post-PDMP)South Carolina PDMP 
became operational 
 
 142 
References 
1.  Shorter E. A Historical Dictionary of Psychiatry. New York: Oxford University Press; 2005. 
2.  American Society of Health-System Pharmacists. AHFS Drug Information 2013. American 
Society of Health-System Pharmacists; 2013. 
3.  Lader M. Benzodiazepines revisited: will we ever learn? Addiction. 2011;106(12):2086-
109. 
4.  Wick JY. The history of benzodiazepines.  Consult Pharm. 2013;28(9):538-48. 
5. The Rolling Stones. Mother’s Little Helper. Flowers (Aftermath). 1967. 
6. Brunton LL, Blumenthal DK, Buxton I, Parker KL, eds. Hypnotics and sedatives. In: 
Goodman & Gilman’s Manual of Pharmacology and Therapeutics. 11th ed. New York: 
McGraw-Hill Medical; 2008:262-70. 
7.  Shader RI, Greenblatt DJ, Ciraulo DA. Treatment of dependence on barbiturates, 
benzodiazepines, and other sedative-hypnotics. In: Shader RI, ed. Manual of Psychiatric 
Therapeutics. 3rd ed. Boston: Little Brown; 1994:93. 
8. Kupfer DJ, Reynolds CF. Management of insomnia. New Engl J Med. 1997;336(5):341-6. 
9. Greenblatt DJ, Shader RI, Divoll M, Harmatz JS. Benzodiazepines: a summary of 
pharmacokinetic properties. Br J Clin Pharmacol. 1981;11(S1):11S-16S. 
10. Mandrioli R, Mercolini L, Raggi MA. Metabolism of benzodiazepine and non-
benzodiazepine anxiolytic-hypnotic drugs: an analytical point of view. Curr Drug Metab. 
2010;11(9):815-29. 
11. Paulose-Ram R, Jonas BS, Orwig D, Safran MA. Prescription psychotropic medication use 
among the U.S. adult population: results from the third National Health and Nutrition 
Examination Survey, 1988-1994. J Clin Epidemiol. 2004;57(3):309-17. 
 
 143 
12. The US pharmaceutical market: looking back and looking ahead. IMS Health. 
http://www.goldstandard.com/wp-content/uploads/The-US-Pharmaceutical-Market.pdf 
Published October 9, 2012. Accessed April 17, 2014. 
13. Top 25 medications by dispensed prescriptions (US). IMS Health. 
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/Press%
20Room/2012_U.S/Top_25_Medicines_Dispensed_Prescriptions_U.S..pdf Published 
March 22, 2013. Accessed April 17, 2014. 
14. Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual 
framework and algorithm for differentiating among compounds. J Clin Psychiatry. 
2005;66 Suppl 9:31-41. 
15. O'Brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66 
Suppl 2:28-33. 
16. Substance Abuse and Mental Health Services Administration, Center for Behavioral 
Health Statistics and Quality. (June 2, 2011). The TEDS Report: Substance Abuse 
Treatment Admissions for Abuse of Benzodiazepines. Rockville, MD. 
17. Duka T, Wüster M, Herz A. Benzodiazepines modulate striatal enkephalin levels via a 
GABAergic mechanism. Life Sci. 1980;26(10):771-6. 
18. LaBuda CJ, Fuchs PN. The anxiolytic effect of acute ethanol or diazepam exposure is 
unaltered in mu-opioid receptor knockout mice. Brain Res Bull. 2001;55(6):755-60. 
19. Lopez F, Miller LG, Thompson ML, Schatzki A, Chesley S, Greenblatt DJ, Shader RI. 
Chronic morphine administration augments benzodiazepine binding and GABAA 
receptor function. Psychopharmacology. 1990;101(4):545-9. 
 
 144 
20. Moroni F, Cheney DL, Peralta E, Costa E. Opiate receptor agonists as modulators of 
gamma-aminobutyric acid turnover in the nucleus caudatus, globus pallidus and 
substantia nigra of the rat. J Pharmacol Exp Ther. 1978;207(3):870-7. 
21. Poisnel G, Dhilly M, Le Boisselier R, Barre L, Debruyne D. Comparison of five 
benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor 
regulation. J Pharmacol Sci. 2009;110(1):36-46. 
22. Rocha L, Tatsukawa K, Chugani HT, Engel J Jr. Benzodiazepine receptor binding following 
chronic treatment with naloxone, morphine and met-enkephalin in normal rats. Brain 
Res. 1993;612(1-2):247-52. 
23. Sasaki K, Fan LW, Tien LT, Ma T, Loh HH, Ho IK. The interaction of morphine and gamma-
aminobutyric acid (GABA)ergic systems in anxiolytic behavior: using mu-opioid receptor 
knockout mice. Brain Res Bull. 2002;57(5):689-94. 
24. Panlilio LV, Thorndike EB, Schindler CW. Lorazepam reinstates punishment-suppressed 
remifentanil self-administration in rats. Psychopharmacology. 2005;179(2):374-82. 
25. Walker BM, Ettenberg A. Benzodiazepine modulation of opiate reward. Exp Clin 
Psychopharmacol. 2001;9(2):191-7. 
26. Walker BM, Ettenberg A. The effects of alprazolam on conditioned place preferences 
produced by intravenous heroin. Pharmacol Biochem Behav. 2003;75(1):75-80. 
27. Walker BM, Ettenberg A. Intra-ventral tegmental area heroin-induced place preferences 
in rats are potentiated by peripherally administered alprazolam. Pharmacol Biochem 
Behav. 2005;82(3):470-7. 
28. Longo LP, Johnson B. Addiction: Part I. Benzodiazepines--side effects, abuse risk and 
alternatives. Am Fam Physician. 2000 Apr 1;61(7):2121-8. 
 
 145 
29. Roache JD, Meisch RA. Findings from self-administration research on the addiction 
potential of benzodiazepines. Psychiatr Ann. 1995;25:153-7. 
30. Suggested definitions and relationships among medication misadventures, medication 
errors, adverse drug events, and adverse drug reactions. Am J Health Syst Pharm. 
1998;55(2):165-6. 
31. Balter MB, Manheimer DI, Mellinger GD, Uhlenhuth EH. A cross-national comparison of 
anti-anxiety/sedative drug use. Curr Med Res Opin. 1984;8 Suppl 4:5-20. 
32. Chen Y, Lader M. Long-term benzodiazepine treatment: is it ever justified? Hum 
Psychopharm Clin. 1990;5(4):301-12. 
33. Mellinger GD, Balter MB, Uhlenhuth EH. Prevalence and correlates of the long-term 
regular use of anxiolytics. JAMA. 1984;251(3):375-9. 
34. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term 
benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18(1):37-48. 
35. Owen RT, Tyrer P. Benzodiazepine dependence. A review of the evidence. Drugs. 
1983;25(4):385-98. 
36. Murphy SB, Tyrer P. The essence of benzodiazepine dependence. In: Lader M, ed. The 
Psychopharmacology and Addiction. Oxford: Oxford University Press. 1988;157-67. 
37. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Persistence of cognitive effects after 
withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin 
Neuropsychol. 2004;19(3):437-54. 
38. Charlson F, Degenhardt L, McLaren J, Hall W, Lynskey M. A systematic review of 
research examining benzodiazepine-related mortality. Pharmacoepidemiol Drug Saf.  
2009;18(2):93-103. 
39. Pétursson H. The benzodiazepine withdrawal syndrome. Addiction. 1994;89(11):1455-9. 
 
 146 
40. Colvin R. Prescription drug addiction—the hidden epidemic: a guide to coping and 
understanding. Omaha, NE: Addicus Books; 2002. 
41. American Psychiatric Association. Benzodiazepine Dependence, Toxicity, and Abuse: A 
Task Force Report of the American Psychiatric Association. Carl Salzman, ed. American 
Psychiatric Press; 1990. 
42. Olnes MJ, Golding A, Kaplan PW. Nonconvulsive status epilepticus resulting from 
benzodiazepine withdrawal. Ann Intern Med. 2003 2;139(11):956-8. 
43. Lann MA, Molina DK. A fatal case of benzodiazepine withdrawal. Am J Forensic Med 
Pathol. 2009;30(2):177-9. 
44. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of 
benzodiazepines I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 
1990;47(10):899-907. 
45. Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the 
syndrome and its clinical management. Acta Psychiatr Scand Suppl.1998;393:95-101. 
46. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of 
benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry. 1990;47(10):908-15. 
47. O'Connor K, Bélanger L, Marchand A, Dupuis G, Elie R, Boyer R. Psychological distress 
and adaptational problems associated with discontinuation of benzodiazepines. Addict 
Behav. 1999;24(4):537-41. 
48. Johnson B, Longo LP. Considerations in the physician's decision to prescribe 
benzodiazepines to patients with addiction. Psychiatric Annals. 1998;28(3):160-5. 
49. Manthey L, Lohbeck M, Giltay EJ, van Veena T, Zitman FG, Penninx BW. Correlates of 
benzodiazepine dependence in the Netherlands Study of Depression and Anxiety. 
Addiction. 2012;107(12):2173-82. 
 
 147 
50. Ekström MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC. Safety of 
benzodiazepines and opioids in very severe respiratory disease: national prospective 
study. BMJ. 2014;348:g445. 
51. Vozoris NT. Benzodiazepines and opioids need to be prescribed with caution in 
advanced COPD. Evid Based Med. 2014;19(5):170. 
52. Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially 
inappropriate Prescriptions): application to acutely ill elderly patients and comparison 
with Beers' criteria. Age Ageing. 2008;37(6):673-9. 
53. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American 
Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in 
older adults. J Am Geriatr Soc. 2012;60(4):616-31. 
54. Illegal drugs in America: a modern history. Drug Enforcement Administration Museum 
and Visitors Center. http://www.deamuseum.org/ida/index/html. Accessed April 30, 
2014. 
55. Controlled Substance Act of 1970, 21 USC §812. 
56. Pickens R. Behavioral pharmacology: a brief history. In: Thompson T, Dews PB, eds. 
Advances in behavioral pharmacology. Vol. 1. New York: Academic Press; 1997:229-57. 
57. 21 U.S.C. § 827 (d)(1). 
58. Prescription drugs: state monitoring programs provide useful tools to reduce diversion. 
United States General Accounting Office. Http://www.gao.gov/new.items/d02634.pdf. 
Accessed November 13, 2013. 
59. Ryan Haight Online Pharmacy Consumer Protection Act of 2008. H.R. 6353, 110th Cong. 
§309 (2008). 
 
 148 
60. Blumenschein K, Fink JL, Freeman PR, James K, Kirsh KL, Steinke DT, Talbert J. Review of 
prescription drug monitoring programs in the United States. 
http://chfs.ky.gov/NR/rdonlyres/85989824-1030-4AA6-91E1-
7F9E3EF68827/0/KASPEREvaluationPDMPStatusFinalReport6242010.pdf. Accessed 
September 4, 2012. 
61. Joranson DE, Carrow GM, Ryan KM, Schaefer L, Gilson AM, Good P, Eadie J, Peine S, Dahl 
JL. Pain management and prescription monitoring. J Pain Symptom Manage. 
2002;23(3):231-8. 
62. Gilson AM, Fishman SM, Wilsey BL, Casamalhuapa C, Baxi H. Time series analysis of 
California's prescription monitoring program: impact on prescribing and multiple 
provider episodes. J Pain. 2012;13(2):103-11. 
63. Fisher J, Sanyal C, Frail D, Sketris I. The intended and unintended consequences of 
benzodiazepine monitoring programmes: a review of the literature. J Clin Pharm Ther. 
2012;37(1):7-21. 
64. Hoffman RS, Wipfler MG, Maddaloni MA, Weisman RS. Has the New York State triplicate 
benzodiazepine prescription regulation influenced sedative-hypnotic overdoses? N Y 
State J Med. 1991;91(10):436-9. 
65. Ross-Degnan D, Simoni-Wastila L, Brown JS, Gao X, Mah C, Cosler LE, Fanning T, 
Gallagher P, Salzman C, Shader RI, Inui TS, Soumerai SB. A controlled study of the effects 
of state surveillance on indicators of problematic and non-problematic benzodiazepine 
use in a Medicaid population. Int J Psychiatry Med. 2004;34(2):103-23. 
66. Schwartz HI. An empirical review of the impact of triplicate prescription of 
benzodiazepines. Hosp Community Psychiatry. 1992;43(4):382-5. 
 
 149 
67. New York State Department of Health. Benzodiazepines: prescribing declines under 
triplicate program. Epidemiology Notes. 1989;4(12). 
68. Drug Enforcement Administration. Multiple Copy Prescription Programs Resource Guide. 
Washington DC: US Department of Justice; 1990. 
69. New York State Department of Health. Benzodiazepines: additional effects of the 
triplicate program. Epidemiology Notes. 1990;5(1). 
70. Reidenberg MM. Effect of the requirement for triplicate prescriptions for 
benzodiazepines in New York State. Clin Pharmacol Ther. 1991;50(2):129-31. 
71. Weintraub M, Singh S, Byrne L, Maharaj K, Guttmacher L. Consequences of the 1989 
New York State triplicate benzodiazepine prescription regulations. JAMA. 
1991;266(17):2392-7. 
72. Wagner AK, Soumerai SB, Zhang F, Mah C, Simoni-Wastila L, Cosler L, Fanning T, 
Gallagher P, Ross-Degnan D. Effects of state surveillance on new post-hospitalization 
benzodiazepine use. Int J Qual Health Care. 2003;15(5):423-31. 
73. Simoni-Wastila L, Ross-Degnan D, Mah C, Gao X, Brown J, Cosler LE, Fanning T, Gallagher 
P, Salzman C, Soumerai SB. A retrospective data analysis of the impact of the New York 
triplicate prescription program on benzodiazepine use in Medicaid patients with chronic 
psychiatric and neurologic disorders. Clin Ther. 2004;26(2):322-36. 
74. Pearson SA, Soumerai S, Mah C, Zhang F, Simoni-Wastila L, Salzman C, Cosler LE, Fanning 
T, Gallagher P, Ross-Degnan D. Racial disparities in access after regulatory surveillance 
of benzodiazepines. Arch Intern Med. 2006;166(5):572-9. 
75. Tassinari CA, Michelucci R, Volpi L, Dravet C, Cano J, Roger J. The use of diazepam and 
clonazepam in epilepsy. Epilepsia. 1998;39(S1):S7-S14.  
 
 150 
76. Wang J, Christo PJ. The influence of prescription monitoring programs on chronic pain 
management. Pain Physician. 2009;12(3):507-15.  
77. Brushwood DB. Maximizing the value of electronic prescription monitoring programs. J 
Law Med Ethics. 2003;31(1):41-54. 
78. Berina LF, Guernsey BG, Hokanson JA, Doutré WH, Fuller LE. Physician perception of a 
triplicate prescription law. Am J Hosp Pharm. 1985;42(4):857-9. 
79. Schwartz HI, Blank K. Regulation of benzodiazepine prescribing practices: clinical 
implications. Gen Hosp Psychiatry. 1991;13(4):219-24. 
80. Compilation of state prescription monitoring program maps. The National Alliance for 
Model State Drug Laws.  2014; http://www.namsdl.org/library/593BC7A6-1372-636C-
DD7A83E6A8F6F0BC/. Accessed October 16, 2014. 
81. 42 U.S. Code § 17501 
82. Blumenschein K, Fink J, Freeman P, Kirsh K, Steinke D, Talbert J. Independent evaluation 
of the impact and effectiveness of the Kentucky All Schedule Prescription Electronic 
Reporting Program (KASPER).  2010; http://chfs.ky.gov/NR/rdonlyres/24493B2E-B1A1-
4399-89AD-1625953BAD43/0/KASPEREvaluationFinalReport10152010.pdf. Accessed 
September 4, 2012. 
83. R.I. Gen Laws § 21-28-3.18 
84. Simeone R, Holland L. An evaluation of prescription drug monitoring programs. 
Washington, DC: U.S. Department of Justice, Office of Justice Programs; 2006. 
85. Twillman R. Impact of prescription monitoring programs on prescription patterns and 
indicators of opioid abuse. J Pain. 2006;7(4):S6. 
86. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death 
rates from drug overdose. Pain Med. 2011;12(5):747-54. 
 
 151 
87. Simoni-Wastila L, Qian J. Influence of prescription monitoring programs on analgesic 
utilization by an insured retiree population. Pharmacoepidemiol Drug Saf. 
2012;21(12):1261-8. 
88. Brady JE, Wunsch H, DiMaggio C, Lang BH, Giglio J, Li G. Prescription drug monitoring 
and dispensing of prescription opioids. Public Health Rep. 2014;129(2):139-47. 
89. Li, G., Brady, J. E., Lang, B. H., Giglio, J., Wunsch, H., & DiMaggio, C. Prescription drug 
monitoring and drug overdose mortality. Injury epidemiology, 2014;1:e9. 
90. Baehren DF, Marco CA, Droz DE, Sinha S, Callan EM, Akpunonu P. A statewide 
prescription monitoring program affects emergency department prescribing behaviors. 
Ann Emerg Med. 2010;56(1):19-23.e1-3. 
91. Green TC, Mann MR, Bowman SE, Zaller N, Soto X, Gadea J, Cordy C, Kelly P, Friedmann 
PD. How does use of a prescription monitoring program change pharmacy practice? J 
Am Pharm Assoc. 2013;53(3):273-81. 
92. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. 
JAMA. 2013;309(7):657-9. 
93. Centers for Disease Control and Prevention (CDC). CDC grand rounds: prescription drug 
overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10-3. 
94. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United 
States. Pharmacoepidemiol Drug Saf. 2006;15(9):618-27. 
95. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, Crosby AE, Paulozzi LJ. 
Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 
2008;300(22):2613-20. 
96. Webster LR, Cochella S, Dasgupta N, Fakata KL, Fine PG, Fishman SM, Grey T, Johnson 
EM, Lee LK, Passik SD, Peppin J, Porucznik CA, Ray A, Schnoll SH, Stieg RL, Wakeland W. 
 
 152 
An analysis of the root causes for opioid-related overdose deaths in the United States. 
Pain Med. 2011;12(S2):S26-35. 
97. Shah NA, Abate MA, Smith MJ, Kaplan JA, Kraner JC, Clay DJ. Characteristics of 
alprazolam-related deaths compiled by a centralized state medical examiner. Am J 
Addict. 2012;21(S1):S27-34. 
98. Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 
2008;182:335-60. 
99. Chan GM, Stajic M, Marker EK, Hoffman RS, Nelson LS. Testing positive for methadone 
and either a tricyclic antidepressant or a benzodiazepine is associated with an accidental 
overdose death: analysis of medical examiner data. Acad Emerg Med. 2006;13(5):543-7. 
100. Oliver P, Keen J. Concomitant drugs of misuse and drug using behaviours associated 
with fatal opiate-related poisonings in Sheffield, UK, 1997-2000. Addiction. 
2003;98(2):191-7. 
101. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and 
comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey 
Replication. Arch Gen Psychiatry. 2005;62(6):617-27. 
102. Karaz SS. Insomnia in psychiatric disorders. In: Attarian HP, ed Clinical Handbook of 
Insomnia. New York: Humana Press; 2004. 
103. Shader RI, Greenblatt DJ, Balter MB. Appropriate use and regulatory control of 
benzodiazepines. J Clin Pharmacol. 1991;31(9):781-4. 
104. Substance Abuse and Mental Health Services Administration, Results from the 2012 
National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series 
H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental 
Health Services Administration, 2013. 
 
 153 
105. Substance Abuse and Mental Health Services Administration, Drug Abuse Warning 
Network, 2011: National Estimates of Drug-Related Emergency Department Visits. HHS 
Publication No. (SMA) 13-4760, DAWN Series D-39. Rockville, MD: Substance Abuse and 
Mental Health Services Administration, 2013. 
106. Cai R, Crane E, Poneleit K, Paulozzi L. Emergency department visits involving nonmedical 
use of selected prescription drugs in the United States, 2004-2008. J Pain Palliat Care 
Pharmacother. 2010;24(3):293-7. 
107. Stitzer ML, Griffiths RR, McLellan AT, Grabowski J, Hawthorne JW. Diazepam use among 
methadone maintenance patients: patterns and dosages. Drug Alcohol Depend. 
1981;8(3):189-99. 
108. Brands B, Blake J, Marsh DC, Sproule B, Jeyapalan R, Li S. The impact of benzodiazepine 
use on methadone maintenance treatment outcomes. J Addict Dis. 2008;27(3):37-48. 
109. Hardo PG, Kennedy TD. Night sedation and arthritic pain. J R Soc Med. 1991;84(2):73-5. 
110. Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine 
combination use. Drug Alcohol Depend. 2012;125(1-2):8-18. 
111. Bair MJ, Wu J, Damush TM, Sutherland JM, Kroenke K. Association of depression and 
anxiety alone and in combination with chronic musculoskeletal pain in primary care 
patients. Psychosom Med. 2008;70(8):890-7. 
112. Clark RE, Xie H, Brunette MF. Benzodiazepine prescription practices and substance 
abuse in persons with severe mental illness. J Clin Psychiatry. 2004;65(2):151-5. 
113. Brunette MF, Noordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among 
patients with severe mental illness and co-occurring substance use disorders. Psychiatr 
Serv. 2003;54(10):1395-401. 
 
 154 
114. Substance Abuse and Mental Health Services Administration, Results from the 2012 
National Survey on Drug Use and Health: Mental Health Findings, NSDUH Series H-47, 
HHS Publication No. (SMA) 13-4805. Rockville, MD: Substance Abuse and Mental Health 
Services Administration, 2013. 
115. Wixson SE, Brouwer ES. Sex differences in benzodiazepine use in the HIV-infected 
population. AIDS Care. 2014;26(10):1218-22 
116. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, Turner BJ, 
Eggan F, Beckman R, Vitiello B, Morton SC, Orlando M, Bozzette SA, Ortiz-Barron L, 
Shapiro M. Psychiatric disorders and drug use among human immunodeficiency virus-
infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721-8. 
117. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, Lo Caputo S, 
Narciso P, Pauluzzi S, Carosi G, Nappa S, Piano P, Izzo CM, Lichtner M, Rezza  G, 
Monforte A, Ippolito G, d'Arminio Moroni M, Wu AW, Antinori A; AdICONA Study Group. 
Self-reported symptoms and medication side effects influence adherence to highly 
active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 
2001;28(5):445-9. 
118. Jolly E, Aguirre L, Jorge E, Luna C. [Acute effect of lorazepam on respiratory muscles in 
stable patients with chronic obstructive pulmonary disease]. Medicina. 1996;56(5 Pt 
1):472-8. 
119. Cohn MA, Morris DD, Juan D. Effects of estazolam and flurazepam on cardiopulmonary 
function in patients with chronic obstructive pulmonary disease. Drug Saf. 
1992;7(2):152-8. 
 
 155 
120. Beaupré A, Soucy R, Phillips R, Bourgouin J. Respiratory center output following 
zopiclone or diazepam administration in patients with pulmonary disease. Respiration. 
1988;54(4):235-40. 
121. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of 
patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 
2004;23(6):932-46. 
122. Vozoris NT, Fischer HD, Wang X, Anderson GM, Bell CM, Gershon AS, Stephenson AL, Gill 
SS, Rochon PA. Benzodiazepine use among older adults with chronic obstructive 
pulmonary disease: a population-based cohort study. Drugs Aging. 2013;30(3):183-92. 
123. Vozoris NT, Fischer HD, Wang X, Stephenson AL, Gershon AS, Gruneir A, Austin PC, 
Anderson GM, Bell CM, Gill SS, Rochon PA. Benzodiazepine drug use and adverse 
respiratory outcomes among older adults with COPD. Eur Respir J. 2014;44(2):332-40. 
124. Winkelmayer WC, Mehta J, Wang PS. Benzodiazepine use and mortality of incident 
dialysis patients in the United States. Kidney Int. 2007;72(11):1388-93. 
125. VA/DoD Clinical Practice Guidelines. US Department of Veterans Affairs. 2014. 
http://www.healthquality.va.gov/post_traumatic_stress_disorder_ptsd.asp. Accessed 
May 19, 2014. 
126. Hawkins EJ, Malte CA, Grossbard J, Saxon AJ, Imel ZE, Kivlahan DR. Comparative safety 
of benzodiazepines and opioids among veterans affairs patients with posttraumatic 
stress disorder. J Addict Med. 2013 Sep-Oct;7(5):354-62. 
127. Lindley CM, Tully MP, Paramsothy V, Tallis RC. Inappropriate medication is a major 
cause of adverse drug reactions in elderly patients. Age Ageing. 1992;21:294-300. 
 
 156 
128. Rawson NSB, D’Arcy C. Self-reported sedative-hypnotic drug use in Canada: an update. 
In: Coburn D, D’Arcy C, Torrance GM, ed. Health and Canadian Society: Sociological 
Perspectives. 3rd ed. Toronto: University of Toronto Press; 1998:214-37. 
129. van Hulten R, Leufkens HG, Bakker A. Usage patterns of benzodiazepines in a Dutch 
community: a 10-year follow-up. Pharm World Sci. 1998;20(2):78-82. 
130. Ohayon MM, Caulet M, Priest RG, Guilleminault C. Psychotropic medication 
consumption patterns in the UK general population. J Clin Epidemiol. 1998;51(3):273-83. 
131. Dealberto MJ, Seeman T, McAvay GJ, Berkman L. Factors related to current and 
subsequent psychotropic drug use in an elderly cohort. J Clin Epidemiol. 1997;50(3):357-
64. 
132. Olfson M, King M, Schoenbaum M. Benzodiazepine Use in the United States. JAMA 
Psychiatry. 2015;72(2):136-42. 
133. Hanlon JT, Horner RD, Schmader KE, Fillenbaum GG, Lewis IK, Wall WE Jr, Landerman LR, 
Pieper CF, Blazer DG, Cohen HJ. Benzodiazepine use and cognitive function among 
community-dwelling elderly. Clin Pharmacol Ther. 1998;64(6):684-92. 
134. Paterniti S, Dufouil C, Alpérovitch A. Long-term benzodiazepine use and cognitive 
decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol. 
2002;22(3):285-93. 
135. Billioti de Gage S, Bégaud B, Bazin F, Verdoux H, Dartigues JF, Pérès K, Kurth T, Pariente 
A. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 
2012;345:e6231. 
136. Billioti de Gage S, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, Pariente A, 
Bégaud B. Benzodiazepine use and risk of Alzheimer's disease: case-control study. BMJ. 
2014;349:g5205. 
 
 157 
137. Cutson TM, Gray SL, Hughes MA, Carson SW, Hanlon JT. Effect of a single dose of 
diazepam on balance measures in older people. J Am Geriatr Soc. 1997;45(4):435-40. 
138. Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, Marra CA. Meta-
analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern 
Med. 2009;169(21):1952-60. 
139. Pariente A, Dartigues JF, Benichou J, Letenneur L, Moore N, Fourrier-Réglat A. 
Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging. 
2008;25(1):61-70. 
140. Xing D, Ma XL, Ma JX, Wang J, Yang Y, Chen Y. Association between use of 
benzodiazepines and risk of fractures: a meta-analysis. Osteoporos Int. 2014;25(1):105-
20. 
141. French DD, Spehar AM, Campbell RR, Palacios P, Coakley RW, Coblio N, Means H, 
Werner DC, Angaran DM. Outpatient benzodiazepine prescribing, adverse events, and 
costs. In: Advances in patient safety: from research to implementation. Vol 1. Rockville, 
MD: Agency for Healthcare Research and Quality;2014:185-98. 
142. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor 
vehicle crashes in elderly drivers. Am J Epidemiol. 1992;136(7):873-83. 
143. Hemmelgarn B, Suissa S, Huang A, Boivin JF, Pinard G. Benzodiazepine use and the risk 
of motor vehicle crash in the elderly. JAMA. 1997;278(1):27-31. 
144. Witek MW, Rojas V, Alonso C, Minami H, Silva RR. Review of benzodiazepine use in 
children and adolescents. Psychiatr Q. 2005;76(3):283-96. 
145. Fortuna RJ, Robbins BW, Caiola E, Joynt M, Halterman JS. Prescribing of controlled 
medications to adolescents and young adults in the United States. Pediatrics. 
2010;126(6):1108-16. 
 
 158 
146. Johnston, L. D., O’Malley, P. M., Bachman, J. G., & Schulenberg, J. E. Monitoring the 
Future national survey results on drug use, 1975–2011. Volume 1: Secondary school 
students. Ann Arbor: Institute for Social Research, The University of Michigan. 
http://www.monitoringthefuture.org/pubs/monographs/mtf-vol1_2011.pdf Accessed 
February 13, 2013. 
147. McCabe SE, West BT. Medical and nonmedical use of prescription benzodiazepine 
anxiolytics among U.S. high school seniors. Addict Behav. 2014;39(5):959-64. 
148. McCabe SE, Boyd CJ, Young A. Medical and nonmedical use of prescription drugs among 
secondary school students. J Adolesc Health. 2007;40(1):76-83. 
149. McCabe SE, West BT, Cranford JA, Ross-Durow P, Young A, Teter CJ, Boyd CJ. Medical 
misuse of controlled medications among adolescents. Arch Pediatr Adolesc Med. 
2011;165(8):729-35. 
150. McCabe SE, West BT, Morales M, Cranford JA, Boyd CJ. Does early onset of non-medical 
use of prescription drugs predict subsequent prescription drug abuse and dependence? 
Results from a national study. Addiction. 2007;102(12):1920-30. 
151. American Pharmacists Association. Drug Information Handbook. 22nd ed. Hudson, OH: 
Lexi-Comp Inc.; 2013. 
152. COPD. American Lung Association. http://www.lung.org/lung-disease/copd/. Accessed 
April 21, 2013.  
153. Trends in COPD. American Lung Association. http://www.lung.org/finding-cures/our-
research/trend-reports/copd-trend-report.pdf. Accessed September 9, 2014.  
154. Global strategy for the diagnosis, management, and prevention of chronic obstructive 
pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease. 
 
 159 
http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf. Accessed 
April 15, 2013. 
155. Wier LM, Elixhauser A, Pfuntner A, Au DH. Overview of hospitalizations among patients 
with COPD, 2008: Statistical Brief #106. Healthcare Cost and Utilization Project (HCUP) 
Statistical Briefs. Rockville (MD): Agency for Health Care Policy and Research (US); 2011.  
156. Roth T. Hypnotic use for insomnia management in chronic obstructive pulmonary 
disease. Sleep Med. 2009;10(1):19-25. 
157. Klink M, Quan SF. Prevalence of reported sleep disturbances in a general adult 
population and their relationship to obstructive airways diseases. Chest. 1987;91(4):540-
6. 
158. Klink ME, Dodge R, Quan SF. The relation of sleep complaints to respiratory symptoms in 
a general population. Chest. 1994;105(1):151-4. 
159. Budhiraja R, Roth T, Hudgel DW, Budhiraja P, Drake CL. Prevalence and 
polysomnographic correlates of insomnia comorbid with medical disorders. Sleep. 
2011;34(7):859-67. 
160. Gay PC. Chronic obstructive pulmonary disease and sleep. Respir Care. 2004;49(1):39-
51. 
161. Di Marco F, Verga M, Reggente M, Maria Casanova F, Santus P, Blasi F, Allegra L, 
Centanni S. Anxiety and depression in COPD patients: The roles of gender and disease 
severity. Respir Med. 2006;100(10):1767-74. 
162. Kunik ME, Roundy K, Veazey C, Souchek J, Richardson P, Wray NP, Stanley MA. 
Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. 
Chest. 2005;127(4):1205-11. 
 
 160 
163. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, 
Wang PS; National Comorbidity Survey Replication. The epidemiology of major 
depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). 
JAMA. 2003;289(23):3095-105. 
164. Parsons LS. Reducing bias in a propensity score matched-pair sample using Greedy 
matching techniques. Proceedings of the 26th Annual SAS Users Group International 
Conference, Cary, NC: SAS Institute Inc, 2001.  
165. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a 
competing risk. The Annals of Statistics. 1988:1141-54. 
166. Simon GE, VonKorff M, Barlow W, Pabiniak C, Wagner E. Predictors of chronic 
benzodiazepine use in a health maintenance organization sample. J Clin Epidemiol. 
1996;49(9):1067-73. 
167. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of 
myocardial infarction and stroke following exacerbation of COPD. Chest. 
2010;137(5):1091-7. 
168. Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined 
mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United 
States. J Acquir Immune Defic Syndr. 2006;42(3):298-306. 
169. Elliott A. Anxiety and HIV infection. STEP Perspective. 1998;98(1):11-4. 
170. Rubinstein ML, Selwyn PA. High prevalence of insomnia in an outpatient population with 
HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19(3):260-5. 
171. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 
2007;3(5 Suppl):S7-10. 
 
 161 
172. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger 
JD, Chesney MA, Moss A. Adherence to protease inhibitors, HIV-1 viral load, and 
development of drug resistance in an indigent population. AIDS. 2000;14(4):357-66. 
173. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. 
Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. 
Ann Intern Med. 2000;133(1):21-30. 
174. Valenstein M, Taylor KK, Austin K, Kales HC, McCarthy JF, Blow FC. Benzodiazepine use 
among depressed patients treated in mental health settings. Am J Psychiatry. 
2004;161(4):654-61. 
175. Ferrando SJ, Wapenyi K. Psychopharmacological treatment of patients with HIV and 
AIDS. Psychiatr Q. 2002;73(1):33-49. 
176. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, 
Hoffman JL, Shader RI. Alprazolam-ritonavir interaction: implications for product 
labeling. Clin Pharmacol Ther. 2000;67(4):335-41. 
177. Lopes M, Olfson M, Rabkin J, Hasin DS, Alegría AA, Lin KH, Grant BF, Blanco C. Gender, 
HIV status, and psychiatric disorders: results from the National Epidemiologic Survey on 
Alcohol and Related Conditions. J Clin Psychiatry. 2012;73(3):384-91. 
178. Vesga-López O, Schneier FR, Wang S, Heimberg RG, Liu SM, Hasin DS, Blanco C. Gender 
differences in generalized anxiety disorder: results from the National Epidemiologic 
Survey on Alcohol and Related Conditions (NESARC). J Clin Psychiatry. 2008;69(10):1606-
16. 
179. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, 
Schoenbaum EE. Impact of active drug use on antiretroviral therapy adherence and viral 
suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377-81. 
 
 162 
180. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance 
with antiretroviral therapy in patients with human immunodeficiency virus: prospective 
assessment with implications for enhancing compliance. AIDS Care. 1996;8(3):261-9. 
181. Roux P, Fugon L, Michel L, Lert F, Obadia Y, Spire B, Carrieri MP. Determinants of 
benzodiazepine use in a representative population of HIV-infected individuals: the role 
of HIV status disclosure (ANRS-EN12-VESPA study). AIDS Care. 2011;23(9):1163-70. 
182. Herek GM, Capitanio JP, Widaman KF. Stigma, social risk, and health policy: public 
attitudes toward HIV surveillance policies and the social construction of illness. Health 
Psychol. 2003 Sep;22(5):533-40. 
183. Hellinger FJ, Encinosa WE. Antiretroviral therapy and health care utilization: a study of 
privately insured men and women with HIV disease. Health Serv Res. 2004;39(4 Pt 
1):949-67. 
184. Substance Abuse and Mental Health Services Administration, Results from the 2013 
National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series 
H-48, HHS Publication No. (SMA) 14-4863. Rockville, MD: Substance Abuse and Mental 
Health Services Administration, 2014. 
185. Fenton MC, Keyes KM, Martins SS, Hasin DS. The role of a prescription in anxiety 
medication use, abuse, and dependence. Am J Psychiatry. 2010;167(10):1247-53. 
186. Blanco C, Rafful C, Wall MM, Jin CJ, Kerridge B, Schwartz RP. The latent structure and 
predictors of non-medical prescription drug use and prescription drug use disorders: a 
national study. Drug Alcohol Depend. 2013;133(2):473-9. 
187. Gordillo V, del Amo J, Soriano V, González-Lahoz J. Sociodemographic and psychological 
variables influencing adherence to antiretroviral therapy. AIDS. 1999;13(13):1763-9. 
 
 163 
188. Vitiello B, Burnam MA, Bing EG, Beckman R, Shapiro MF. Use of psychotropic 
medications among HIV-infected patients in the United States. Am J Psychiatry. 
2003;160(3):547-54. 
189. Newville H, Roley J, Sorensen JL. Prescription medication misuse among HIV-infected 
individuals taking antiretroviral therapy. J Subst Abuse Treat. 2015;48(1):56-61. 
190. Hansen L, Penko J, Guzman D, Bangsberg DR, Miaskowski C, Kushel MB. Aberrant 
behaviors with prescription opioids and problem drug use history in a community-based 
cohort of HIV-infected individuals. J Pain Symptom Manage. 2011;42(6):893-902. 
191. Silverberg MJ, Ray GT, Saunders K, Rutter CM, Campbell CI, Merrill JO, Sullivan MD, 
Banta-Green CJ, Von Korff M, Weisner C. Prescription long-term opioid use in HIV-
infected patients. Clin J Pain. 2012;28(1):39-46. 
192. Tsao JC, Stein JA, Dobalian A. Pain, problem drug use history, and aberrant analgesic use 
behaviors in persons living with HIV. Pain. 200715;133(1-3):128-37. 
193. Robinson-Papp J, Elliott K, Simpson DM, Morgello S; Manhattan HIV Brain Bank. 
Problematic prescription opioid use in an HIV-infected cohort: the importance of 
universal toxicology testing. J Acquir Immune Defic Syndr. 2012;61(2):187-93. 
194. Salzman C. Treatment of anxiety. In: Salzman C, ed. Clinical Geriatric 
Psychopharmacology. 2nd ed. Baltimore: Williams & Wilkins; 1992:189-212. 
195. Manchikanti L. National drug control policy and prescription drug abuse: facts and 
fallacies. Pain Physician. 2007;10(3):399-424. 
196. Buurma H, Bouvy ML, De Smet PA, Floor-Schreudering A, Leufkens HG, Egberts AC. 
Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther. 
2008;33(1):17-23. 
 
 164 
197. Peirce GL, Smith MJ, Abate MA, Halverson J. Doctor and pharmacy shopping for 
controlled substances. Med Care. 2012;50(6):494-500. 
198. Breitbart W, McDonald MV, Rosenfeld B, Passik SD, Hewitt D, Thaler H, Portenoy RK. 
Pain in ambulatory AIDS patients. I: Pain characteristics and medical correlates. Pain. 
1996;68(2-3):315-21. 
199. Breitbart W, Rosenfeld BD, Passik SD, McDonald MV, Thaler H, Portenoy RK. The 
undertreatment of pain in ambulatory AIDS patients. Pain. 1996;65(2-3):243-9. 
200. Dobalian A, Tsao JC, Duncan RP. Pain and the use of outpatient services among persons 
with HIV: results from a nationally representative survey. Med Care. 2004;42(2):129-38. 
201. Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric history 
and psychologic adjustment as risk factors for aberrant drug-related behavior among 
patients with chronic pain. Clin J Pain. 2007;23(4):307-15. 
202. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, Lin LS, An Q, Mermin J, 
Lansky A, Hall HI; HIV Incidence Surveillance Group. Estimated HIV incidence in the 
United States, 2006-2009. PLoS One. 2011;6(8):e17502. 
203. Murri R, Fantoni M, Del Borgo C, Visona R, Barracco A, Zambelli A, Testa L, Orchi N, Tozzi 
V, Bosco O, Wu AW. Determinants of health-related quality of life in HIV-infected 
patients. AIDS Care. 2003;15(4):581-90. 
204. Jia H, Uphold CR, Wu S, Reid K, Findley K, Duncan PW. Health-related quality of life 
among men with HIV infection: effects of social support, coping, and depression. AIDS 
Patient Care STDS. 2004;18(10):594-603. 
205. Berger-Greenstein JA, Cuevas CA, Brady SM, Trezza G, Richardson MA, Keane TM. Major 
depression in patients with HIV/AIDS and substance abuse. AIDS Patient Care STDS. 
2007;21(12):942-55. 
 
 165 
206. Cruess DG, Antoni MH, Gonzalez J, Fletcher MA, Klimas N, Duran R, Ironson G, 
Schneiderman N. Sleep disturbance mediates the association between psychological 
distress and immune status among HIV-positive men and women on combination 
antiretroviral therapy. J Psychosom Res. 2003;54(3):185-9. 
207. Kremer H, Sonnenberg-Schwan U, Arendt G, Brockmeyer NH, Potthoff A, Ulmer A, 
Graefe K, Lorenzen T, Starke W, Walker UA; German Competence Network HIV/AIDS. 
HIV or HIV-therapy? Causal attributions of symptoms and their impact on treatment 
decisions among women and men with HIV. Eur J Med Res. 2009;14(4):139-46. 
208. Robbins JL, Phillips KD, Dudgeon WD, Hand GA. Physiological and psychological 
correlates of sleep in HIV infection. Clin Nurs Res. 2004;13(1):33-52. 
209. Reid S, Dwyer J. Insomnia in HIV infection: a systematic review of prevalence, correlates, 
and management. Psychosom Med. 2005;67(2):260-9. 
210. Costa e Silva JA, Chase M, Sartorius N, Roth T. Special report from a symposium held by 
the World Health Organization and the World Federation of Sleep Research Societies: an 
overview of insomnias and related disorders--recognition, epidemiology, and rational 
management. Sleep. 1996;19(5):412-6. 
211. Brown S, Atkinson H. Correlation of subjective sleep complaints, absolute T-4 cell 
number and anxiety in HIV illness. Sleep Res. 1991; 20:363. 
212. Darko DF, McCutchan JA, Kripke DF, Gillin JC, Golshan S. Fatigue, sleep disturbance, 
disability, and indices of progression of HIV infection. Am J Psychiatry. 1992;149(4):514-
20. 
213. Moeller AA, Oechsner M, Backmund HC, Popescu M, Emminger C, Holsboer F. Self-
reported sleep quality in HIV infection: correlation to the stage of infection and 
zidovudine therapy. J Acquir Immune Defic Syndr. 1991;4(10):1000-3. 
 
 166 
214. Hudson AL, Portillo CJ, Lee KA. Sleep disturbances in women with HIV or AIDS: efficacy 
of a tailored sleep promotion intervention. Nurs Res. 2008;57(5):360-6. 
215. Omonuwa TS, Goforth HW, Preud'homme X, Krystal AD. The pharmacologic 
management of insomnia in patients with HIV. J Clin Sleep Med. 2009;5(3):251-62. 
216. Rihs TA, Begley K, Smith DE, Sarangapany J, Callaghan A, Kelly M, Post JJ, Gold J. 
Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. 
HIV Med. 2006;7(8):544-8. 
217. Núñez M, González de Requena D, Gallego L, Jiménez-Nácher I, González-Lahoz J, 
Soriano V. Higher efavirenz plasma levels correlate with development of insomnia. J 
Acquir Immune Defic Syndr. 2001;28(4):399-400. 
218. Prescription Monitoring Act. South Carolina Department of Health and Environmental 
Control. http://www.scdhec.gov/administration/drugcontrol/pmp-legislative-
summary.htm. Accessed May 5, 2014. 
219. Dispenser’s implementation guide. South Carolina Department of Health and 
Environmental Control. http://www.scdhec.gov/administration/drugcontrol/docs/sc-
dispensersimplementationguide.pdf. Accessed May 5, 2014. 
220. Practitioner/pharmacist database access request procedures. South Carolina 
Department of Health and Environmental Control. 
http://scdhec.gov/administration/drugcontrol/pmp-practitioner-pharmacist.htm. 
Accessed May 6, 2014. 
221. Compilation of state prescription monitoring program maps. The National Alliance for 
Model State Drug Laws. http://www.namsdl.org/library/243EAD20-1C23-D4F9-
74994590D8E1BDCF/. Accessed May 6, 2014. 
 
 167 
222. Law enforcement procedures for report request. South Carolina Department of Health 
and Environmental Control. http://www.scdhec.gov/administration/drugcontrol/pmp-
law-enforcement.htm. Accessed May 6, 2014. 
223.  Drug control. South Carolina Department of Health and Environmental Control. 
http://www.scdhec.gov/administration/drugcontrol/. Accessed October 10, 2012. 
224. Prescription monitoring programs – state law and policy profiles. The National Alliance 
for Model State Drug Laws. http://www.namsdl.org/library/8DB6720C-91EE-8472-
E365F7818C02C8B5/. Accessed January 20, 2015. 
225. State and county quick facts. United States Census Bureau. 
http://quickfacts.census.gov/qfd/. Accessed February 11, 2015. 
226. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of 
interrupted time series studies in medication use research. J Clin Pharm Ther. 
2002;27(4):299-309. 
227. Regional and state employment and unemployment archived news release. United 
States Department of Labor Bureau of Labor Statistics. 
http://www.bls.gov/schedule/archives/laus)nr.htm. Accessed September 15, 2014. 
228.  S.C. Code § 44-53 
229. Prescription drugs: state monitoring programs may help to reduce illegal diversion. 
http://www.gao.gov/new.items/d04524t.pdf. Accessed November 26, 2012. 
230. Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series 
designs in health technology assessment: lessons from two systematic reviews of 
behavior change strategies. Int J Technol Assess Health Care. 2003;19(4):613-23. 
 
 168 
231. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of 
mental disorders with alcohol and other drug abuse. Results from the Epidemiologic 
Catchment Area (ECA) Study. JAMA. 1990;264(19):2511-8. 
 
 169 
Curriculum Vitae 
SARAH E. WIXSON 
   
   
Education   
   
Lexington, KY 
University of Kentucky 
College of Pharmacy 2011 - 2015 
Doctor of Philosophy   
Pharmaceutical Sciences 
Track: Pharmaceutical Outcomes and Policy 
Dissertation Title: “Medication misadventures: the case of benzodiazepines” 
   
Lexington, KY 
University of Kentucky 
Graduate School 2012 - 2013 
Graduate Certificate  
Informatics   
   
Lexington, KY 
University of Kentucky 
College of Agriculture 2009 – 2011 
Master of Science   
Agricultural Economics  
Thesis Title: “Price asymmetric relationships in the commodity and energy markets” 
   
Lexington, KY 
University of Kentucky 
College of Agriculture 2004 – 2008 
Bachelor of Science  
Agricultural Economics  
   
   
Research and Academic Positions  
  
2011 – Present Graduate Research Assistant, Institute for Pharmaceutical Outcomes and Policy, University of Kentucky 
2011 – 2014 Teaching Assistant, Pharmacy Practice and Science, University of Kentucky 
  
2010 – 2011 Teaching Assistant, Agricultural Economics, University of Kentucky 
  
2008 Laboratory Assistant, Agricultural Economics, University of Kentucky 
   
   
   
   
   
 
 170 
Academic Honors and Awards  
  
2014 International Society for Pharmacoepidemiology (ISPE) Scholarship to attend annual meeting 
  
2014 
Best Student Poster Presentation, International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual 
International Meeting, Montreal, Canada 
   
2013 International Society for Pharmacoepidemiology (ISPE) Scholarship to attend annual meeting 
   
2013 University of Kentucky Student Support Funding, awarded for travel to professional meetings to present research (twice) 
   
2012 University of Kentucky Student Support Funding, awarded for travel to professional meetings to present research 
   
2011 University of Kentucky Student Support Funding, awarded for travel to professional meetings to present research 
   
   
Affiliations   
  
2013 – Present International Society for Pharmacoepidemiology 
  
2011 – Present International Society for Pharmacoeconomics and Outcomes Research 
   
2011 – 2015 
Department of Pharmacy and Science Graduate Education Research 
Committee, University of Kentucky, Graduate Student 
Representative 
   
2011 – 2012 Agricultural and Applied Economics Association 
  
2010 – 2011 Southern Agricultural Economics Association 
   
   
Bibliography   
  
Peer Reviewed Publications  
 
Wixson SE, Blumenschein K, Goodin AJ, Talbert J, Freeman PR. Prescription drug 
monitoring program utilization in Kentucky community pharmacies. Pharm Pract. 
2015;13(2):540. 
 
 
 
 
 171 
Wixson SE, Blumenschein K, Goodin AJ, Higgins GE, Vito GF, Talbert J, Freeman PR. Law 
enforcement perceptions of a prescription drug monitoring program. International Journal of 
Police Science & Management. 2014;16(4)288-296. 
 
Wixson SE, Brouwer ES. Sex differences in benzodiazepine use in the 
HIV-infected population. AIDS Care. 2014;26(10):1218-22. 
   
Published Abstracts   
 
Wixson SE, Brouwer ES. Benzodiazepine use in the HIV-infected population. 
Pharmacoepidemiology and Drug Safety. 2013 October;22(s1): 499. 
   
Wixson SE, Blumenschein K, Brouwer ES, Freeman PR, Talbert T. Impact of South Carolina’s 
prescription drug monitoring program on the use of benzodiazepines in a commercially insured 
population. Value in Health. 2013 May;16(3): A248. 
   
Wixson SE, Talbert J, Blumenschein K, Freeman PR. Impact of prescription monitoring programs 
on pharmacists’ controlled substance dispensing behavior. Value in Health. 2012 June;15(4): 
A29-A30. 
   
Wixson SE, Katchova AL, Woods TA, Hu W. The role of specialty food stores and farmer’s 
markets in the procurement of local foods. Journal of Agricultural and Applied Economics. 2011 
Aug;43(3): 471. 
   
Non-Peer Reviewed Contributions  
 
Wixson SE, Katchova AL. Does price asymmetry exist in commodity and energy markets? 
Prepared for the Agricultural and Applied Economics Association (AAEA) Annual Meeting, July 
2011. Available at: 
http://ageconsearch.umn.edu/bitstream/103735/2/AAEA%20Poster%20Presentation%20ID134
76.pdf. 
 
Wixson SE, Katchova AL, Woods TA, Hu W. The Role of Specialty Food Stores and Farmer’s 
Markets in the Procurement of Local Foods. Prepared for the Southern Agricultural Economics 
Association (SAEA) Annual Meeting, February 2011. Available at: 
http://ageconsearch.umn.edu/bitstream/97969/2/The%20Role%20of%20Specialty%20Food%20
Stores%20and%20Farmers%20Markets.pdf. 
   
   
Scholarly Presentations  
   
Podium   
 
Optimizing prescription drug monitoring programs to support law enforcement activity. Hal 
Rogers Prescription Drug Monitoring Program National Meeting, Washington DC, September 
2014. 
 
 
 
 172 
The role of specialty food stores and farmer’s markets in the procurement of local foods. 
Southern Agricultural Economics Association (SAEA) Annual Meeting, Corpus Christi, TX, 
February 2011. 
   
Posters   
 
Wixson SE, Brouwer ES. Increased benzodiazepine abuse among HIV-infected individuals in the 
United States. International Conference on Pharmacoepidemiology & Therapeutic Risk 
Management. Taipei, Taiwan, October 2014. 
 
Wixson SE, Blumenschein K, Goodin AJ, Freeman PR, Talbert J. Community pharmacist 
characteristics associated with use of a prescription drug monitoring program.  International 
Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, Montreal, 
Canada, June 2014. 
   
Wixson SE, Brouwer ES. Benzodiazepine use in the HIV-infected population. 29th International 
Conference on Pharmacoepidemiology & Therapeutic Risk Management. Montreal, Canada, 
August 2013. 
 
Wixson SE, Blumenschein K, Brouwer ES, Freeman PR, Talbert J. Impact of South Carolina’s 
prescription drug monitoring program on the use of benzodiazepines in a commercially insured 
population. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
Annual Meeting, New Orleans, LA, May 2013. 
   
Wixson SE, Talbert J, Blumenschein K, Freeman PR. Impact of prescription monitoring programs 
on pharmacists’ controlled substance dispensing behavior. International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, Washington DC, June 
2012. 
 
Wixson SE, Katchova AL. Price asymmetric relationships in commodity and energy markets. 
European Association of Agricultural Economists (EAAE) 123rd Seminar, Dublin, Ireland, 
February 2012. 
   
Wixson SE, Katchova AL. Does price asymmetry exist in commodity and energy markets? 
Agricultural and Applied Economics Association (AAEA) Annual Meeting, Pittsburgh, PA, July 
2011. 
   
   
Scientific Journal Peer Review  
  
Journal of the American Pharmacists Association  
  
  
Research Experience  
   
Benzodiazepine use in the COPD population and the risk of mortality. Faculty Advisor: Dr. Emily 
S. Brouwer, 2014-2015. 
 
 
 173 
Optimizing prescription drug monitoring programs to enhance law enforcement activity. Faculty 
Advisor: Dr. Patricia R. Freeman, 2012-2015. 
   
Benzodiazepine use in the HIV-infected population. Faculty Advisor: Dr. Emily S. Brouwer, 2012-
2015. 
 
Impact of South Carolina’s prescription drug monitoring program on the use of benzodiazepines 
in a commercially insured population. Faculty Advisor: Dr. Karen Blumenschein, 2012-2015. 
  
Prescription drug monitoring programs: the consumer’s perspective on the “chilling effect”. 
Faculty Advisor: Dr. Karen Blumenschein, 2012-2013. 
   
   
Teaching Experience   
  
Summer 2014 
PPS 760 – Techniques in Secondary Data Research: Prepared and 
presented a workshop on how to use Stata for outcomes research. 
Topics included understanding Stata interface, importing data into 
Stata, data analysis commands, data manipulation, and descriptive 
statistics; 8 students; 1 lecture 
  
Fall 2013 
PPS 910 Introduction to Pharmacy Practice and Science: Assisted 
with course development; prepared and presented lecture on 
research in pharmaceutical outcomes and policy; graded student 
assignments, presentations, and term papers; maintained course 
records; 140 students; 1 lecture 
  
Spring 2013 & 2014 
PPS 920 Communication and Behavior in Pharmacy Practice: 
Prepared and presented lecture on introductory health economics; 
maintained course records; graded student assignments; 140 
students; 1 lecture 
   
Fall 2012 
PPS 910 Introduction to Pharmacy Practice and Science: Assisted 
with lecture and development of laboratory exercise for conducting 
literature reviews in an academic setting; maintained course 
records; graded student assignments; 140 students; 4 lectures 
   
Spring 2011 
AEC 321 Agricultural Futures Markets: Assisted with course 
development; provided lectures on hedging agricultural 
commodities; coordinated a guest lecturer; graded student 
assignments; 40 students 
  
Fall 2010 
AEC 320 Agriculture Product Marketing and Sales: Assisted with 
course development; provided guest lectures on inventory 
management; updated course website on a weekly basis; graded 
student presentations and written assignments; 30 students 
  
  
 
 174 
Spring 2008 
AEC 302 Agricultural Management Principles: Provided assistance 
to students on the creation of financial worksheets for an 
agricultural management setting; 45 students 
 
